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The work presented in this thesis is two-fold: (i) development of single agents that 
provide inhibition of both the growth of malaria parasites and of tumour cells in vitro, 
and (ii) inclusion of these potential novel inhibitors in cyclodextrin host molecules in 
an attempt to render these dual drugs water-soluble. 
(i) Of all the current clinically established antimalarials, the 4-aminoquinolines have 
proven to be the most significant and efficacious for the treatment and prophylaxis of 
malaria. However, their efficacy has decreased by the spread of drug resistant strains 
of the causative agent Plasmodium Jalciparum. Future research into 4-aminoquinoline 
derivatives as antimalarial agents is still warranted and justified on the basis of several 
considerations. The quinoline moiety has also been shown to be a substructure in 
multi-drug resistance reversal agents against certain cancer cell lines and antitumour 
agents which have demonstrated the ability to act as differentiation-inducing agents. 
The strategy employed for this project was to hybridize chalcone moieties and their 
Mannich base derivatives with the 4-aminoquinoline moiety. This dual drug concept 
uses the basic structure of the chalcone scaffold, which has a wide range of known 
antimalarial and anticancer activities, and is hybridised with the 4-aminoquinoline 
moiety, in order to exert maximal biological activity and overcome or prevent drug 
resistance. Structural variation on the aromatic rings of the chalcone scaffold allowed 
preliminary structure-activity relationship studies to be undertaken. 
Synthesized compounds were evaluated against chloroquine-sensitive and 
chloroquine-resistant Plasmodium Jalciparum strains. Despite the lower 
antiplasmodial activities associated with these compounds compared to chloroquine, 
the target compounds on average possess favourable resistance indices. Cytotoxicity 
assays were performed on HeLa cells to establish the sensitivity of the cancer cell 
lines to the synthesized compounds. A general trend observed against both 
Plasmodium Jalciparum strains and HeLa cells is that target hybrid 2, in which the 4-
aminoquinoline moiety is attached to ring B, is more active than target hybrid 1, in 











preliminary structure-activity relationship studies demonstrate the importance of 
meta-relationship between the 4-aminoquinoline moiety and the ketone linker and a 
methoxy-substituent on the chalcone aromatic ring, for both antiplasmodial and 
anticancer activity. 
Conversion of the chalcones into the corresponding Mannich bases led to an increase 
in potency against both D 1 0 and W2 strains and HeLa cells in vitro. Mannich base 
derivatives showed greater antiplasmodial activities in the resistant W2 strain (lCso 
ranging from 0.004 to 0.08 J.lM) than the reference drug chloroquine (ICso = 0.099 
J.lM). The ability of the phenolic Mannich base derivatives to inhibit ~-haematin 
formation and the cysteine protease falcipain 2 was also determined, in efforts aimed 
at understanding the mechanism of action. There is a fairly good correlation between 
antimalarial activity against D 1 0 and inhibition of ~-haematin formation. There was 
no correlation between the ability of the compounds to inhibit falcipain 2 and 
antiplasmodial activity against W2 in vitro. The pyrrolidine-derived Mannich base 
CDM37 is a promising antimalarial agent as it shows superior activity in both the 
chloroquine-sensitive (lCso = 0.111 J.lM) and chloroquine-resistant (lCso = 0.0039 
J.lM) P. Jalciparum strains as well as inhibition of falcipain 2 (ICso = 11.51 J.lM) and ~­
haematin formation (0.219 equiv). 
(ii) Cyclodextrins have the ability to form inclusion complexes with various guest 
molecules and are of interest in this project due to their ability to act as solubilisers, 
stabilisers and carriers of poorly soluble drug molecules. Two ~-cyclodextrin 
complexes and three y-cyclodextrin complexes were formed with selected target 
compounds by the method of kneading. Although five inclusion complexes were 
obtained as established by powder X-ray diffraction, subsequent recrystallization of 
the kneaded material did not yield single crystals required for full X-ray structure 
determination, which is an essential requirement for pharmaceutical use of 
cyclodextrin inclusion complexes. Consequently the hypothesis of improving the 
water-solubility and hence the bioavailability of target compounds through 










































Differential Scanning Calorimetry 
2' -Deoxyuridylic acid 
Deoxythymidine-5-phosphate 
Effective dose of a drug necessary to produce a therapeutic 











































High resolution mass spectroscopy 
Histidine-rich protein II 
Hot Stage Microscopy 






Multi-drug resistance reversal 
Mole 
Mass spectroscopy 
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Thin layer chromatography 
Thioredoxin reductase 
Ultra-violet 
World Health Organization 
The following abbreviations are used in the EXPERIMENTAL chapter: 
cm- I wavelength 
s singlet 
d doublet 
dd doublet of doublets 
EI Electron impact 
FT Fourier transform 
Hz Hertz 















mlz mass to charge ratio 
8 chemical shift 
ppm parts per million 
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Chapter 1: Introduction 
CHAPTER 1 
INTRODUCTION 
1.1 History of Malaria 
Malaria, a disease caused by the parasitic protozoa of the genus Plasmodium, is one of 
the most serious and widespread threats to human health. I The malaria parasite and 
the human race have had a long host-parasite connection; references to malaria are 
found in myths, legends and historical accounts of ancient Egypt, China, India and 
Greece.2 For many centuries, the cause of malaria was attributed to a poisonous vapor 
emanating from stagnant water, a theory that gave the disease its name from the 
Italian word "mal' aria" meaning "bad air". Civilizations as early as the Etruscans 
(l51 millennium BC) drained marshes and swamps in an effort to combat the disease.3 
The first important step towards identifying the true cause of the disease was taken by 
Meckel in 1847, who associated a pigment he saw in the blood, spleen and liver of 
cadavers with malaria infection.5 However, it was not until 1880 that the French 
surgeon Charles Alphonse Laveran made the crucial finding that not only the pigment 
but also a parasite itself was present in the blood of malaria patients. After the 
protozoal cause of malaria was elicited by Laveran, the next step forward was made in 
1899 by Ronald Ross, a British physician, who demonstrated that the female 
Anopheles mosquito was the vector for malaria.2 In 2002 the genome of Plasmodium 
Jalciparum and other malaria parasites was determined by an international team of 
scientists with the hope to design more effective antimalarial drugs, insecticides and 
vaccines.4 In many ways, the history of malaria reflects the development of science 
and medicine over the centuries, from myth and superstition to a thorough scientific 
basis. 
1.2 Global Distribution of Malaria 
Although malaria was once prevalent in North America and other temperate regions, 
the disease today occurs mainly in tropical and subtropical countries, in particular 
Sub-Saharan Africa and South-East Asia.3,5 According to the World Health 










Chapter I: Introduction 
ca,e, diagnosed annually. kading to 1.1·2.7 million deaths.' About <)0% of these 
deaths occur in Sub-Saharan Africa. where malaria also presents major obstac l ~s in 
social and economic de,elopment. The seriousness of malaria has been increasing in 
recent years. "'ith epidemics occurring in new areas as a resull of de teriorating social 
and economic conditions. changing land utilintion. in,eclicide-resistant mosquitoes 







1.3 Biology oftbe Malaria Parasite 
Malaria in humans is caused by four species of Plasmodium parasites. namely P. 
jaldparum. P. ..i .. ax. P. ovall! and P. malaria~. each of which produces a 
charact~rislic clinical illlles,. Pla.\·modiumfalciparum is the most common species in 
tropical areas and the most dangerous of the four species, accounting for half of all 
clinical cases and 90% of fataliti es from the disease. Plasmodium virax is the moSt 
widespread species. existing in tropical and somc temperate zones. The other two 
plasmodia species are kss common and have a variable distribl1tion worldwide.' 
fortunately, the biology of P.fa!ciptlrum is the best understood of the four species as 
methods for in vitro cultllfe have been available for three decades.9 
Knowledge of the biolog}· of the malaria parasite is fundamental in understanding the 











Chapler I Introduction 
1.3.1 Life Cycle of the Malaria Parasite 
The life cycle of the malaria parasite is complex and involves a sexual stage that 
occurs jn the mid-gut of the mosquito, and an asexml stage, which takes place in the 
human host: first in th" li'"r and then in red blC>Od cells (Figure 1.2). 
.--.... ---- -- / ' . ' ." .'~ £ .. .".,~ ..... 
Figure 1.2: Lif. qcle ofthe malaria p"",i!' 
A human infection begin> with the bite of an infected female Anopheles mo>quito 
while taking a blood meal in order to nourish her egg>. To ensure an "ven !lowing 
meal, the mosquito injects anticoagldant sali\u that contains toc infectious ,porozoites 
inll' the hwnan hloodstream. The thread-like sporozoites rapidly take refuge from the 
human"s immlme system def<![]ses by j[]\·ading hepatoC}1es in the liver. where lh~y 
undergo as~xual amplification and dewlop into an exoerytlmlC)lic (hepatic) schizont 
during the next 5-15 days. The hepati~ sehi~_ont. containing up to 30 000 meromites. 
bur:.ts upon matuntlion relea,ing tlte m~rozoites into tfle bloodstream wher~ th~y 
invade the red blood cells (~rythn.lC}les). In the erythrocyte. as~xuaJ ampJificmion 
once again <XCUT, leading to the formation of el)lhrocytic schi~onts. through ring and 
trophozoite stages. The cl)lhrocyte containing lite mature schizont rupture,. releasing 
a new generation ofmcmzoites, which could invade other red blood cells: it is during 
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proliferate in this maimer until the death of the host or until they are controlled or 
tenninated by the host's immune system or by drugs. 
During this repeated ~yde. ,ome meruzoites difTerentiate into minogametol:ytes 
(male) and macmgametoc)le~ (female), which can be tran~milted to the Anopheh:s 
mO"l.uito during a blood meal. In the mid-gut of the mosquito, mature gametocyles 
es.:ape from the erythroc;'1e to form gametes: fertilization then occurs producing 
zygote" which develop into oC>kinetes. The ookinete penetrates the epithelial cells and 
develops into an oocyst. lletween 7-15 days, dependinll on the species and ambient 
temperature. a ~ing1e Oll<:)st divide~ and ruptures to fonn more thall 10 000 
sporozoites. y,hich migrate into the ,alivary glands. ""'hen the infeded mosquito feeds 
again. the Plasmodium life ~yde i~ completed. The time duration on the P jalcipanl1n 
is sl.lJllmari)"ed in Table I. 
Tabte I : Longth ofthe [Jitforom Stage, of l.if. ("yclo of P/a.'mndium falc.)",,,,m' 
Oocyst, 
, 
t. {) 't 
blood stream 
1.3,2 Biocbemistry of the fOOlJ Vacuole 
1.3.2.1 BackgroUDlJ 
M",. 1 hOUT 
The intraer)1hroc)"tic location of the malaria para~ite, providing a safe environment 
from the host's immune sy~tem , leads to a greater difticulty in obtaining the required 
nutrient, from the external environment.' The parasite thus modifies the host cell in 
,everal way~ and intertwines its metaboli,m with that of the host . Upon invasion of a 
human erythrocyte. th~ parasite grows and mature, wrrounded by c}10,01 consisting 
predominately of haemoglobin. Due to the rapid groMh and multiplication rale of the 
para,ite. it requires a ready source of amino acids but has a limited ability to 
synthesize them de 110\'0. 11 The parasiti~ truphomile ~in;um'ent~ thi~ problem by 











Chapt~r 1: introduction 
haemoglobin-derived amino acids in its oVln prol~ins.ll Allhough 60-80% of the 
haemoglobin originally prcs.:nl in the red blood cell is degra\kd,1l14 (here is c\idcnce 
that only a small quantity of amino a<:lds is used. l ! To explain this, it has been 
suggested that the parasite digests haemoglobin, not onl) as a source of nutrients_ but 
also to maintain osmotic stability'" and to make space for ilS~lf within the r~d blood 
cell. I' A key organdle through which the para~ilc carri~s out haemoglobin 
degradation and other important biochemical processes is a specialized acidic (pH 5-
5.5) food \ 'acuole (Figure 1.3). The haemoglobin-rich red blood cell cytosol is 
ingested by the process of endocytosis \'ia all invagination in the parasitophoTOUS 
\3ClKl]ar membrane known as a cytosome and then transported to the food vacuole 
(f-V) by transport vesicks." 
.~ -."." . 
..... "" 
.' .. m. 
l)j~ruption of haemoglobin catabolism causes parasite ~a(h in vitro and ill vhm. The 
vital and specialized process of haemoglobin degradation within the I"ood vacuok 
provides prOllllslflg targets t"r the development 01· novel antimalarial 
chemotherap,;utic agents. 
\.3.2.2 lIaemoglobin Degradation Pathway 
Haemoglobin degradalion 10 pt:pti~ fragment~ is I"a<;ililaled by multiple proteases 
within the food va<:uole. The distinct but overlapping roles of these proteolytic 
enElmes suggest thai h~moglobin catabolism occurs via a semi ordered pathway. '9,2() 
Three distinct classes of proteases have been isolaled and puri fied from the food 
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Then: fin: Jllur aspartic prokflse, (plasmepsins L II and IV and hislo-aspartic protea,e, 
or I!AP).2V.21 two c}steine proteases (falcipain 2 and 3)l ~ and a /ioc lllt:talloprotease 
(ralcil}sin).I ~ The s<'qU<'nce of events leading to the liberation of free amino add, is 
bt:lieved to occur a, shown in Fi"ure 1 4 and summarized 1->clow 
0 
( .) Par.6i.t. cytoplasm 
Hern<tglobin 1/'" 
Pl"_'m~p'i:JV H"'<- ~ 
(lalclpaw-l?) ~"'DP 






falci:y,m Smaller Pfmdr-J fI) Peptides , Peplides Peptidas 
/ ' " 
F i~. r. l.J : lIaemog looin d.gradation "ithin food vacuole" 
(a) Plasmcpsin L II and IV commence the degradillion pmce" by cleaving native 
haemoglohin at the >arne site. location u33Phe-34Leu in the a chain:w 
cleaving the hinge region that maintains quaternary ,tn.lCturt:. The denalur~d 
haemoglobin then undergocs secondary cleavage" "ith piflsmepsin I 
preferring phenylalanine at the P I position and pla,m~psin II preferring other 
hydrophobic p;:>sitions, especially leucine. at th.:: PI' position:~o Pla,mep,in IV 
filld IIAP furt:h<:r digt:st the haemoglobin to fonn ocnatured globin Iragments. 21 
(b) Onc~ tt.;, aspflrtic pTllt~a,es have initiated proteol}sis to form d~natured 
haemoglobin, lalcipain 2 and 3 tht:1l h)'drolyze these globin fragments into 
peptide tragments 10-15 amino fl Cid, in kngth. The c)'>Idn~ proteases are 
incapable of degrading native hflemllglobin fit ph},iologi~al vac;ulliar pH. 
There is evidence, howevcr, that cystdnc protea<ocs may aet upon nativt: 
haemoglobin under mild reducing conditions,14 due to the observation of 
swollen food vacooles filled with undegradcd globin when parasite, arc treated 
with cysteine protease inhibitors 2 1 There is also eviocnce that lalcipain 2 is 
involved in clea\'ing specilk ~omponents of the host elJ1hrocyte membrane 
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(c) Falcil)'sin, a zinc metalloproleu8e. fUlKtions dov,ustream ill the h~emoglobjn 
degradatioll pn.iCe". FalcilY8in carmot cleave haemoglobill or globin, but is 
capable of proteo] yscs of Ih" reptid", into short oligomers (6-8 amino acids) at 
sit~s polar ill charact~r, ",jlh churg"d residues at the PI alld/or P4' po,ilions. 
(d) The ,hort oligom~rs are then IramJ1ort~d OUi of the food vacuole illio Ihe 
para,ite cytopla,m ",here they are hydrolyzed b), amiaopeplidases into amino 
acids n~cessar)' for cell growlh. On~ such amioo]Xptidasc is Pln,-modium 
jillciparum amino]Xptidase of the \11 group of metalloproteases (PfA-\lll. 
Food 
Vacuole 
N-terminal amiM acids L~u and Ala. 
Cytoplasn7 
During this proce8' of hUl:llKlglobin degradation, haem 111 its f<'TTol.lS form 
(f~rropro10porphynn IX or Fe(lI)PPIX) is released as a by-product (FigllT~ 1.5) and 
autoxjdis~d by O2 to a-hJ\!matin (aquuferriprotoporphyrin IX or HlO-Fe(III)PPIX), 
which i, th~ f~rric lorm,li This karls to till: production of hydrogen ]Xroxid~ through 
th~ on~ ~kctron oxidation of Fe(1I). In addition \0 oxidative as,ault, u-haematin is 
toxic l0 the parasite and reqwres a u.:toxilication m~chanism. It is well established 
thm haemmin is converted to haemozoin, u highly insolLlbk microcrystalIill<: 
substance.!1 There is no comp1ck agreement as to ho", ha~mowin i8 l')rm~d in the 
malarial parasite and proposals incluck catalysis by lipids and/or cataly,is by hislidine 
rich prokin 2 (HRP_2),I! Most (approx, 95%) of the iron resulting from th~ 
degradation is converted to hacmoLoill and the r~mainder is J'Os-ihly degrad.:d to free 
iron. It has b\:en suggested that haemmin may he degrad~d illto Mil-haem iron by 
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1.4 Prevention and Control of Malaria 
Effective malaria prevention can be carried out by a number of strategies:3 
1. Eliminating existing infections that act as a source of transmission. This 
method of prevention requires aggressive treatment of malaria-infected 
people, as well as continuous surveillance to diagnose and treat infection 
promptly. Although this approach has been successful in North America 
and Europe, it is unfortunately not realistic in developing countries of 
Africa and Southeast Asia, who lack the infrastructure and resources 
necessary.7 
11. The use of prophylactic drugs has also been effective for travelers and 
people living in endemic areas. There are several considerations when 
prescribing chemoprophylactic drugs and depends on the particular 
location, which has implications on type of species and parasite 
transmission intensity, as well as individual circumstances. Some available 
drugs include proguanil, mefloquine, doxycycline and Malarone® 
(atovaquone/proquanil ). 
111. Eliminating exposure to mosquitoes can be achieved by several methods. 
Some of these methods include permanently destroying bodies of stagnant 
water by systematic drainage; treating such environments with insecticides 
to kill mosquito larvae and adult mosquitoes; or using repellent creams 
containing diethyltoluamide, protective clothing or insecticide-treated nets 
to prevent contact with mosquitoes. 
The discovery of the insecticidal properties of dichlorodiphenyltrichloroethane 
(DDT) in the 1940s enabled large-scale, wide-area approaches to malaria control 
for the first time.28 The World Health Organization (WHO) endorsed this 
approach and in 1955 submitted a proposal for the eradication of malaria 
worldwide. The global eradication program involved mass spraying of DDT, 
antimalarial drug treatment and surveillance. The eradication program was very 
successful in some countries, and virtually eliminated illness and death due to 
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In other countries, the program sustain or reduce malaria significantly, with sub-
Saharan Africa being completely disregarded in "global" eradication efforts.28 The 
hope of global eradication was finally abandoned in 1969 due to a number of 
factors such as lack of financial support, health care workers and community 
participation, political upheavals and mass population movement, as well as 
insecticide-resistant mosquitoes and drug-resistant parasites. The WHO thus 
decided to shift its focus to malaria control. Control programs are based on the 
+: 11 . b' . 29 10 owmg 0 ~ectlves: 
1. Early diagnosis and rapid treatment of malaria cases 
11. Sustainable preventive measures adapted to local situation 
111. An immediate and vigorous response to epidemics 
IV. A wareness of infection risk 
In 1998 the Roll Back Malaria (RBM) movement was launched to coordinate 
international malaria control. The central goal of RBM is to reduce the global malaria 
risk, morbidity and mortality by half by 2010. This mandate hopes to accomplish this 
by meeting targets on insecticide treated nets distribution, intermittent presumptive 
therapy in pregnant women, prompt and effective treatment and epidemic 
preparedness?8 Malarial control requires a multifaceted approach, with the 
availability of effective and affordable drugs being of great importance. 
1.5 Antimalarial Chemotherapy 
1.5.1 Introduction 
Ideally, a chemotherapeutic agent used in the treatment of P. Jalciparum malaria 
should be active against drug-resistant strains, provide cure within a reasonable time, 
be safe with minimum side effects, be suitable for children and pregnant women, 
orally active and perhaps most importantly, be affordable.30,3] Unfortunately, the 
current drugs available and those in development, more often than not require a 
compromise among desired features. Most clinically established drugs were not 
rationally designed based on identified targets but through the unexpected 
identification of antimalarial activity of natural products (quinine and artemisinin), 
compounds derived from natural products (chloroquine and artesunate), or 
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The reeent impro,'em~nt in the understanding of the hioch~mistry of the malaria 
para,ite, detennination of the genome sequence of I'. Ialciparum and advance, in 
malaria genetics has allowed for the determination of many potential drug targ~t~. 
Und~rstanding on the mode of action of dinicall)' establish~d drugs has bc~n 
improved due to these advaoces made. 
1.5.2 Classification of Antimalarial Drugs 
Th~ curr~nt clinically establish~d chem01h~rap..-:utic ag~nts can Ix: classified by i.) the 
stag~ of the malaria life ~ycle which the )' are targeting or ii.) by thdr mechani~m of 
action]'·)-I 
1.5.2.1 Classification according to the Stage ofthe Life Cycle 
Depending on the slage in the malarial liIe c)'de ,,,,here lhe)' ad upon. antimalarial 
drug, can Ix: da;;sili~d a, blood ~chizonticide~, ti" ll~ ,chizonticide,. gametocide, and 
~pnrontocides {"I able 2).JJ 
Blood ;;ChiZOllticid~, arc drugs that ~uppr~s, th~ production of pia;;modia in the 
er)1hroc}1e, during tk a,exual intra~r}1hroc)1ic ;;Iage of the malaria lifo, C}Cle. Ti>sue 
,chizonticide;; are active in the liv~r stage ofth~ para,iw life c}cle and prevent lhe 
devdopment of hepatic ,chizonts. Due to the fact they act upon th~ dcvelopm~ntal 
stages of the malaria life cycle. tissu~ schizonticid~s are mor~ commonly used for 
proph} la~lic purposes lhan ~uralive. Another group 01' anlimalarial agenls acling in 
th~ liver ,tage, of the malaria life c}cle are the hypnozoiticide~. "hich ,ho,", activil} 
by de<,trnying the liver >ehizonticides of l'.l'it·UX and l'. ()ml~. Gamelocid~, eradical~ 
lh~ intraeT)1hrocyli~ sexual form of the para,ite lher~by pre,'enting human 10 
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sporozoites in the mosquito. Although most of the current chemotherapeutic agents 
act upon the intraerythrocytic stages of the malaria life cycle, there are numerous 
drugs that target several stages of Plasmodium life cycle. 
1.5.2.2 Classification according to Mode of Action 
Antimalarial drugs can also be classified according to their mode of action in which 
they exert antimalarial activity. There are four major modes of action for the current 
clinically established antimalarial drugs: 33 drugs which interfere with the haem 
detoxification pathway, drugs which inhibit nucleic acid synthesis, drugs which 
interfere with protein synthesis and those that act by oxidative stress. 
1.5.2.2.1 Drugs acting on Haem Detoxification 
This category of chemotherapeutic agents includes the most common antimalarial 
drugs; that being the 4-aminoquinolines such as chloroquine 1.1 and amodiaquine 1.2 
and the quinine-type aryl amino alcohols such as quinine 1.3, quinidine 1.4, 
mefloquine 1.5 and halofantrine 1.6 (Figure 1.6). 
HN~C 
£6~~ Chloroquine 1.1 CI ~ N~ 
~OH( 
~N 
£6'" H: --/ Amodiaquine 1.2 CI ~ N~ 
MeO MeO 
Quinine 1.3 Quinidine 1.4 
~ 
Mefloquine 1.5 ~ Halolanlrin. 1.6 
CI 
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Despite many years of use and study, the exact mechanism of action of quinoline 
drugs is not completely understood. Nevertheless, it has been known since the 1960's 
that chloroquine and other quinoline-type antimalarials form complexes with 
haematin.35 It is thus generally accepted that this category of antimalarial drugs 
interfere with the detoxification of free haem, preventing its incorporation into 
haemozoin. However, it is likely that inhibition of parasite growth is due to a number 
of synergistic effects. 
Chloroquine was developed as an antimalarial during W orId War II and is one of the 
most successful drugs ever made. This was based on its affordability, safety, oral 
administration and high efficacy (prior to resistance). Unfortunately resistance to 
chloroquine is now widespread. Amodiaquine, a congener of chloroquine, was 
introduced over 40 years ago and is used as a second line drug in many African 
countries. It has greater efficacy against chloroquine-resistant P. Jalciparum infections 
but is not recommended due to its association with hepatitis and agranulocytosis. 
Quinine is one of the active components contained in the bark of the cinchona tree, 
which was one of the first agents used for the treatment of malaria, with its use dating 
back over 350 years. Currently, quinine is mainly used as a parenteral drug for severe 
Jalciparum malaria in part due to symptomatic toxicity and a complex administration 
and monitoring.36 Another active component extracted from the cinchona tree is 
quinidine, the diastereoisomer of quinine at the secondary alcohol group, which is 
more potent and toxic than quinine and used as an antiarythmic. In an effort to 
overcome chloroquine resistant P. Jalciparum strains, mefloquine and halofantrine 
were developed. Mefloquine, a quinoline methanol derivative, was an effective 
antimalarial and due to its long half-life (15-33 days) is a good prophylactic. Decline 
in its use is a result of the development of resistance and undesirable side effects. 
Halofantrine is a phenanthrene methanol derivative and is used for uncomplicated 
cases of multi-resistant Jalciparum malaria. Due to a low therapeutic index, treatment 
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1.5.2.2.2 Inhibitors of Nucleic Acid Synthesis 
This category of antimalarials includes the folate antagonists, sulfonamides and 
naphthoquinones and is active against the primary exoerythrocytic and asexual blood 
stages of the malaria parasite.32,33 Folate antagonists, such as pyrimethamine 1.7 and 
proquanil 1.8 (Figure 1.7), exert antimalarial activity by exploiting the structural 
differences between the parasite and host enzyme dihydrofolate reductase (DHFR). 
Dihydrofolate reductase catalyses the regeneration of tetrahydrofolate, a highly 
versatile carrier of one-carbon units. These drugs inhibit parasite DHFR, thereby 
causing a depletion oftetrahydrofolate and an inhibition of DNA synthesis.33 
CI 




Figure 1.7: Chemical structures of folate antagonists 
Pyrimethamine is used only in combination with a sulfonamide (e.g. Sulfadoxine, in 
Fansidar) and this pyrimethamine-sulfadoxine (SP) treatment has replaced 
chloroquine in many countries as a first line treatment of Jalciparum malaria. 
Unfortunately, resistance usually develops within a few years; aided by the slow 
elimination of SP from the body.37 The pro-drug proguanil is metabolized by 
cytochrome P450 to the active metabolite cycloguanil, which then inhibits DHFR. 
Due to rapid resistance of both P. Jalciparum and P. vivax, this drug is now only used 
in combination with chloroquine or atovaquone. The cause of resistance to these 
DHFR inhibitors is believed to be a result of single mutations on the encoding gene of 
the enzyme. 
The antimalarial activity of sulfonamides such as sulfadoxine 1.9 and sulfones such as 
dapsone 1.10 (Figure 1.8) is due to their ability to inhibit dihydropteroate synthase, 
another enzyme involved in folate metabolism, by mimicking p-aminobenzoic acid. 
Dihydropteroate synthase catalyses the formation of dihydropteroate from 
hydroxymethyldihydropterin, which ultimately results in reduced pyrimidine 
synthesis and thus reduced DNA, serine and methionine formation. Although 











Chapter 1: Introduction 
resistance to sulfonamides due to single mutations on the corresponding gene is widespread.33 
Dapsone 1.10 
~ N~ 
H2N~_~ v 02-NH~ 
Sulfadoxine 1.9 MeO OMe 
\ } -~ }II""~CI 
Figure 1.8: 
o OH Atovaquone 1.11 
Chemical structures of sulfadoxine, dapsone and atovaquone 
The last class of nucleic acid inhibitors is the naphthoquinones, with the most efficacious 
example being atovaquone 1.11 (Figure 1.8). Atovaquone is thought to inhibit mitochondrial 
respiration in the parasite and is used in combination with proguanil to give rise to Malarone®. 
Although the mode of action and synergy of this combination is not completely understood, its 
activity has been attributed to inference with mitochondrial membrane potential.33 
1.5.2.1.1 Inhibitors of Protein Synthesis 
Antibiotics such as tetracycline 1.12 and doxycycline 1.13 (Figure 1.9) are often used in 
conjunction with other drugs to combat resistant P. Jalciparum malaria or alone as a prophylactic 
agent. They inhibit parasite protein synthesis by acting on the ribosomes of the mitochondria 
and/or apicoplast. 
OH 
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1.5.2.2.4 Drugs Generating Oxidative Stress 
This group of antimalarials consists of artemisinin 1.14 and its semi-synthetic 
derivatives (most commonly used artemether 1.15 and sodium artesunate 1.16, Figure 
1.10), which are used for treatment of both uncomplicated and severe Jalciparum 
malaria. The artemisinins are very effective antimalarials due to their high potency, 
low prevalence of drug resistance and relative safety.36 Artemisinin and its derivatives 
are preferentially used in combination with mefloquine in order to reduce 




R = CH3. Artemether 1.15 
R = COCH2CH2C02Na, Sodium Artesunate 1.16 
CH3 
Figure 1.10: Chemical structures of artemisinin and derivatives 
Although the mode of action is not completely understood, it is generally accepted 
that activity is due to the generation of free radicals by an haem-iron mediated 
mechanism, eventually resulting in total disorganization of the parasite.33 One 
suggested mechanism involves cleavage of the peroxide bond in the presence of Fell 
haem, followed by electron transfer generating free radicals in the parasitised red 
blood cells, followed by alkylation of the parasite proteins.38 The reactive free radicals 
generated may also cause oxidative stress. However, there is some skepticism 
regarding this mode of action as it has not been confirmed in vivo. Other hypothetical 
proposals to account for artemisinin antimalarial activity includes inhibition of 
nuclear factor NF -kB and inhibition of inducible nitric oxide synthase, an enzyme that 
catalyses the production of nitric oxide.39 Nitric oxide is a free-radical gas that easily 
diffuses through cell membranes and has influences on many physiological processes. 
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1.5.3 Cysteine Proteases as Targets in Antimalarial Chemotherapy 
Malarial cysteine proteases play crucial roles in parasite infection and development 
and thus have been considered as preferential targets for therapeutic interventions. 
Parasitic cysteine proteases contain two principal amino acid residues that are actively 
involved in the hydrolysis of peptide bonds, namely Cys 25 and His 159. 
The cysteine proteases utilize the cysteine thiol group for nucleophilic attack on the 
amide carbonyl, thus hydrolyzing amide bonds in peptides and proteins. Cysteine 
protease inhibitors, which have electrophilic moieties, exploit this mechanism by 
reacting with the active-site cysteine residue. Incubation of cultured malaria parasites 
with cysteine protease inhibitors developed swollen food vacuoles that contained 
large quantities of undegraded globin, implicating a role for the falcipains40 (section 
1.3.2.2). Recent studies have demonstrated that cysteine protease inhibitors not only 
blocked globin hydrolysis but also inhibited earlier stages in haemoglobin degradation 
pathway,41 alluding to the fact that cysteine proteases are also required for initial steps 
in the haemoglobin degradation. It has also been shown in vivo that a fluoromethyl 
ketone is capable of curing a murine infection of malaria42 and similarly a vinyl 
sulfone cysteine protease inhibitor were also shown to be potent against murine 
models of malaria.43 The degree of inhibition correlated with their inhibition of 
haemoglobin degradation and parasite development, further supporting the hypothesis 
that falcipain is the cysteine protease required for haemoglobin degradation. There is 
also evidence that falcipain 2 is involved in cell rupture and release of merozoites?6 
All of the above implies that cysteine proteases are potential targets for antimalarial 
chemotherapy. 
1.6 Fundamental Understanding of Cancer 
Cancer is a general term to describe many disease states, each of which is 
characterized by cancer cells that undergo a rapid, abnormal and uncontrolled cell 
division.44 In normal tissues, the rate of new cell growth and death are kept in balance, 
ensuring that each tissue maintains a size and architecture appropriate to the body's 
needs. In cancer cells this balance is disrupted, with the malignant transformation of a 
cell resulting through the accumulation of mutations in specific classes of genes 
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fi~ur~ 1.11: COOlpa,ison of ooTmal cell di"isioo and uf1<Dntroll.d gToMh In "ne ... cell'" 
Two cla,ses of genes, proto-oncog~nes and lllITIOT suppressor gen~" which stimulate 
~nd inhibit cell division respectively. account lor much of the Wlcontrolled 
proliferation associated with canccr!l Mutated fnnns of pmln-oncngen.::s called 
carcinogenic oncogenes can cause the stimulatory proteins to bt.come overactive, 
resulting in excessive multiplication. Mutations in tumor ,llppres,or genes, on the 
other hand, cause inactivation of suppressor proteins and thus depriving thc cells of 
needed restraints on proliferation. rhe body docs however have backup systems that 
guard against uncontrolled division. One such system is lhe cell's ability to tmdergo 
apoptosis, where the cell commit, suicide if some ess~ntial compon~ms are damaged 
or deregulated. De.-doping cancer cdb d~vise several mdilods of evading apoplosis, 
sllCh as inactivating the p53 prot~in, "'hich help> to trigger cell suicjd~, or by making 
exces,jve amounts ofthe prot~in Flc1-2, which wards olT apoptosis:J A,sociuted with 
unconlroll~d cell gro""h and division is Ihe invasion of the tumor into surrmmding 
normal tissue. Metastasis is the most fe~red aspect of cancer and what in fact makes 
cancer,o lethal. Malignant cells ha.-e the ability 10 ,pr~ud to dislant sit~s in the hody, 
by evading inhibitory me,sage, issued Irom n~ighhollT tissllCs, and thus disrupting 
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Fij!ul" 1. 12: Cnmporison nj mal ignanl and h"ni~n ,umor," 
To mda'ta.~izc succ<,~,fully. cancer cd l ~ have t,) detach Ihcmsclvc~ fwm their 
original location, invade a blood or lymphatic vessel. travel through the circulation tn 
a distant site and establish a new tumor. At en:ry point. cancer cells must evade the 
controls that keep llOnnal cells in place. 
1.7 Current Treatment for Cancer 
"'·lost .urrent treatments aim to combat lln<;omTolled g:ro"'lh, !i~sue inv,,<;ion and 
metastasis and include surge!)', radiation and ,h~motJwrap)' . 
1.7. 1 Su~el)' 
Surgery was the earl i",,! estahl i,hed therapy for canc~r and "h~,"" feasible is the mo,t 
widdy u<;<,d approa<:h, Surgical removal of a tumor ha~ benetits ,,,eh as being quick, 
efficient and provide~ a method to confirm (hat a (umor has been completely excised. 
Unfortunatdy, this lorm oftreatm~nt has several limitations:'" 
I. Completc elimination of microscopic ext~nsions of .am'cr .clls is not 
guarantced 
11. Large amounts <.,f ll<'althy tissue may ha'~ to be r~mo,~d damaging 
func tinning or appearance 
Ill. Cancerous cells in vital organs or structures cannot be surgically ~mo'ed 
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1.7.2 Radiation Therapy 
Radiation therapy involves the irradiation of powerful x-rays or gamma rays in the 
region of the tumor. Radiation treatment causes sufficient genetic damage to kill cells 
directly or to induce apoptosis. In many instances, radiation therapy is preferable to 
surgery as healthy tissue is preserved, as normal tissue can recover more readily than 
cancerous cells. It is also has other advantages of destroying microscopic extensions 
of cancerous tissue and treatment is received without hospitalization. Cancer of the 
uterine cervix and larynx, early stages of both prostate cancer and Hodgkin's disease 
are treated well with radiation therapy.45 As with surgery, this therapy may fail to 
eradicate all cancerous cells and also cannot treat widespread metastasis, as irradiating 
the whole body will damage vital delicate tissue. 
1. 7.3 Chemotherapy 
One common denominator for all types of cancers, due to rapid cell division, is the 
constant demand for DNA and its precursors. Therefore, most chemotherapeutic 
agents typically exert activity by interfering with the cells ability to replicate DNA, 
with fast-growing cancer cells being more drastically affected than normal cells. 
Some common families of chemotherapeutic agents include the antimetabolites, 
topoisomerase inhibitors, alkylating agents and plant alkaloids.45 Antimetabolites 
exert activity by mimicking molecules necessary in biochemical reactions. An 
example is the transition-state inhibitor 5-fluorouracil 1.17, which is converted to the 
fluorinated analogue of 2' -deoxyuridylic acid 1.18 in the body (Figure 1.13) and is 
used to treat breast, liver and skin cancers.46 This analogue binds covalently and 
irreversibly to the active site of the thymidylate synthase, an enzyme that catalyses the 
conversion of2'-deoxyuridylic acid (dUMP) to deoxythymidine-5-phosphate (dTMP, 
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Topoisomerase inhibitors prevent topoisomerase enzymes from reattaching the cleaved ends of 
DNA during replication. This causes DNA strand breaks in cells that are dividing, resulting in 
cell death. Alkylating agents are highly electrophilic compounds that form strong covalent bonds 
with nucleophilic groups in DNA "building blocks". This disruption produces defects in the 
normal double helical structure of DNA such as breaks and incorrect links between or within 
strands. If these defects are not repaired, apoptosis will be triggered. Cis-diammonia 
dichloroplatinum (II), known as cisplatin 1.19, is an alkylating agent used for the treatment of 
testicular and ovarian tumors (Figure 1.14). Cisplatin forms links within DNA strands, thus 
inhibiting transcription.46 The last family of chemotherapeutic agents are those derived from 
plants that can prevent cell division by binding to the protein tubulin. Tubulin polymerizes in the 
cell cytoplasm to form microtubles that have various functions within the cell such as exocytosis, 
release of neurotransmitters, and maintenance of shape and mobility of cells. Tubulin has crucial 
functioning in the mitotic phase of the cell cycle. Upon initiation of cell division, microtubules 
depolymerize to tubulin, which repolymerize to form spindles that act as a framework on which 
duplicate chromosomes are transferred to the daughter cell. 
Drugs such as vinblastine 1.20 and vinblastine 1.21 (Figure 1.14) bind to tubulin and prevent this 





R= CH 3 vinblastine 1.20 
R= CHO vincristine 1.21 
Figure 1.14: Chemical structures of cisplatin, vinblastine and vicristine 
The available chemotherapeutic agents often bring on serious side effects that limit the doses 
physicians can administer, and many of the most common cancers are not yet curable with 
chemotherapy alone and thus also involve surgery and radiation. Some of the current 
chemotherapy has another fundamental weakness, that being drug resistance to structurally and 
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CHAPTER 2 
4-AMINOQUINOLINE-BASED CHALCONES AND MANNICH 
BASE DERIVATIVES 
2.1 Introduction 
In this MSc project, one of the main objectives is to develop single agents that provide both 
inhibition of the growth of malaria parasites and of tumour cells. The strategy was to hybridize 
chalcone moieties and their Mannich base derivatives with the 4-aminoquinoline moiety. This 
dual drug concept uses the basic structure of various known antimalarial or anticancer 
pharmacophores and/or bioactiphores, with different modes of action, in order to exert maximum 
activity and overcome or prevent drug resistance. The following chapter describes the known 
antimalarial and anticancer activities of the aforementioned organic scaffolds and the concept of 
cyclodextrin inclusion complexes in an attempt to render these dual drugs water-soluble. 
2.2 4-Aminoquinolines in Malaria 
2.2.1 Introduction 
Of all the current clinically established antimalarials, the 4-aminoquinolines have proven to be 
the most significant and efficacious for the treatment and prophylaxis of malaria. The most 
important of the 4-aminoquinolines, chloroquine was as a result of a rigorous antimalarial 
research program in the United States during World War II and has been the basis of antimalarial 
chemotherapy for over 50 years. Chloroquine is one of the most successful chemotherapeutic 
agents ever synthesized based on its safety, affordability and high efficacy. However, the spread 
of drug resistant parasites has reduced the efficacy of 4-aminoquinoline antimalarial drugs. 
Nonetheless, there remains a great deal of interest in 4-aminoquinolines, the sub-structural 
moiety of chloroquine vital for antimalarial activity, in the hope that new derivatives with similar 
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2.2.2 Mechanism of Action 
Despite many years of use and study, the exact mode of action of chloroquine and 
other 4-aminoquinoline antimalarials remain to be elucidated. It has been known since 
the 1960s that chloroquine and other 4-aminoquinolines form complexes with 
haematin I and there is now considerable evidence that "haem" [either in the form of 
free haematin, histidine rich protein 2 (HRP-2) bound haematin or haemozoin] is the 
target of these drugs. Some of evidence leading to this conclusion includes the 
following: 
1. Chloroquine IS only active against the blood stages of the Plasmodium 
parasite, and in particular against the trophozoite stage during which 
haemoglobin degradation is maxima1.2 
11. Plasmepsin inhibitors, which reduce the release of haematin from 
haemoglobin, are antagonists of quinoline antimalarials.3 
Ill. Although chloroquine is chiral, both enantiomers are active, signifying an 
achiral target, consistent with haematin.4 
IV. The biological activity of chloroquine and 4-aminoquinoline derivatives are 
directly proportional to the degree of inhibition of ~-haematin. 5 
In this view, the commonly accepted hypothesis of the observed antimalarial activity 
of the 4-aminoquinolines is interaction with haematin in the food vacuole of the 
parasite, inhibiting haemozoin formation and so interfering with the detoxification of 
haematin. 
Selective accumulation of chloroquine in the food vacuole can be explained by its 
weak base properties, and occurs by passive diffusion. At neutral pH, chloroquine can 
diffuse freely through membranes, and upon entering the acidic food vacuole, 
chloroquine is protonated and trapped within the food vacuole. The precise manner in 
which the 4-aminoquinoline derivatives inhibit haemozoin formation and how this 
leads to parasite death is unresolved. One possibility is that the drugs form 1r:-7t 
complexes with free haematin, preventing its incorporation into haemozoin and so 
causing an accumulation of haem, which is toxic to the parasite. The chloroquine-
haematin complex itself is also toxic to the parasite. However, the presence of haem 
does not seem to be fatal to the parasite as it can be disposed of by diffusion out of the 
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the haem-chloroquine complex that is the toxic event as it protects haem from 
degradation by glutathione. The accumulation of haem or haem-chloroquine complex 
in the cytosol and membranes of the parasite causes or at least contributes to cell 
death. It is likely that these drugs inhibit parasite growth by a number of additive 
effects. The uncertainty over the mode of action of chloroquine and other 4-
aminoquinolines is a serious obstacle in the rational design of novel drugs of this type 
2.2.3 Mechanism of Chloroquine Resistance 
Drug resistance in the case of malaria can be defined as "the ability of a strain of the 
malaria parasite to multiply or survive in the presence of normal dose or up to the 
maximum tolerated concentration of an antimalarial drug".7 Resistance to chloroquine 
was first reported in 1959 in South America and since then has spread to most malaria 
endemic areas of the world. The fact that chloroquine resistance appeared many years 
after its use suggests the resistance has a mutagenic basis. Chloroquine-resistant 
parasites accumulate less drug in the food vacuole than the chloroquine-sensitive 
strains, excluding the drug from its site of action. 8 This could be a result of enhanced 
efflux, reduced uptake or a combination of both. Chloroquine resistance has been 
attributed to enhanced efflux, a mechanism known to operate in multi-drug resistant 
cancer cells. Resistance in these multi-drug resistant cancer cells can be reversed in 
vitro by the chemosensitiser verapamil and it has been confirmed that verapamil could 
improve the sensitivity of chloroquine resistant parasites to chloroquine, suggesting a 
similar mechanism of resistance. Multi-drug resistance (MDR) in cancer cells is 
brought about through the action of an A TP-dependent transport protein called P-
glycoprotein (Pgp), which pumps the drugs away from its site of action.9 P. 
Jalciparum possesses a transmembrane glycoprotein, P-glycoprotein homologue 1 
(Pgh 1), coded for by the gene pJmdr 1 which resembles the mammalian protein Pgp. IO 
Based on the current evidence available, chloroquine resistance cannot be conferred 
by Pghl alone and requires mutations in other genes. Recently, resistance is strongly 
linked to mutations in the pJert gene, which codes for the protein PfCR T (P. 
Jalciparum chloroquine resistance transporter) located on the food vacuole membrane 
of the intraerythrocytic parasite. I 1,12 A common mutation across chloroquine resistant 
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Hypotheses for reduced drug accumulation due to altered uptake rate include 
mutations in the Na + /H+ exchanger13 , change in vacuolar pH 14 and alteration in 
membrane permeability. 
2.2.4 Overcoming Chloroquine Resistance 
Chloroquine resistance may be reversed by two possible methods; that is with the use 
of chemosensitisers or by making structural changes to the drug. Ideally, 
chemosensitisers are structurally and functionally distinct compounds without any 
inherent cytotoxicity, which can completely reverse the resistance of cells to the 
action of the drug. Since the initial demonstration of verapamil chemosensitisation of 
chloroquine-resistant parasites, many other agents have been identified that are 
capable of reversing resistance in vitro to some extent. IS All of these compounds 
contain a protonatable nitrogen and sensitise resistant P. Jalciparum to chloroquine by 
increasing drug accumulation. The phenomenon of chemosensitisation has been 
extended to other quinoline type drugs that show resistance and future prospects for 
the use of quinoline compounds have thus improved considerably. 
There are a significant number of review articles reporting on the antimalarial 
properties of 4-aminoquinolines.S,1S-18 Studies reporting on the structural 
modifications to chloroquine and the resultant effect on activity against chloroquine 
resistant parasites are also numerous. Chloroquine analogues that retain the 4-amino-
7-chloroquinoline moiety but in which the aminoalkyl side chain is changed are active 
against chloroquine resistant parasites. This is observed in compounds with shortened 
(2-3 carbon) and lengthened (l0-12 carbon) side chains,19 those with shortened side 
chains with methyl branches and bulky groups attached to the terminal amine20 and 
those with bulky groups such as ferrocene in the side chain.21 Modifications to the 
aminoquinoline nucleus such as replacement of the 7 -chI oro group or substitutions on 
the aminoquinoline ring had only moderate effects or no effect at all. 19 Removal of the 
7-chloro group actually resulted in a marked decrease in antiplasmodial activity and is 
thus crucial for activity. Due to the likelihood that these structurally modified 
compounds act against the same target as chloroquine, this target remains a useful one 
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dual acting drugs incorporating the 4-aminoquinoline moiety. Some examples 
include: 
1. The 4-aminoquinoline hydroxamate-basedl,4-bis(3-aminopropyl) piperazines 
2.1 (Figure 2.1) which potentially target the Plasmodium Jalciparum 
aminopeptidase of the Ml family of metalloproteases (PfA-Ml) as well as 
inhibiting haemozoin formation. 22 
11. The 4-aminoquinoline-based glyoxylylhydrazones 2.2 (Figure 2.1), which may 
act as cysteine protease inhibitors and metal chelating agents, thus potentially 
targeting the fa1cipains and the metalloproteases falcilysin and PfA-M1.23 
111. The isatin-based 4-aminoquinoline thiosemicarbazones 2.3 (Figure 2.1), which 
have activity against the cysteine protease falcipain 2 and are also capable of 
metal chelation and inhibition of haemozoin formation. 24 
HN~ ~~N,/R 
~ ~ ~ £6'-': ~ ~N~ R .0 ~ ~N_ ~ -~, CI N I( I( OH 
o 0 
)lA . .J 2.2 
CI N 
2.1 R= NHz, H, isopropyl 
2.3 R = H, CI 
Figure 2.1: Chemical structures of 4-aminoquinoline-based dual drugs 
2.3 Quinoline Derivatives in Cancer Therapy 
2.3.1 Background 
Chloroquine and other quinolines have demonstrated the ability to act as multi-drug 
resistance reversal agents.25-28 A number of quinolines including chloroquine have 
also been reported to act as differentiating-inducing agents, that modulate gene 
expression to control tumor growth?9 A series of quinoline derivatives have been 
reported as potent and selective cytotoxic agents. 3D,3] Recently, chloroquine has been 
reported to inhibit cell growth and induce cell death.32 These activities of chloroquine 
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2.3.2 Multi-drug Resistance Reversal Agents 
Multi-drug resistance (MDR) is a major obstacle III cancer chemotherapy. As 
discussed in the previous section (2.2.3), it is generally believed that the most 
common mechanism of resistance is P-glycoprotein-mediated MDR. Increased 
expression of P-glycoprotein (Pgp), which is expressed on the plasma membrane of 
drug-resistant tumor cells, lowers the intracellular concentration of cytotoxic agents 
by effluxing them out of the cells. MDR reversal agents are thought to compete with 
anticancer drugs in binding to Pgp, or block the efflux mechanism, thus resulting in a 
decrease of drug efflux.9J3 Chloroquine and various quinoline derivatives were 
studied in vitro and shown to act as multi-drug resistance reversal (MDRR) agents for 
vincristine-resistant and vinblastine-resistant cancer cell lines?5 It was found that 
some derivatives were more effective MDRR agents than verapamil and showed very 
low toxicity.34 Quinine and its derivatives have shown activity in vitro and in vivo as a 
MDR reverters in non-Hodgkin's lymphoma, vinblastine-resistant and hormone-
refractory prostate cancer cells.26-28 The structural requirements important for MDR 
activity in quinoline derivatives are the presence of a nitrogen atom, a hydrophobic 
moiety, two or more planar aromatic rings and a positive charge at physiological 
pH.25J3 When the quinoline ring is replaced by a naphthyl or phenyl ring, activity 
decreases considerably. Thus the quinoline moiety plays an important role in drug 
.. 25 actIVIty. 
2.3.3 Differentiation-inducing Quinolines 
Differentiation therapy entails the use of chemotherapeutic agents that modulate gene 
expression to control tumor growth?9 The therapeutic effect of most current 
differentiation-inducing agents is not strong when compared to conventional 
chemotherapeutic agents and are used in combination with conventional 
chemotherapy or radiation therapy to potentiate the effect.35 In a study conducted by 
Strobel et af it was demonstrated in vitro that various quinoline derivatives stimulated 
cell differentiation at growth inhibitory concentrations in MCF -7 human breast tumor 
cells.29 Among the compounds tested, quinolines with a 4-substitution such as 
chloroquine, hydroxychloroquine, amodiaquine, quinidine and quinine, were most 
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Three potential mechanisms are proposed to account for the observed cell growth 
inhibition and differentiation: (i.) E2FI suppression, (ii.) DNA damage and (iii.) 
histone deacetylase (HDAC) inhibition.29 
1. The transcription factor E2FI is a cell regulatory protein that promotes cell 
growth by stimulating the G I-S cell cycle transition. It also plays a role in cell 
differentiation, with down- regulation necessary for differentiation of cells, as 
well as having the potential to initiate apoptosis in cells, making E2F 1 an 
excellent molecular target. Strong suppression of E2F 1 alone inhibits growth 
by preventing cell cycle progression. The data in the study demonstrated that 
suppression of E2F 1 by the quinoline derivatives is characteristic of in vitro 
activity and is thus consistent with these hypotheses. 
11. Moderate suppression ofE2FI, together with generation of DNA damage, also 
promotes differentiation through activation of the p53-Rb pathway. The 
quinoline derivatives screened exhibited variable capacities to induce DNA 
damage and apoptosis. 
111. Histone deacetylases are a common target of tumor differentiation agents36 
and interestingly many of the HDAC inhibitors were initially used as 
antiprotozoal agents.37 Histones are proteins that form a scaffold around which 
a cell's DNA is wrapped. Modification of these histone proteins by acetylation 
controls the tightness of the DNA around the histone proteins and, 
consequently, controls the expression of the genes. In cancer, increased HDAC 
expression results in deacetylation of histone proteins, which causes the DNA 
to be wrapped too tightly around the histones, thereby inhibiting gene 
expression. The inappropriate deacetylation of tumor suppressor genes, a 
molecular defect, may silence these genes, resulting in the progression of 
cancer. HDAC inhibitors selectively switch on these tumor suppressor genes, 
something traditional chemotherapy may not do. 
2.3.4 Anti-tumor Activity of Quinoline Derivatives 
Quinoline derivatives have been evaluated in vitro as anti-tumor agents in comparison 
to available drugs such as adriamycin and vincristine. Abel et al reported a series of 
azoylylalkylquinolines that were more cytotoxic on KB cells (human nasopharyngeal 
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adriamycin.3o Another study conducted evaluated the anticancer activity of another 
series of quinoline derivatives against the human breast cancer T 4 7D cell line, with 
some compounds showing a growth inhibitory effect greater than that of vincristine 
and similar to that of adriamycin.31 Recently chloroquine has demonstrated the ability 
to inhibit cell growth and induce cell death, depending on the concentration 
administered, in A549 lung cancer cells.32 It was found at concentrations from 0.25 -
32 j..lM, chloroquine inhibited A549 lung cancer proliferation by increasing lysosomal 
volumes and thus enlarging the plasma membrane surface. Apoptosis and necrosis 
occurred at chloroquine concentrations above 32 j..lM. Chloroquine thus may be of use 
in lung cancer therapy by careful dosage administration. Therefore, from the evidence 
mentioned above, potential anti-tumor agents containing a quinoline ring are good 
candidates for further investigation. 
2.4 Justification for Research into Aminoquinolines 
As it has been demonstrated in sections 2.2 and 2.3, future research into 
aminoquinoline derivatives is still warranted and justified on the basis of several 
considerations: 
• Aminoquinolines have proven to be the most successful class of compounds 
for the treatment and prophylaxis of malaria 
• Drug resistance is due to reduced drug accumulation and there is no change in 
the structure of the drug target 
• Analogues of chloroquine have shown activity against chloroquine resistant 
strains of the parasite 
• Haemoglobin degradation pathway has a proven history of being an excellent 
therapeutic target 
• 4-Aminoquinolines have acceptable toxicity profiles and are well tolerated 
• Shown to act as multi-drug resistance (MDR) reversal agents of certain cancer 
cell lines 
• Quinoline derivatives have demonstrated the ability to act as anti-tumor and 
differentiation-inducing agents. 
• Chloroquine and other quinoline derivatives have shown inhibition of cell 
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2.5 Bioactivities of Chalcones 
2.5.1 Introduction 
Chalcone is a broad term given to compounds that have a 1,3-diphenylprop-2-en-l-
one scaffold (Figure 2.2) and occur naturally in plants as precursor compounds for 
synthesis of different classes of flavonoids. There has been a resurgence of scientific 
interest in this group of natural products due to a wide range of beneficial biological 
activities, which are reliant on the structural modifications made to the chalcone 
scaffold. Some examples include substituents on the aromatic rings A and B,38 
replacement of the phenyl rings with various heterocyclic and polyaromatic rings,39 
substitution on the enone linker40 and cyclisation of the chalcone.41 
o 
R R' 
Figure 2.2: General structure of chalcones indicating rings A and B 
The presence of the reactive a-B-unsaturated system and the relative flexibility of 
chalcones allow interactions with a diverse range of enzymes and receptors, thus 
chalcones are recognized as a "privileged structure" in drug design. Pharmacological 
activities cited in the literature include anti-inflammatory,42 antileishmanial,38,43 anti-
invasive,44 nitric oxide inhibition45 and modulation of P-glycoprotein-mediated multi-
drug resistance,46 to name but a few. In the context of this project, antimalarial, anti-
proliferative and tumour-reducing properties are known and will be discussed in the 
sections that follow. The multiple activities and structural diversity of chalcones make 
this class of compounds a good candidate as dual acting drugs, to provide inhibition of 
both the malaria parasite and tumour growth. 
2.5.2 Antimalarial Activity of Chalcones 
Interest in the antimalarial activity of chalcones was encouraged by the discovery of 
licochalcone A (Figure 2.3), an oxygenated chalcone isolated from the roots of 
Chinese liquorice, which showed significant antimalarial activity in vitro and in 
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chalcones and their derivatives using both molecular modelling and in vitro testing, 
with malarial cysteine protease acting as the most likely target. 39 
HO OH 
o OMe 
Figure 2.3: Chemical structure of licochalcone A 
Most of the activity of chalcones is due to the a-~-unsaturated system, which is a 
Michael acceptor and is capable of undergoing conjugate addition with the sulfhydryl 
group of the cysteine side chain (Figure 2.4). In addition, this conjugated linker 
generates a linear, almost planar structure, that has been demonstrated by modelling 
programs to have favourable interactions with the long cleft of the active site of 
malarial cysteine protease.39 
t Thiol RSH 
o H SR 
------. Ph~Ph 
Figure 2.4: Reaction of a representative chalcone (Michael acceptor) and a nucleophilic thiol (RSH)48 
However, investigations into cysteine protease inhibition as the mode of action has 
established that antimalarial activity is not always correlated with inhibition of 
malarial cysteine protease 49 and this comes as no surprise due to the wide range of 
pharmacological properties of chalcones.5o A more recent target investigated for 
antimalarial chalcones are the parasite-induced new permeability pathways.51 New 
permeability pathways (NPP), that are absent from the uninfected erythrocyte 
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have a higher permeability to a range of low molecular weight solutes, inorganic and 
organic ions, amino acids, sugars and nucleosides. The primary role ofNPP is thought 
to be acquisition of nutrients but there is evidence that shows that they may have a 
bifunctional role and are also required for the removal of metabolic waste from the 
infected cells,52 making these pathways an attractive drug target. A series of chalcones 
with known antimalarial activity were screened as inhibitors of new permeability 
pathways and a significant number had good activity.51 The structural requirements 
for antimalarial activity in chalcones will be discussed in section 3.1.1. 
2.5.3 Cytotoxic and Chemoprotective Properties of Chalcones 
Chalcones have been identified as cytotoxic and chemoprotective agents by various 
research groups, and have exhibited anticancer activity against a variety of cancer cell 
lines and animal cancer models. The recognition of these broad anticancer properties 
have resulted in a sustained interest in chalcones and in understanding how they exert 
their cytotoxic or chemoprotective activity. 
2.5.3.1 Cytotoxic Chalcones 
Chalcones have displayed cytotoxic activity against many different tumour cell lines 
in the low micromolar range (lC5o < 50~M).48 Most of the reports of anticancer 
activity are focused on the anti-mitotic activity of chalcones. Edwards et al proposed 
that chalcones interact with the thiol residue present at the binding site of tubulin,53 
interfering with the dynamics of tubulin polymerisation and depolymerisation, leading 
to mitotic arrest. This hypothesis was based on the structure-activity relationships of 
colchicine-tubulin binding and the observation of preferential reactivity of the enone 
moiety of chalcones towards thiols, thus implying chalcones should interact in a 
similar way to colchicine. This hypothesis has been backed up by a subsequent study 
in which an alkoxylated chalcone was shown by cell cytometry to cause an 
accumulation of cells in the G21M phase, which is an indication of disruption of the 
mitotic spindle.54 Chalcones also react readily with glutathione (GSH), a protein thio1 
important for detoxification of xenobiotics. This chalcone-GSH interaction has been 
widely investigated55 and has shown to increase the toxicities of chalcones. Indeed, 
depletion of intracellular GSH is associated with pathways leading to apoptosis and 
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between the human oncoprotein MDM2 and p53.57 The MDM2 oncogene, which is 
over-expressed in a variety of tumours, inhibits the tumour suppressor protein p53 by 
binding to its transactivation domain and thus allowing cell cycle progression of 
defective cells. Chalcones have shown to bind in or near the tryptophan pocket of the 
p53 binding cleft of MDM2 and promote dissociation of the complex, releasing the 
tumour suppressor protein p53. There are numerous series of hydroxylated chalcones 
that have shown potent cytotoxic activities against tumour cell lines such as B 16 
murine melanoma, HCT 116 human colon cancer, A31 human epidermoid carcinoma 
as well as a non-tumour endothelial cell line (human umbilical venous endothelial 
cells or HUVEC).58 Due to the fact that these cancers differ significantly in their 
genetic source as well as the observation of selective cytotoxicity towards the 
HUVEC cell line, the authors proposed that these chalcones act as angiogenesis 
inhibitors. 59 Other proposals for activity of hydroxychalcones include the induction of 
apoptosis,6o and induction of mitochondrial uncoupling and membrane collapse.61 
2.5.3.2 Chemoprotective Chalcones 
Cancer is the culmination of years of genetic and biochemical changes in cells, rather 
than a single, fixed event and there is the possibility for intervention at several 
biological levels. Chemoprotection is an approach that uses natural or synthetic 
compounds to prevent, halt or reverse carcinogenesis. Chalcones were initially 
considered as chemoprotectants due to their structural similarity to stilbene, a motif 
found in anti-estrogen drugs such as tamoxifen, that has demonstrated the ability to 
prevent breast cancer in women who are at increased risk.34,38 Secondly, the a-~­
unsaturated system of chalcones can bind to certain receptors leading to either 
inhibition of enzymes important for a carcinogenic event or induction of phase II 
enzymes, a widely recognized chemoprotective mechanism.48 The chemoprotective 
roles of chalcones are mainly due to their antioxidant properties and their ability to 
scavenge free radicals, which are involved in various stages of carcinogenesis.48 A 
single antioxidant pharmacophore may not exist in chalcones but phenolic hydroxyl 
groups have been found important for antioxidant activity. Chalcones are potential 
inducers of phase-2 enzymes such as glutathione S-transferase and quinone reductase, 
which are involved in the metabolism of xenobiotics.49 Chalcones can also exert an 
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2.6 Mannich Bases 
2.6.1 The Mannich reaction 
The Mannich (aminomethylation) reaction involves condensation of a substrate 
possessing a reactive hydrogen atom with a nonenolizable aldehyde, usually 
formaldehyde, and a primary or secondary amine (Scheme 2.1). The product of this 
multi-component condensation reaction is known as a Mannich base, in which an 
aminomethyl group replaces the active hydrogen of the substrate. Since the initial 
studies by Carl Mannich of the chemistry of this reaction, Mannich bases have been 
the subject of numerous mechanistic studies62-64 and have received attention for their 
synthetic utility,62,63,65 pharmaceutical activities and numerous other applications in 
polymer chemistry such as surface active agents, paints and dyes.66 
R-H 
R1 , 






Scheme 2.1: Representation ofthe Mannich reaction 
The interest in Mannich base derivatives of target compounds in this project is two-
fold. Firstly, the Mannich reaction introduces a basic function that can increase the 
water-solubility via salt formation, which is important for bioavailability of target 
compounds. The basicity also ensures target compounds could potentially accumulate 
in the acidic food vacuole of the malaria parasite, Secondly, Mannich base 
derivatives of target compounds will be very reactive and at a lower pH associated 
with tumour cells or the acidic food vacuole, can undergo deamination leading to the 
formation of vinyl ketones. These generated vinyl ketones can potentially react with 
various cellular thiols important for parasite or tumour growth (described in sections 
2.5.2 and 2,5,3). This change in pH may therefore be used as a prodrug concept 
whereby the cytotoxic agent is released at its site of action. 
2.6.2 Antimalarial Mannich Bases 
Since amodiaquine 1.2 (Figure 1.6, p 11), a Mannich base derivative of chloroquine, 
was shown to be an effective antimalarial against chloroquine-resistant parasites, there 
have been numerous studies of structural analogues of amodiaquine that may 
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has a low bioavailability and is rapidly metabolised to a bis-deethylated metabolite71 or excreted 
as the 5'-glutathionyl ester.72 Investigations into Mannich base compounds with structurally 
modified side chains that are less susceptible to metabolism led to antimalarials such as 
amopyroquine 2.4, tebuquine 2.5 and the tert-butyl analogue 2.6 (Figure 2.5). All of these 
analogues were found to be more active against chloroquine-resistant strains of the P. jalciparum 
parasite than amodiaquine and chloroquine.67-7o 
CI 
I ~ /- f: 
CI N 
2.6 
R = methyl, ethyl, propyl, isopropyl, 
s-butyl,cyclohexyl 
Figure 2.5: Chemical structures of amodiaquine analogues 
Ward et al undertook a structure-activity investigation on N-tert-butylamino derivatives of 
amodiaquine 2.7 (Figure 2.5) to determine factors important for antimalarial activity.69 The 
results indicated that replacement of the diethylamino group with a N-tert-butylamino group led 
to a substantial increase in activity in both chloroquine-resistant and chloroquine-sensitive 
strains. Drug lipophilicity and the type of alkyl side chain (especially a propyl or isopropyl 
group) at the 5' position were found to be important for activity. More recently, a high-
throughput screening of compounds identified Mannich bases exemplified by the unsaturated 
Mannich base 2.8 (Figure 2.6) as a new set of thioredoxin reductase (TrxR) mechanism-based 
inhibitors.73 An a-a-dimethyl-~-amino ketone 2.9 for which deamination is blocked and the 
saturated Mannich base 3-(dimethylamino)propiophenone 2.10 (Figure 2.6) were designed in 
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Thioredoxin reductase catalyses the reduction of the protein thioredoxin disulfide 
(Trx) to the dithiol in the presence ofNADPH (equation 2.1). 
INADPH + Trx(Sh NADP+ + Trx(SHh I 
• (equation 2.1) 
TrxR shows potential as a drug target as it protects the parasite against oxidative 
stress and is essential for survival of the parasite.74 Another favourable factor ofTrxR 
as a antimalarial drug target is that the protein sequences at the C-terminal cysteine 
residue of parasitic TrxR differ significantly from human TrxR and thus inhibitors 
may be designed to interact specifically with the parasite enzyme.73 Davioud-Charvet 
et aF3 hypothesised that the Mannich bases containing electrophilic centres could 
inactivate TrxR by interacting with the C-terminal cysteine residues, Cys 540' and 
Cys 535'. It was found that Mannich base 2.8, which is capable of bisalkylation, was 
the most effective in comparison to 2.9 and 2.10 which only have one electrophilic 
centre capable of alkylation. The proposed mechanism for TrxR inactivation by the 
unsaturated Mannich base 2.8 is outlined in Scheme 2.2. 
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Scheme 2.2: The proposed mechanism for TrxR inactivation by 2.873 
Inhibition of TrxR can only occur when the oxidized enzyme, (Eox), is converted by 
NADPH to its predominant reduced form, EH2. This two-electron-reduced form, 
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observed at approximately 540 nm, makes the thiols at Cys 540' and Cys 535' 
available to attack the olefinic bond. The Mannich base 2.8 undergoes a Michael 
addition with the most exposed thiol Cys 540', and then His509' catalyses 
deamination of 2.8, which is followed by addition of the thiol Cys535' to the 
generated double bond. The formation of the macrocyclic species 4 results in 
irreversible inactivation of the TrxR. 
2.6.3 Anticancer Properties of Mannich Bases 
Dimmock and collaborators have performed investigations into the anticancer and 
cytotoxic properties of Mannich bases.55 ,75,76 Interest in Mannich bases was spurred 
by the fact that these compounds could act as prodrugs of a,~-unsaturated ketones 
since Mannich bases can undergo deamination at physiological pH. This deamination 
has been demonstrated in vivo and simulated in vitro.75 There are several reasons for 
the evaluation of a,~-unsaturated ketones as anticancer agents. Firstly, these 
compounds react preferably as thiol alkylators and have an insignificant affinity for 
amino or hydroxy nucleophiles.77 Hence shortcomings of certain alkylating agents 
such as mutagenicit/8 and carcinogenicit/9 due to interactions with nucleic acids are 
avoided. The mode of action of these compounds also differs from current alkylating 
agents such as melphalan, which is useful in overcoming resistance that has developed 
towards this drug. Indeed it has been demonstrated that these a,~-unsaturated ketones 
display cytotoxicity towards melphalan-resistant and melphalan-sensitive tumour cell 
lines.80 Furthermore, these compounds have selective toxicity towards rapidly 
growing tumour cells compared with normal cells due to a higher demand of cellular 
thiols necessary in various processes of cell division and growth, as well as their 
involvement in detoxification mechanisms. Examples include inhibition of the mitotic 
phase of the cell cycle and inhibition of the enzyme TrxR and GSH necessary for 
detoxification of reactive oxygen species and xenobiotics. Results from numerous 
studies by Dimmock et al revealed that conversion of a,~-unsaturated ketones into 
their Mannich base derivatives, thus possessing two sites for thiol alkylation, was 
accompanied by an increase in bioactivity both in vitro and in vivo.75 This was 
attributed to the concept of sequential toxicity81 and several series of Mannich bases 
have been designed in light of this concept.55,75,76 Of note are the Mannich base 
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as well as various other cancer cell lines. 55 The hypothesis of sequential cytotoxicity 
is shown in Scheme 2.3 for a representative chalcone Mannich base derivative. 
Initially there is a nucleophilic attack by the cellular thiol at the ~-carbon of the 
olefinic bond (intermediate A), followed by deamination of the monothiol adduct 
(intermediate B) and attack by a second thiol at the generated double bond to give 
bisalkylated product C. This process of deamination and alkylation can occur again 
giving product E. Thus increased cytotoxic activity is not only due to the greater 
number of electrophilic sites available for nucleophilic attack by cellular thiols but 
also due to the successive release of two or more cytotoxic agents, which is more 
damaging to tumour cells than normal cells. 55 
• 
SR 
~c:?' OH _ .. _R_SH_~O R "" I "" I SR "" I I,? SR" RS H 0 R RS H 0 
E D 
Scheme 2.3: Reaction sequence illustrating the concept of sequential toxicity 
The increased reactivity of Mannich base derivatives of compounds containing an a,~­
unsaturated system may also be due to the stabilization effect of the reaction 
intermediate shown in Figure 2.7. This stabilization is aided by the inductive effect of 
the quadrivalent nitrogen atom and hydrogen bonding. 
+ 
Figure 2.7: Stabilization of reaction intermediate75 
Thus, Mannich base derivatives of chalcones are novel alkylating agents that display 
significant cytotoxic activity as well as being free mutagenic effects, making these 
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2.7 Cyclodextrins 
2.7.1 Chemical and Physical Properties ofCyclodextrins 
Cyclodextrins (CDs) are cyclic, toroidal shaped oligosaccharides that are the products 
of the enzymatic degradation of starch. Due to the unspecificity of the 
glucosyltransferase enzyme, the cyclic oligosaccharides are composed of D-
glucopyranose units of various lengths linked by a-I,4-glycosidic bonds.82 There are 
three major or parent cyclodextrins and several minor, rare ones that differ from each 
other by the number of glucopyranose units. The a-, ~- and y-cyclodextrins are made 
up of 6, 7 and 8 glucose units respectively and are crystalline, homogenous and 
nonhygroscopic substances83 (Figure 2.8). 
o 
HOH_~6 / X HOH;.HC 0 
~ .. ,y O~~ 
/._______ 2 0 H H 0 
----0 ~O 3 
(a) O. 
Figure 2.8: Schematic diagram of (a) conformation and labelling of glucopyranose unit, (b) a-CD, (c) 
~-CD and (d) y-CD 
As a consequence of the rigid 4C I-chair conformation of the glucopyranose units and 
intramolecular hydrogen bonding between 02-H" 03' and 02 ... H-03', the CDs have 
overall shape reminiscent of a 'truncated cone.' Intramolecular, interglucose hydrogen 
bonds stabilize the conformation of the CD macrocycles. Cyclodextrins have a 
hydrophobic cavity and a hydrophilic exterior. The hydrophobicity arises due to the 
cavity containing hydrogen atoms from the C3-H and C5-H methane groups, the C6-
H2 methylene groups and the glycosidic oxygens (04). The hydrophilic exterior is 
due to the primary hydroxyl groups (06) on the narrower side of the cone and the 
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cyclodextrins are s.oJuhle in aq~ol1s media and are capable of encapsulating 
hydrophobic gue,! molecules within their cavities. In order lo improv~ solubility's of 
parent cyck>dex!rin~. especially 11-CD, the hyUrOXi·j groups can be chemically 
ffil>dilied. For lhis ptlfpo~e. the 02 and 06 positions of j3-CD ha\' ~ been methylated to 
form heptakh;(2.6-di-O-methyl)-ll-cyck>dextrin (DJMFH) and additionally at the 03 
position to form heplaki>(2.J,6-1ri-O-mcthyl)-I'-cydodextrin (TRIMEB). Some of the 
c haracteri<;(ics of lhe parenl o;yclodexlrins are 8ummari zed in Table 3. 
T. hi, .1: eh""!",;,!",, (If ~-CD. r-CD ,nrl "(-CD" 
2.7.2 Cydodextrin Inclusion Complexes 
The most impol1an! Ji:aturc of cyclodcxtrins IS their ability to form inclusic'n 
complexes with various gu<:st molecules. The ca,"i~' allows Ihe CD to act as a host 
molecule to a ,"ariety of guest compounds, The inclusion of guest molecules ean oceur 
in t"o mo<k~: molecular inclusion and lattice inclusion. Molecular inclusion in\'olv~s 
~neapsulation of a gu<:~t molecule "ilhin a ~ingle CD cavity. In lattice inclusion. the 
host molecules form solid lallice~ lhat contain ,"oids that are capable of inclusion. Due 
to the size and hydrophobic nature of the cyclodextrin cavity. complexes arc fomled 
when the included molecule is compatibk with the dimensions of the ca\'ity and 
orientated in such a way as to achie\'e maximal contact hct"een the hydrophobic parr 
of the guest and the apolar CD cavily. Complex formalion with larger molecules is 
also possible. with onl}, cerrain groups or side chains fining intt) the cavilY. The 
inclnsion ofa gu<:st in a CD ca\'ily is essentially a substitution of the included waler 
molecules by a less polar guest. The driving force of complexation is not fully 
nnder:.lood with several faclor~ contributing 10 lhe process.!4 An inilial conlribuling 
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hydrophobic guest molecule (Figure 2.9),83 which lowers the energy of the system 
(unfavoured polar/apolar interaction to more favoured apolar/apolar interaction). 
Additional factors such as van der Waals forces, hydrogen bonding and hydrophobic 
interactions as well as CD strain release have also been found to be important driving 
forces behind complexation. 
.. w.. ... e .. • 
~., ... t •• , .,..!"~ .... " ~ .. ". .. .... f' ••• • 'I. II •• • ••• 
" .. , .••• ,-. __ "" t ........ . 
~'-: -"t·;""':::- _.' ........ :..:*.:~: ... :-: .. : ... : ~:.:'.~: 
too.' ...... ...~ .t •• " ... 't .......... _ .. .... . ...  . '. '.. . .. ?:"..... ". ". . k-.. fJ I- ...... • ... : .!.- - .. -: . • • 
.~ .... <- ....... •• ,'·t \; .• , ".' ..... t.~ :1 
.~. .... I"' J:' .'.. • t·. - '-J' .. . . I·· .. ,. ... t --~~ -- ,1'" .... : •• \ ~-- : .. 
t •••• , ,. '.. J ... •  • ... I ..... 'I . r 
• •• ~..."....."...,... " .. I ~. 
~"~... • • .. j • • ~ '. ~ .' ~. .• ,'-.-.... -.t.-.. J • - • • -,- --10' ' .... "~" '.. '-, ..::-t-\-"· .' . · · ... ,. --~-'-... ,. • -. A.' ... . if.' •••• ,. ••• .,,.. .... 4-.. .... ... • • • • •• • • • • 
• • •• •• 111 t ..... .. ••• • " 
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...., -- . . ... ... .. 
Figure 2.9: Hypothetical schematic representation of CD inclusion complex formation, where the 
small circles represent molecules ofwater83 
The ability of cyclodextrins to form inclusion complexes has applications in food, 
cosmetics and pharmaceutical industries and for analytical purposes. In the context of 
this project. the interest in cyclodextrins is due to their ability to act as solubilisers, 
stabilisers and carriers of poorly soluble drug molecules.85 
Cyclodextrins are true drug carriers, bringing the hydrophobic drug into solution, 
keeping it in a dissolved state, and transporting it to the lipophilic cell membrane. Due 
to the fact that the cell has a higher affinity for the drug than the CD, it remains in the 
aqueous phase and the bulk of the CD is metabolised in the colon by the colon 
microflora.83 The primary metabolites (acyclic maltose, maltose and glucose) as with 
starch, are then further metabolised, absorbed and finally excreted as C02 and H20. 
The pharmaceutical use of cyclodextrin inclusion complexes requires that they are 
structurally characterised in order to verify complexation, so that regulatory 
requirements are met as well as to validate patent claims of novelty. 85 A number of 
analytical techniques may be used such as UV, IR and Raman spectroscopy, thin-
layer chromatography, NMR spectroscopy, mass spectroscopy, X-ray diffraction, 
thermogravimetry and differential scanning calorimetry.83,86 A convenient and 
relatively fast technique for determination of complexation is that based on the 
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phenomenon whereby two or more crystalline phases have identical or quasi-identical 
packing motifs87 and thus have similar unit cell dimensions and similar internal 
arrangement of molecules. This implies that common atoms of these phases have 
approximately the same co-ordinates.88 Caira and co-workers have systematically 
classified the majority of the structurally characterized CD complexes obtained from 
the Cambridge Structural Database into distinct isostructural series.85 The powder x-
ray diffraction (PXRD) patterns within a series are essentially the same, regardless of 
the nature of the included guest.85 Thus, comparisons of gross peaks can be made 
between experimental PXRD patterns and reference patterns of parent cyclodextrins 
and their complexes to determine if inclusion took place. Successful matching of the 
experimental pattern with the computed reference pattern not only establishes 
inclusion of the guest molecule but also generates important structural information 
such as crystal packing arrangement and space group.85 This technique served as the 
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2.8 AIMS AND OBJECTIVES 
Overall Objective: 
The main objective of this MSc study is to develop single agents that provide 
inhibition of both the growth of tumour cells and malaria parasites. This multi-
therapeutic strategy is achieved by hybridising various known anti-malarial and anti-
cancer pharmacophores and/or bioactiphores together with the 4-aminoquinoline 
moiety. For this purpose, hybrid molecules 1, 2 and 3 (Figure 2.10) were designed as 
potential dual acting drugs. 
o R1 
1 m CI N 
COM04 R1 = H, R2 = CI 
COM05 R1 = CI, R2 = CI 
COM06 R1 = H, R2 = CI (meta) 
COM07 R1 = H, R2 = F 




2 m CI N 
R8 
COM13 R3 = H, R4 = H, R5 = OMe 
COM14 R3 = OMe, R4 = H, R5 = OMe 
COM15 R3 = OMe, R4 = OMe, R5 = OMe 
COM20 R3 = H, R4 = H, R5 = OH 
COM21 R3 = H, R4 = OMe, R5 = OH 
NRR COM37 NRR = pyrrolidinyl, R8 = H 
COM38 NRR = piperidinyl, R8 = H 
COM39 NRR = morpholino, R8 = CH2-morpholine 
COM40 NRR = 1-ethyl-piperazinyl, R8 = H 
COM41 NRR = t-butylamino, R8 = H 
COM42 NRR = dimethylamino, R8 = H 
COM43 NRR = diethylamino, R8 = H 
COM44 NRR = dimeth lamino, R8 = OMe 
Figure 2.10: Chemical scaffold of target compounds 
Specific Aims: 
1. To synthesise novel exploratory libraries of 4-aminoquinoline-based chalcones 
and their Mannich base derivatives. 
2. To improve water solubility properties of selected compounds by cyclodextrin 
inclusion and preparation of salt derivatives. 
3. In collaboration with appropriate laboratories, to evaluate synthesised 
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CHAPTER 3 
Synthesis and Characterization of Target Compounds 
3.1 4-Aminoquinoline-based Chalcones 
3.1.1 Rationale of Drug Design 
The well-known antimalarial and anticancer properties of both chalcones and the 4-
aminoquinoline unit, presented in the previous chapter, led to the design and synthesis 
of an exploratory group of 4-aminoquinoline-based chalcones. The rationale in this 
regard is based on a multi-therapeutic strategy in which the presence of two known 
antimalarial and anticancer pharmacophores should provide maximal inhibition of 
both the malaria parasite and tumour growth. These hybrid compounds may also 
potentially overcome or slow down drug resistance, as compounds aimed at multiple 
targets are less likely to be rendered ineffective compared to those aimed at a single 
target. The rationale for the design of target compounds is summarized in Figure 3.1. 
* Haematin binding (malaria parasite) 
* Differentiating-inducing and 
MDR reversal (tumour cells) 
\ HN 
Alkylation of enzyme active site thiols 
1 R 
o 
/ * Accumulation in the malaria parasite acidic food vacuole * Increased solubility via salt formation 
Inhibition of haemozoin formation (malaria arasite) 
Figure 3.1: Rationale for design of target compounds 
Various studies have been done on 4-aminoquinoline-haematin interactions in both 
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there is dispute over the stoichiometry of interactions between the drug and haematin, it is 
generally considered that these complexes occur through pi-stacking of the aromatic ring of the 
drug over the porphyrin ring. This coplanar, hydrophobic interaction is the major source of 
stability of these 11:-11: complexes. Structure-activity relationship studies have revealed that not 
only hydrophobic interactions but also electronic factors are important for haematin binding and 
thus inhibition of haemozoin formation. 2 The position of the electron-donating amino group on 
the aminoquinolines determines the extent of complexation, with only the 2- and 4-
aminoquinolines forming strong complexes with haematin. This is due to an increase in electron 
density within the pyridine ring, which favours stacking over the electron poor region of the 
porphyrin ring.! Another electronic factor contributing to strong association of 4-aminoquinolines 
to haematin may be due to the resonance interaction between the amino group and the quinoline 
nitrogen atom. This means that 4-aminoquinolines have lower pKa values than other 
aminoquinolines and can be protonated and are thus cationic.! This cation-11: interaction has been 
demonstrated to be of significant importance for complexation.3 Modification of substituents on 
the quinoline ring are of less importance, however, moving the chloro group from the 7-position 
appears to destabilize the complex. Finally, the weak base properties of these 4-aminoquinolines 
are a requirement for accumulation of these drugs in the food vacuole of the malaria parasite 
through pH trapping. The structural features of importance for MDR-reversal activity include a 
quinoline ring, a hydrophobic moiety and the presence of a nitrogen atom, charged at 
physiological pH.4-6 Compounds contributing to anti proliferative activities lacked a discernible 
common chemical feature other than the quinoline ring. 7 
Target compounds 1 and 2 (Figure 3.2), which differ in the position of attachment of the 4-
aminoquinoline moiety, were designed and synthesized in order to determine whether there is a 
potentially favourable substitution pattern. Chemically, the reactivity of chalcones is dependent 
on the electrophilicity of the ~-carbon. In this view, CDM04-CDM07 (target hybrid 1) were 
synthesised with ring B having electron-withdrawing substituents, such as halogens, which serve 
to enhance the electron deficiency of the ~-carbon, and thus its reactivity towards nucleophiles.8 
Based on literature findings, oxygenated chalcones, especially those substituted on ring A, serve 
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This oxygen functionality is also a structural feature associated with good antimalarial activity.8,IO 
CDM13-15 and CDM20-CDM21 (target hybrid 2) were synthesized for this purpose, with 




COM04 R1 = H, R2 = CI 
COM05 R1 = CI, R2 = CI 
COM06 R1 = H, R2 = CI (meta) 
COM07 R1 = H, R2 = F 





COM13 R3 = H, R4 = H, R5 = OMe 
COM14 R3 = OMe, R4 = H, R5 = OMe 
COM15 R3 = OMe, R4 = OMe, R5 = OMe 
COM20 R3 = H, R4 = H, R5 = OH 
COM21 R3 = H, R4 = OMe, R5 = OH 
Figure 3.2: Chemical scaffold of target compounds 1 and 2 
In addition CDM21 shows structural resemblance to curcumin, a plant extract showing a wide 
array of pharmacological activities (Figure 3.3). 
OH MeO ~ ~ OMe ":: 
~ ~ 
OMe ~ HN HO OH 
ill 0 CDM21 Curcumin ~ /.. CI N 
Figure 3.3: Chemical structures ofCDM21 and curcumin, depicting structural similarities 
CDM08 (target hybrid 1) was designed with a dimethoxy substitution on ring B for comparison 
purposes. Besides, the reactivity of the enone linker towards cellular thiols, the presence of the 
a,~-unsaturated system is also important to make the chalcones adopt a more rigid, extended 
conformation. From modelling studies, this linear, almost planar structure fits well in the long 
cleft of the active site of the malarial cysteine protease.!O Finally, the chemical synthesis of the 4-
aminoquinoline-based cha1cones is relatively simple as well as being versatile, with many 
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3.1.2 Synthesis and Characterization of 4-Aminoquinoline-Chalcone Hybrid 1 
3.1.2.1 Retrosynthetic Analysis (CDM04-CDM08) 
The retrosynthesis of target compounds CDM04-CDM08 is shown in Scheme 3.1 and involves 
two simple disconnections. An a,B disconnection leads to the aminoquinoline acetophenones 
CDMOI-CDM03, which have the para, meta and ortho relationships respectively, and the 
commercially available aromatic aldehydes. Further analysis of aminoquinoline acetophenones 




HN~ U R2 Claisen_SChmm~; HN ~ I + 





COM04 R1 = H, R2 = CI 
COMOS R1 = CI, R2 = CI 
COMOS R1 = H, R2 = CI (meta) 
COM07 R1 = H, R2 = F 
COMOS R1 = OMe, R2 = OMe 
ij CoN "e"'oohil" ,e"liteh" 
+d 
H2N 
4,7 -dichloroquinoline 2-,3- or 4-amlnoaceto henone 
Scheme 3.1: Retrosynthetic analysis of 4-am inoquinoline-chalcone hybrid 1 
3.1.2.2 Synthesis of Aminoquinoline Acetophenones CDMOI-CDM03 
The 4-amino-7-chloroquinoline-acetophenones CDMOI-CDM03 were prepared following a 
modified literature procedure described by Raynes et ai, Scheme 3.2. 11 
HN 
~COCH' 
.. ill CDM01 (para) I '-':: '-':: CDM02 (meta) CDM03 (ortho) CI .0 N""'::: ii 
4,7-dichloroquinoline 
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These compounds were synthesized via a nucleophilic substitution reaction by refluxing the 
aminoacetophenone and an equimolar equivalent of 4,7 -dichloroquinoline in ethanol for 2-4 
hours, followed by neutralization with aqueous ammonia. The crude products were purified by 
recrystallization from ethanol to give 1-[ 4-(7-chloro-4-quinolinyl)amino ]phenyl]-ethan-l-
one(CDM01), 1-[3-(7 -chloro-4-quinolinyl)amino] phenyl]-ethan-l-one (CDM02) and 1-[2-(7-
chloro-4-quinolinyl)amino]phenyl]-ethan-l-one (CDM03) in 79%, 94% and 60% yields 
respectively. The structures of these compounds were confirmed using 'H and l3C NMR. 
3.1.2.2.1 Mechanistic Details 
The nitrogen atom within the quinoline ring makes this aromatic system n-electron deficient by 





Figure 3.4: Canonical structures depicting inductive and mesomeric effects ofN-atom in the quinoline ring 
The C-4 position of 4, 7-dichloroquinoline is further enhanced towards nucleophilic attack due to 
the close proximity to the nitrogen atom and the presence of the electron-withdrawing chloro 
group. The nucleophilic amine group of aminoacetophenone attacks the quinoline ring at the C4 
position, dearomatising the ring with the quinoline nitrogen acting as an'electron sink'. The 
chloride is displaced when the electron pair on the nitrogen is returned to the ring and regains 
aromaticity (Scheme 3.3). The driving forces behind this regioselective attack are thus the 
resonance stabilization that occurs and the close proximity of C-4 to the N-atom. 
Cl-~ 
m
~ ~H2R £OH ..... +HR 
=~- I ~ ~I =-= I ~ ~ 
Cl ~ N CI ~ N""":: 
CDM01-CDM03 
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3.1.2.3 Synthesis of 4-Aminoquinoline Chalcones CDM04-CDM08 
Chalcone derivatives CDM04-CDM08 were synthesized by a base-catalyzed Claisen-Schmidt 
condensation of an aromatic aldehyde with the appropriate 4-aminoquinoline-derived 
acetophenones. In order to determine optimum reaction conditions, the condensation reaction was 
attempted using Ba(OH)2, KOH and NaOH as catalysts as well as using KF-Ah02 under 
ultrasonic irradiation. A literature procedure detailed by Go et al8 using a 3% w/v methanolic 
solution of NaOH provided the most convenient and high yielding reaction conditions and was 
thus the general procedure used for preparation of the target chalcones (Scheme 3.4). The product 
was obtained as a yellow precipitate after a short period of stirring but required 24 h to go to 
completion. A minimum amount of methanol must be used to ensure formation of a solid 
product. Formation of the ortho-product, with respect to the position between the carbonyl and 




COM04 R1 = H, R2 = CI 
CI ~ N"" COMOS R1 = CI, R2 = CI 
COM06 R1 = H, R2 = CI (meta) 
COM07 R1 = H, R2 = F 
COMOS R1 = OMe, R2 = OMe 
Scheme 3.4: Reagents and conditions i,) 3% w/v NaOH, MeOH, reflux, 24 h 
3.1.2.3.1 Mechanistic Details 
The mechanism of the Claisen-Schmidt condensation is shown in Scheme 3.5. It involves a base-
mediated enolization of the 4-aminoquinoline-derived acetophenone, in which the base removes 
an acidic proton adjacent to the carbonyl group. This is followed by nucleophilic attack by the 
resulting enolate ion on the aromatic aldehyde to form the aldol product. This ~-hydroxy ketone 
then undergoes a base-catalysed elimination (E 1 cB) to give the more stable conjugated chalcone 
system. 















Chapl~r 3: Synlhesis anti Characl~riz3lion ofTarg~t Compounds 
The yields of the synthesized ~ompound, 3nd their respective melting points 3re given 
in Table 4. 
c 0 
,~c CDMI}5 " 229-233 . m 
~c 
Ji,c CDVlI)6 " 11 ~ ·220 
" N" 
.. du. CDM07 '" 1 ~ 9· 1 91 J )) 
-~- CDMO~ " 239-242 ,.D:) 
The lihered pr~clpl lales orCDMU-I and CDMUS were wa,h~d wilh cold melhanol lo 
}idtl pure product~_ The filtered precipitatcs of COMU6, CO.\107 and COM08 still 
contain~d trace 3mnunts of unreacted methyl ketone and further purification was 
needed. Hybrids COl\106 and COM08 were recrystallized from ethyl acetate and 
methanol. respceti~-ely. CO:\107 was very insoluble and was purified by column 
ehromatngraphy. Purity wa~ checked by TLC before characterization by 'H and ' -' c 
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3.1.2 Synthesis and Characterization of 4-Aminoquinoline-Chalcone Hybrid 2 
3.1.2.1 Retrosynthetic Analysis (CDM13-CDMI5 and CDM20-CDM21) 
Generation of the 4-aminoquinoline-chalcone hybrid 2 was achieved by considering the 
retrosynthetic analysis shown in Scheme 3.6. 
~R3 ;4a,0 n I I ~H 
£X)
HN "'" "'" Claisen.SCh:t6;~dt HN 0 
~ ~ 0 I ~ ~ 
I~ ~ ~ ~ 




o substituted acetophenone 
~ FGI oxidation 
~QOO=~=CI:=~=:h=iI;» ~-t 
)lA.,) substitution C,MNJ 
CI N 
+H2NV I OH ~ 
4,7·dichloroquinolme 3-aminobenz I alcohol 
Scheme 3.6: Retrosynthetic analysis of 4-aminoquinoline-chalcone hybrid 2 
Retrosynthesis of target compounds 2 follow similar disconnections to target compounds 1, with 
the difference being that the 3-aminobenzaldehyde was not commercially available for 
nucleophilic aromatic substitution with 4,7-dichloroquinoline, and the 3-aminobenzyl alcohol 
was thus used. The intermediate 4-aminoquinoline-derived benzyl alcohol was then oxidised to 
the appropriate aldehyde. 
3.1.2.2 Synthesis of 4-Aminoquinoline Chalcones CDMI3-CDMI5 
The intermediate 4-aminoquinoline-based benzyl alcohol was synthesised vIa a nucleophilic 
aromatic substitution reaction between 4,7-dichloroquinoline and 3-aminobenzyl alcohol, as 
described in section 3.1.2.2, to give [3-(7-chloro-quinolin-4-ylamino)-phenyl]-methanol 
(CDM09) in 98% yield (Scheme 3.7). The ortho-product [2-(7-chloro-quinolin-4-ylamino)-
phenyl]-methanol (CDMI0) was synthesised in low yield (33%), however attempts at 
synthesising the para-product failed, with 1 H NMR spectra of the isolated product showing only 
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4,7 -dichloroquinoline 
~CH,oH 
------.... ill'" H~ ~ COM09 (meta) 
ii CDM10 (ortho) 
CI 0 N~ 
Scheme 3.7: Reagents and conditions i.) Aminobenzyl alcohol, ethanol, 80-85°C, 2-4 h ii.) NH40H 
The next step in the synthesis involved oxidation of the intermediate benzyl alcohol 
(CDM09 or CDMI0) to the appropriate aldehyde, (CDMll or CDMI2) by the 
Parikh-Doering oxidation method,12 a modification of the method originally 
developed by Pfitzner and Moffat. 13 CDM09 and CDMI0 were stirred with Et3N in 
DMSO, followed by the addition of the sulfur trioxide pyridine complex to afford the 
aldehydes CDMll and CDM12 in yields of 97% and 81 % respectively (Scheme 3.8). 
These intermediates were characterised by IH NMR and l3C NMR, with the 
disappearance of the CH2 and OH group in the region of 84.50 ppm and 85.20 ppm, 
respectively and the appearance of aldehyde proton at around 810.0 ppm confirming 
their formation. 
~CH,OH ~O 
~ ------" ~ ~ CO:11 (mela) 
CI)lANJ CI)lANJ CDM12 (ortho) 
Scheme 3.8: Reagents and conditions i.) S03.Pyr complex, Et3N, OM SO, rt, 72 h 
3.1.3.2.1 Mechanistic Details 
The mechanism of Parikh-Doering oxidation reaction (Scheme 3.9) is similar to that 
of the Swem oxidation. The charged oxygen atom of DMSO attacks the sulfur atom 
of the S03.pyr complex to give an electrophilic sulfur compound. The alcohol then 
reacts with this sulfonium ion that is formed to give a new sulfonium salt. This 
compound is stable enough to be deprotonated by Et3N, forming a sulfonium ylide 






















II ~ -o-s-o,) 
II "+ 
OJ ~~H 
Scheme 3.9: Mechanism of Parikh-Doering oxidation 
+ so 2-
4 
After work-up of the above reaction, the product was isolated without further 
purification. The final step in the synthesis is the base-catalyzed Claisen-Schmidt 
condensation reaction between the 4-aminoquinoline-derived aldehyde CDMll or 
CDM12 and a series of methoxylated acetophenones to afford CDM13-CDMIS in 
75%, 70% and 70% yields respectively (Scheme 3.10). Condensation of the ortho-




R3~R_5 ___ m,-,:: H~ ::::,... 0 
yv I h- h CDM13R3=H,R4=H,R5=OMe 
o CI N CDM14 R3 = OMe, R4 = H, R5 = OMe 
CDM15 R3 = OMe, R4 = OMe, R5 = OMe 
Scheme 3.10: Reagents and conditions i.) 3% w/v NaOH, MeOH, Reflux, 24 h 
3.1.3.3 Synthesis of 4-Aminoquinoline Chalcones CDM20-CDM21 
For the synthesis of hydroxylated chalcones, CDM20 and CDM21, it was necessary 
to protect the phenolic group on the substituted acetophenones before condensation, in 
order to improve product yields. Phenolic protons are relatively acidic (pKa ~ 10) in 
comparison to methyl ketone protons (pKa > 20) and will be deprotonated more 
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~ 
:8- J"~ H-oVy 
o 




Figure 3.5: Deprotonation of phenolic proton to give resonance stabilized phenoxide anion 
This results in limited conversion of methyl ketone into enolate ions and it thus 
becomes necessary to protect the hydroxy group of the starting materials, 4-
hydroxyacetophenone and acetovanillone, as tetrahydropyranyl ethers. This was 
accomplished by stirring the hydroxylated starting materials, pyridinium p-
toluenesulfonate and 3,4-dihydro-2H-pyran in methylene chloride for 72 h to afford 1-
(4-tetrahydro-2H-pyran-2-yloxy-phenyl)ethanone CDM16 and 1-[3-methoxy-4-
(tetrahydro-pyran-2-yloxy)-phenyl]-ethanone CDM17 in 99% and 95% yields, 
respectively. CDM16 and CDM17 then underwent a Claisen-Schmidt condensation 
with the 4-aminoquinoline-derived aldehyde CDMll to give the intermediate 
products CDM18 and CDM19. Finally, removal of the THP protecting group under 
mild acidic conditions gave the final products CDM20 and CDM21 in good yields. 
This approach used is depicted in Scheme 3.11. 
Rff __  
HO 
4-hydroxyacetophenone R = H 
Acetovanillone R = OMe CDM16 R = H CDM17 R =OMe 
(') (Y0y0,! 
~V
ii •. ~ 0 R 
)lA.,J CDM18 R = H 
CI N I ;;; COM1. R • OM, 
~
~OH 
~ I 0 ~ I 
mH: 0 R I /- CDM20 R = H CIoN CDM21 R = OMe 
Scheme 3.11: Reagents and conditions i.) 3,4-dihydro-2H-pyran (I.6eq), pyridinium p-
toluenesulfonate (0.1 eq), CH2CI2, ft, 72 h ii.) 3% w/v NaOH, MeOH, Reflux, 24 h iii.) 4M HCI, 
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The structures. isolated yields and respeclive melting point, 01' the resultant .\-
aminoquinoline-based chalconc hybrid 2 arc depicled in Table 5. 
I able" 4-Aminoquiooline-based chalcono hyhrid 2 with thei r rc..,pec\i,~ yielJ, ooJ mcILIng p"inh 
CDM B 75 2.14 ·257 
C [)MI4 '" 
C [)M I5 '" 179·181 
c [):m o '" 
CD'\121 225 ·227 
3.1..\ Cbaractc ri satit>n of Ta~ct Compt>und' 
All the IH J\jMR SPCClfa of the rcsuham products displayed two common diagnostic 
dOllblels aroUlld " 8 ppm and ,j 7 ppm. integrating for 1 proton each. and hu\e 
coupling !;Ollstant value, oclwccn 15-16 Hz. These peaks correlate to the methine 
proton, on the double hond of the cr.p·unsaturnted system and also conlinn that the 
Ir(lm-i,om~r i~ fonned preferentially. the fonnation of the proposed products was 
also con tinned by the disappearance of the methyl htone peak present ill the starting 
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aldehyde proton at ~ 6 10 ppm for target hybrid 2. The I3C NMR spectra that were 
obtained are also consistent with the proposed structures, with the carbonyl carbon 
(C=O) of the a,~-unsaturated system observed in the region of 6 187 ppm in 
comparison to the methyl ketone carbonyl group of the starting material which 
appears at 6 196ppm or the aldehyde carbonyl group at ~ 6 190 ppm. A representative 
IH NMR spectrum is shown of compound CDM04 from target hybrid 1 (Figure 3.6) 
and of compound CDM13 from target hybrid 2 (Figure 3.7). 
li/ppm Multiplicity JlHz H 
o 17 10 11 18 19 
:Q ,9 '<:::: 20 I 15 16 I ~ 23,9 
5 HN 14 13 12 21 CI 
4a~ 22 6 ~ ,)3 
CI:Q-N'" 2 
1 
9.43 s - NH 
8.62 d 5.1 H2 
8.41 d 8.8 H5 
8.21 d 8.8 HIO, HI2 
8.0 d 15.6 HI7 
7.97 d 2.4 H8 
7.92 d 8.8 H19, H23 
7.73 d 15.6 HI6 
7.64-7.61 dd 2.4,9.2 H6 
7.53 d 8.4 H9, HI3 
7.50 d 8.8 H20, H22 
7.32 d 5.2 H3 
H8 
1 
HI9, H23 H20, H22 
H17 / HI), Hl~ I 
II II II ~ ! HI6 H6 I 1/ H3 
" i\,II~ J I )~! "U II ,,'i, li/iL-
J J u V H"J \ Iv ~:U~~~~_)'U'L~~~ _' ~~__ . )'u"'L-J"v':~i ~
HlO,HI2 
H2 H5 
I I I I I I I I I I I I 
820 800 '80 -60 
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H18,H22 H19, H21 
H3 ~5i .111 H1~H8lL::31 'I H6 H,!"," 10 ". i. ! 
H2 I ~ ,I : '" III I I 'I II V~ 
!:il " 'I,:, ' 1~1 IJI I ~,!~, /' ii ~ r I !·U 





II/ppm Multiplicity JlHz H 
9.20 5 - NH 
8.48 d 5.1 H2 
8.45 d 9.0 H5 
8.16 d 8.7 H18, H22 
7.95 d 15.6 HI5 
7.89 d 2.0 H8 
7.84 5 - HI3 
7.73 d 15.6 HI6 
7.65 d 8.0 HII 
7.59-7.55 dd 2.1,9.0 H6 
7.53-7.48 t 8.1 HIO 
7.43 d 8.1 H9 
7.08 d 8.7 H19, H21 
6.94 d 5.1 H3 
3.82 5 - OCH, 
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Characteristic IR bands included the peaks around 3300 cm-] and ~ 1670 cm-] due to 
NH and c=o stretches respectively. All compounds depicted the presence of the other 
functional groups with ArH and C=C stretches appearing around ~1560 cm-] and 
~ 1600 cm-] respectively. Elemental analysis confirmed the molecular formula and 
purity of the compounds. 
3.1.5 Crystallographic Analysis 
Within this project, single crystal X-ray crystallography was a tool used primarily for 
elucidation and confirmation of target compound structures, but the accurate 
molecular structures determined using this method may also be of potential use in 
molecular modelling studies. Guided by the X-ray structure, molecular modelling may 
be used to obtain a better understanding of structural factors that contribute to activity 
as well as to investigate potential structural modifications of target compounds 
important for optimising activity. Single crystals obtained for CDM06 (target hybrid 
1) and CDM14 (target hybrid 2) were coated with Paratone N oil and mounted on a 
goniometer head and their diffraction intensities collected on a Nonius Kappa CCD 
diffractometer. Crystals were cooled in a stream of N2 using a Cryostream cooler 
(Oxford Cryosystems, UK). The program XPREP]4 was used to determine the space 
groups of CDM06 and CDMI4. CDM06 crystallized in the orthorhombic system in 
the space group Pca2] and CDM14 crystallized in the triclinic system in the space 
group P-l (based on IE2 - 11 = 0.999). This choice was confirmed by successful 
refinement of the structures in the aforementioned space groups. Both structures were 
solved using SHELXS-97,]5 which revealed the position of all non-hydrogen atoms 
which were then refined isotropically on F2 using full-matrix least-squares in the 
program SHELXL-97.]6 All non-hydrogen atoms were then refined anisotropically. 
Hydrogen atoms were placed in idealised positions using a riding model and refined 
isotropically with temperature factors 1.2 times those of their parent atoms. The 











Chapter 3: Synthesis and Characterization ofTargcl Compollnd~ 
Tabl. 6: Cry'tal and refinement data ofCDM06 and CDM14 
The s1ruc1ures of the asymmetric units of CDM06 and CDMI4 and the atomic 
numbering are ,ho\\'n in Figure 3.8 and Figure 3,() res]X'cliveJy. The hydrog~n alom, 
are named after their parenl atoms. The crystal SlruClllR'S further confimlet1that the 
(llclini~ ~md in these ~()mp<)tln..h adopted the E configuration. 
Fig" '" J.~: Cry,tal WucWre of C[)M06 depict ing labelling and cQnformatiooal "'Peets 
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The crystal structure depicted in figure 3.8 ~hows that the two ring systems deviate 
from planarity with regard to the n.0-l1nsaturated system. Ring B containing the Cl 
(29) atom lies slightly above the plane of the a,0·unsatlmlled system with th", \or,ion 
angle of 17. 5(lt between ring C(l3)-C(14)·C(lS)-C(l6}-C(l7)-C(lRJ and ring 
C(231-('(24)-C(25)-('(26)-C(27)-('(28). "I he quinoline ring lies below the plane of the 
a.0-lUlsaturated system with the orientation of the two rings. C(13)-C(14)-C(15)-
C(J6)-C(17)-C(J8) Jnd C(2}C(3)-C(4)-C(11 }-C(5)-C(6)-C(7)-N(8)-C(IO)-C(9), with 
respect to each other &scrilxd by the torsion Jngle of 47.83(8)°. The latter deviation 
is due to steric interaction, Ixlween the hydrogen atom 116 on the quinoline ring: Jnd 
the hydrogen atom 1114 on the aromatic ring A. 
"',,, 
'"'1 CI~J) 
Figure 3.9: Cry, tat ,tructurt of C[)~tI4 depi<t ing labelling 000 cooformMion"i asp. cts 
H alOm , I,",'~ bu " otnin~d for clarity 
The Ihree ring ,ystems in the crystal strucmrc ofCU)'1I4 depicted in Figure 3.9 are 
not coplanar, with the terminal rings. C(23)-C(24)-C(25)-C(26)-C(27)-C(2R) and 
C(2)-C(3)-C(4)-C(II)-C(5)-C(6)-C(7)-~(8)-C(IO)-C(9). being nearly coplanar with a 
torsion angle hem-een them being 11.9(1)°. The nonplanarity between the (,,~­
unsaturatcd ring system and Ihe adjaceni ring_ is due to s(cne interactions. As with 
('0.'\106 there is a ,teric interacti,-,., bem-een (he hydrogcn atom H6 on (he quinoline 
ring and the aromatic hydrogen Hl4 of the middle ring sys(em causing a tor,ion angk 
C(6)-C(5)-N(12)-C(l3) or 42.7(1)". The tor,ion angle O{291-C(24)-C(231-C(21) 
between the mdhoxy-,ub,titlfted aromatic ring and ring C13-Cl8 is 34.3(2)". The 
middle ring. C13-CI8, howevcr, is coplall!lr with thc a,~-un,aturated 'ystem. The 
nonplanari(} between the a,~-tmsaturated system and the methox}-sub,tituted 
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029 of the C2-1 metllOx~' group amI the hydrogen atom H20 of the u.~-unsall.lraled 
'}SlCm. The torsion angle fomled through this intramolecular hydrogen bonding is 
106", typical of a six-membered ring. If the methoxy-substiluted ring is rotated to be 
planar with the u,j)-unsaturated system. there will be a repulsion between the methoxy 
group and the hydrogen atom of the a,j)-I.lIlsaturated system and thus this 
nonplanarity. with a torsion angle C'(24)-C(23)-C(2l)-C(lO) of -32.8(5)", limits 
repulsive interaction,. 
The cry,tal Slructul1' of CDJ\.I06 sh,.,ws no intemlO[ecuJar hydrogen bonding and the 
crystal lanice is stabilized by hydrophobic interactions. The zigzag packing motif of 
C DM 06 is depicted in Figure 3.10 showing hydrophobic int~ractions and lour 
molecules ofCDM 06 per unit celL 
Figure 3,10: Packing di"gmm of CD:vt06. viewed along [0101_ 
CD'11 4 packs in ,uch a way to fonn channel~ in ",hich ~oh' ent molecules may re~idc 











~1~u", 3. 11 : View of r-"'kln ~ """"" 1100 I. <kpi<.1in~ 1''''''''lioo of ch,.,"tl, 
There MC IWO m"k-,,~ks 01· CD'114 po:r unit ce ll. with Ihe oxy"",, "tom 0(:;4) of mclhaJlOI 
hydro~rt b<>llding w the an i !i~ typ" hydros<'n 1-1 12 of C J)M I4 am! lh~ m<1h}1 h ~ <.lr<,gcn of 
,ntlhalll,l h} drogcn bowing w Nit (If u", ~ h~ r mule" .. '" of COM 14. ·lIle:;.: imcr.ll.·lions and !he 
i nlrJmolt'<" lIlar bonding d i.scu."<SCd p<evi"u.~! ) .......... ".:n !he o.\ ygcn 310m 0 2" (If IIIe (."24 melh,,~ y 
I!fOIiP lIn<lth .. h~ tl rugcn alOin H20 of IIIe o.~· .. ns;"' .. rJI .. tl sY"' .. m :ore tkpictcd in ~igurc 3. 12 . 
.. ... '"" 
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Th~se immnolecular ~nd imramolecular h)drogen bonds stabilize the crystal structure 
and their distances and related angles are given in Tuble 7 as calculated by 
PLATONI7 , wher~ a deootes symmetry related position x. i - I'. z and b denotes 
>ymmetry rdated po silion 1 +x. -1 -+ )'. /" 
Tab!. 7, lIydrogen bood distance, and angle, of CVYl14 
figure 3.13 shows the packing of CDM14 molccl.llcs linked hy the solven( molecule. 
Th..., packing consish of a rihbon-like repealing motif A-13-/\-R where A is the 
molecule IX',itinned "jth the ('I group pointing upwards and 13 is the molecule 
positioned with CI grol.lp pointing dov-nwards. 











Chapler 3: Synlhe~i~ and Ch;mICleri/</litln or Targel Compounds 
[he two thermal analytical methods used for analysing the single crystals CDVl06 
and CDMl4 were HOI Stage \Iicro,cop), (HSM) and Differential Scanning 
Calorimetry (OSC). Hot stage microscopy experiments with crystal immcr:scd In 
silicone oil "ere used to determine whether these crystals contained solvent of 
crystallisation. lmage~ captured for CDM06 continned th<l! the crystals were not 
~ol\'aled and the md! onset was at 21 SoC (Figure 3.141. 
, 
Fi~ur. J.l~: HSM pootos ofCDM86 a! (a) 2~"C alJd (b) 220"( 
HSM experiment~ ~howed lhat CDMI4 contained ,niven! with desohation starting at 
11loe (bllbhle I'onnation) and melt on,el temperature at 175°C (Figure 3.15). 
, b , 
Fig"" 3.15: HSM P~OI()' ~f onll ~ at (0) 25"C, (h) I I I "(' and (0) I 77"C 
DifTerential scanning calntimdl) is llsed tn measlll'c the rate nI' heat ab>orbed or 
~volved by a ,ample, dlll'ing a temperature programme. nsc wa~ ".,ed tn confinn the 
melting point of CDi\114 and the onset temperature of des.olvation of methanol. The 
DSC curve showed a broad end01henn with an onset temperatllre of deoolvalion at 
II we. The broad peak has a shoulder corresponding to the desoivation of methanol 
and the highest point of the peak corresponds to the melting of CDM14 at 14i"(' 
(Figure 3.16), This temperature differ~ from that recorded from the hot stage due to 
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Ttw;, t~m~ratUT~ at ,,"~ \ch the methallOl dc:wl ";lr~, in ~om;"aris.on 10 il~ normal boil in£ 
point (Tb = M.7'C) is an indication of tile ~bti\'( stability ofth~ ~(l l' ntcd ~r}'~taL A 
\'alu~ of T,,,,/T , gre at~r than one indi <:al~' J n: 1 .. livc ly stable structur~ : the T,,,, /T, value 
of toc system is 1.6 indi<.:ilting that til<' !k)1\'al ~d cry~tal is stable. Th..:: TOA trace shows 
;I m:lliS loss of 7.2 % al 110"('. "'hich j~ consis l~1I1 ", i111 a 1:1 m.'tllanol $Oh air of 
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3.1.6 Improving Solubility 
One of the limiting factors involved in bioavailability and thus the efficacy of these 
hydrophobic target compounds is their insolubility in aqueous media. In this project, 
two methods were used in order to potentially improve water solubility properties of 
target compounds, those being formation of salt derivatives and inclusion into 
cyclodextrins. 
3.1.6.1 Salt Formation 
The citrate salt derivatives of all the 4-aminoquinoline-based chalcone target 
compounds were prepared via a simple procedure involving protonation of the 
quinoline nitrogen with citric acid. Citrate salts were prepared due to their well-known 
low toxicity and the ready availability of citric acid. An equimolar equivalent of citric 
acid was dissolved in a minimum amount of acetone and added dropwise to the heated 
acetone solution of the target compound. The citrate salts precipitated out of solution 
when cooled at 4°C overnight and the resulting precipitates were filtered to give the 
salt derivatives with good yields (Table 8). The IH NMR spectrum confirmed the 
formation of the citrate salts, with the appearance of two doublets between 8 2-3 ppm 
that integrate for two protons each, arising from geminal coupling of each pair of the 
CH2 protons of citric acid. The chemical shifts of the other protons remained 
relatively unchanged, except for those correlating to the quinoline ring, which showed 
a downfield shift. This trend confirms salt formation via protonation of the quinoline 
nitrogen. This method of salt formation only improved the solubility of target 
compounds very slightly. This could be attributed to the fact there is only one charged 
centre, which may be insufficient to overcome the strong non-polar character of the 
large target compounds. It may be of interest to produce salt derivatives of mineral 
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Tabl. 8: Citr.te .. It deri"",i"., of 4-omiooqu inoli,Je-ch.lcOll e hybrid, 
,D:\111 197_ 19R 
CVM1J 208 ·2 11 
















Chapler 3: Synthesis and Characterization ofTarsct Compound;; 
3.1.6.2 Cydodextrin Inclusion Complexes 
Target compounds C01'l113-COI\1I5 and their citrate salt derivatives C01\127-
CD'\129 were "elected for cyclod~xtrin inclusion \la'ed Oil their obs~ned activity in 
\'ilro. especially in cancer cell model" Kneading, co-precipitation and co-sol~cnt 
method, were employed using jl-CD and 1'-CD in both I: I and 2: I (CD: drug) molar 
ratios. All co-precipitation and co·solvation experiments were unsuccessnll, yielding 
ollly native-CD single crystals which were conlirmed on the X-ray dilTractomder by 
comparison 01' known unit cell dim~n"ion" of native-CD and it- complexes with the 
experimental unit cd! dim~nsions. Tr.., powder X-ray diffraction (PXRD) patt~rns 
obtained Irom kneading ~xP<'riments w~re compared with th~ computed PXRD 
patterns. kno"n as is(lstrl.lctural series. to detcnninc if complexation had occurred. 
The rXRD palterns (Figure 3.17) of the knead~d material of COM 14 (I: 1 B·CD:drug 
ratio) and CD,'\115 (2:1 p-CO:drug ratio) did oot match the rXRD pattern for native 
poCO and thus indicated that inclusion complexes had formed. The pallerns howe\~r 
did not match any previously identified isostructural series,'~·19 but were isostructural 
with each other, with the conclusion that new poCO inclusion complexes of CDM 14 
and COMIS had probably been formed. Recrystallization 01' the kneaded complex 
failed to give X-ray grade single crystal> needed in order to con linn inclusion. 
1" , 
• , 
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The PXRD patterns of knQad~d mawrials for the otkr targd compounds attempted 
fllr ;nclu8;on in 11-CD >how~d thal no inclusion complex had fomled as the patterns 
matched thai (1f native poCO. 
r-CD is a more likely canJidatr to fonn inclusion complexes wilh the compounds in 
this study due to the cavity of tile CD being larger than that of j)-CD. Three kneading 
experiments were attempted with "(-CD and COMB, COM!" and CDMI5 in a 1:1 
host:drug ratio. The PXRD traces of 1\.\0 of the y-CD complexes, CDM14 and 
(,D'1I5. were in rea><-mabk agreement ",jtb the PXRD pattern for isostructural series 




_Jl,-__ .. ~N 
, 
• " 2 theb (degrees) 
Figure 3.18: a) CGlnpm.d rXRD IT"". tor known ~-C[l compl., and .~p.ri"",rnal rXRD IT",," of(b) 
r-CD-CD-'!! ~ complex and (e) y-CD-CDM 15 wmplex 
All observed y-C D complexes comaining gu~sl molecuk8 ha.y~ the ,arne packing 
arrangem~nl and lhus a considerahlc amount of structural information can be 
inferred. I! These complexcs crystallize in the tetragonal space group P42 12 with 
channel packing. Thc chalUlels have three y-CD Illokcules in one asymmetric unit 
stacked together in head-lo-h<:ad (A and R), tail -lo-la il (R and C) and head-to-tai1 (C 
and A ') packing modes (Figure 3.19), While the lcvel of agreement hctwccn panern 
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pattern 'a' is a reference pattern, obtained by averaging those for all known y-CD 
inclusion complexes. The intensities registered are therefore artificial and one does 
not expect them to correspond exactly with those for the prepared complexes. 
Similarly, peak positions may vary depending on the unit cell size variation, a 
function of the nature of the guest and crystal water content. 
Figure 3.19: The packing arrangement ofr-CD complexes 
The y-CD molecules possess four-fold crystallographic symmetry and this requires 
guest molecules to be disordered. Due to this disorder, details of the geometry of the 
guest inclusion cannot generally be ascertained by crystallographic analysis. 
Although from the above experiments four inclusion complexes were obtained, 
subsequent recrystallization did not yield single crystals intended for full X-ray 
structure determination, which is essential for pharmaceutical use of cyclodextrin 
inclusion complexes. Consequently the strategy of improving the water-solubility and 
hence the bioavailability of target compounds through cyclodextrin inclusion could 
not be fully explored. 
3.2 Mannich Base Derivatives of 4-Aminoquinoline-Chalcones 
3.2.1 Rationale of Drug Design 
The rationale for the design of 4-aminoquinoline-based chalcones has been discussed 
previously in section 3.1.1. Mannich base derivatives of the target hybrid 2 were 
synthesized due to their superior biological activity in comparison to target hybrid 1. 
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were synthesized due to the previously discussed biological activity of hydroxylated 
chalcones (sections 2.5.2 and 2.5.3). Both acyclic and cyclic amines were used in 
order to explore preliminary structure-activity relationships of these hybrid 
compounds. Conversion of the 4-aminoquinoline-derived chalcones into their 
Mannich base derivatives was done due to the following considerations. Firstly, the 
presence of an additional protonatable nitrogen would increase the compounds' water-
solubility properties via salt formation and also enhance accumulation in the acidic 
food vacuole of the malaria parasite via pH trapping. Secondly, at the lower pH 
associated with tumour cells or the acidic food vacuole, these phenolic Mannich base 
derivatives can undergo deamination to give very reactive intermediate enones that 
can potentially react with various cellular thiols important for parasite or tumour 
growth. These phenolic Mannich base derivatives may therefore be used as prodrugs 
whereby the cytotoxic agent is released at its site of action. Despite the numerous 
examples of antimalarial Mannich bases and wide interest in chalcones, antimalarial 
Mannich base derivatives of chalcones remain an unexplored field. Investigations of 
cytotoxic activity of phenolic Mannich base derivatives of chalcones by Dimmock et 
apo revealed that these compounds are a promising new class of cytotoxic agents due 
to good biological activity and absence of mutagenic effects. These Mannich bases 
were designed using the concept of sequential toxicity. Figure 3.20 summarises the 
chemical features of phenolic Mannich base derivatives of the 4-aminoquinoline-
based chalcones and their potential biological action. 
*Haematin binding (malaria parasite) 
*Differentiating-inducing and 
MDR reversal (tumour cells) 
\ HN 
Alkylation of enzyme active site thiols 
I R1 OH~(( 
Masked vinyl ketone o 
I 
*Accumulation in the malaria parasite acidic food vacuole 
*Increased solubility via salt formation 
Inhibition of haemozoin formation malaria arasite 
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3.2.2 Retrosynthetic Analysis 
The synthesis of the Mannich base derivatives was envisaged via two synthetic routes 
depicted in Scheme 3.12: path a, in which the starting material undergoes a Mannich 
reaction followed by a Claisen-Schmidt condensation reaction and, path b, involving 
the aminomethylation of the 4-aminoquinoline-based chalcone. 
~O 
V.) 
CI N a,S 
a I Claisen-Schmidt 
NRR 
CDM37 NRR = pyrrolidinyl, RB = H 
CDM38 NRR = piperidinyl, RB = H 
CDM39 NRR = morpholino, RB = CH2-morpholine 
CDM40 NRR = 1-ethyl-piperazinyl, RB = H 
CDM41 NRR = I-butylamino, RB = H 
CDM42 NRR = dimethylamino, RB = H 
CDM43 NRR = diethylamino, RB = H 
CDM44 NRR = dimethylamino, RB = OMe 
~ C-N 
b ~ aminomethylation 
R8 
OH 
mHN~H +~~ NRR 
+ CH,o + NH-RR 
~ ~ 0 .,;:;; 
I OH 
CI .,;:;; N/- D R8 
C-N 
aminomethylation 




Scheme 3.12: Retrosynthetic analysis of Mannich base derivatives of target hybrid 2 
3.2.3 Synthesis of Phenolic Mannich Base Derivatives 
The starting point in the synthesis of Mannich base derivatives via path a involved an 
aminomethylation reaction of 4-hydroxyacetophenone to yield the respective phenolic 
Mannich base derivative. This was performed using traditional methodology, i.e., 
heating the substituted amine with equimolar equivalents of paraformaldehyde in 
methanol for 2 h. Upon condensation of the amine and aldehyde, the resulting reactive 
intermediate was treated with the substrate to afford the phenolic Mannich base 
derivatives CDM30-CDM36, after purification by column chromatography. The 
second step in the synthesis involves a base-catalyzed Claisen-Schmidt condensation 
reaction of CDM30-CDM36 with the 4-aminoquinoline-derived aldehyde to yield the 
Mannich base derivatives CDM36-CDM41 in moderate yields. This approach used is 
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~o I ~ R8 ___ "~o I ~ Ra ~ // OH OH 








CDM30 NRR = pyrrolidinyl, R8 = H CDM37 NRR = pyrrolidinyl, R8 = H 
CDM31 NRR = piperidinyl, R8 = H CDM38 NRR = plpendmyl, R8 = H . 
CDM32 NRR = morpholino, R8 = CH
2
-morpholine CDM39 NRR = morpholino, R8 = CH2-morphohne 
CDM33 NRR = 1-ethyl-piperazinyl, R8 = H CDM40 NRR = 1-ethyl-plperazlnyl, R8 = H 
CDM34 NRR = I-butylamino, R8 = H CDM41 NRR = I-butylamlno, R8 = H 
CDM35 NRR = dimethylamino, R8 = H CDM42 NRR = dlmethylamlno, R8 = H 
CDM36 NRR = diethylamino R8 = H CDM43 NRR = dlethylammo, R8 = H 
, CDM44 NRR = dimethylammo, R8 = OMe 
Scheme 3.13: Reagents and conditions i.) RJR2NH (2eq), CH20 (2eq), MeOH, 65°C, 2 h then addition 
of substrate ii.) 3% w/v NaOH, MeOH, Reflux, 72 h, 
Synthesis of the target compounds via path b, that is aminomethylation of the 
hydroxylated chalcones CDM20 and CDM21, was attempted using various reaction 
conditions. The amine both as it free base and as hydrochlorides, formaldehyde either 
as an aqueous solution or paraformaldehyde and various solvents such as ethanol, 
methanol, acetonitrile and NMP were used in order to improve reaction times and 
yields. These attempts, however, were unsuccessful except for the formation of 
CDM44, which was achieved by heating dimethylamine hydrochloride and 
paraformaldehyde in NMP for 2 h, followed by addition of CDM21 and further 










0 ill 0 ill I ~ h I ~ h CDM21 CDM44 CI N CI N 
Scheme 3.14: Reagents and conditions i.) (CH3)2NH.HCl, CH20, NMP, 70°C, 4 days. 
The structures, isolated yields and respective melting points of the resultant Mannich 
base derivatives of the 4-aminoquinoline-based chalcones are depicted in Table 9. The 
low yields observed may be due to factors such as the competing reaction of 
deprotonation of the phenolic proton (Fig. 3.5, p62) as well as difficulty In 
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T obi. 9: Monni,h bJ'" deri .. ",ives of 4·Am in"'! uinnlinc_ba,cd ,haknne, with [heir TO,I""";"< yie ld, 
arlO 1ll. ltin~ lX'i"" 
cmB7 17 209-211 
CDM38 
CDM39 15 233-235 
CDM"O 12 214-216 
cmHl 1 I 232-234 
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3.2.4 Mechanistic Details 
The mechanism of the Mannich reaction has been well investigated21 ,22 and is thought 




+ H,O.. HO-CH -N/ 
2 '" +H 
mo", pattway ° tl + HN/ 
+ H" "-
"-
+ /NH '" / 
==~ .. N-C-N 
+ H / H2 '" 
mapr pattMay 
Scheme 3.15: Two possible reaction pathways of the Mannich reaction 
The preferred pathway depends on the nature of the reactants and the reaction 
conditions employed. Pathway A is widely accepted as the favoured route in which 
the nucleophilic amine attacks the more electrophilic substrate, which is 
formaldehyde, to give the condensation product, an imine salt. The electrophilic salt 
can now add to the phenol group of the substrate to give the product of the reaction, a 
Mannich base in which an aminomethyl group replaces the active hydrogen of the 
substrate. The proposed mechanism is given in Scheme 3.16. 
e;r+I/HH 6( --.. I NMe2 - I "'-':: NMe2 
~ ~ Mannich Base 
Scheme 3.16: Reaction mechanism ofMannich reaction 
Phenols undergo aminomethylation at the ortho and para positions due to activation 
at these positions by the hydroxyl group. The regioselectivity is influenced by the 
nature and position of substituents on the phenol ring. The ortho position is usually 
preferred, although para-substitutions can occur when the ortho positions are blocked 
or have large substituents, as the attacking species shows considerable steric 
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postulated mechanism involving a hydrogen-bonded complex depicted in Figure 3.21. 
For the Mannich bases in this study, the para position was blocked and thus 
aminomethylation occurred vicinal to the hydroxy group. The aminomethylation of 
the 4-hydroxyacetophenone starting material is also chemoselective, as this substrate 
has two sites for reaction with the aminomethylating agent. This chemoselectivity can 
be accounted for by comparing the transition states for both possible functional 
groups that may undergo attack, that is, the phenol group and the alkyl keto group. 
Aminomethylation at the active hydrogen of the phenol yields a more resonance-
stabilized intermediate and is thus favoured (Figure 3.21). Reaction conditions are 
also important for chemoselectivity, with the alkyl keto group reacting under acidic 
conditions and phenols under neutral or basic conditions. 
(\ 
". ~,H, 0 
(~ ;,!.:-~ ~ 
~~ 
(I I (' ~ 
~x ~ ~ li 
OH ( OH 
~ 
a b c 
Figure 3.21: Chemical structures depicting regioselectivity due to a.) Hydrogen-bonded complex and 
reaction intermediates explaining chemoselectivity between the b.) alkyl keto group and c.) phenol 
group. 
3.2.5 Characterization of Target Compounds 
All Mannich base derivatives were characterized by IH and l3C NMR, IR, mass 
spectrometry and elemental analysis. As for the IH NMR of the 4-aminoquinoline-
based chalcones, resultant products displayed two common diagnostic doublets 
around £5 8 ppm and £5 7 ppm, correlating to the methine protons on the double bond of 
the a,p-unsaturated system. Additional IH NMR spectroscopic evidence for 
confirmation of the proposed structures came from the appearance of a singlet, 
integrating for two hydrogens at ~ 8 3.7 ppm which is consistent with the expected 
CH2 of the aminomethyl group. This was confirmed in the l3C NMR spectrum with a 
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Figure 3.22 shows a IH NMR spectrum of representative compound CDM43. 
6/ppm Multiplicity J/Hz 
9.15 s -
8.48 d 5.2 
CI 8.45 d 9.2 
7.98-7.96 dd 2.4. 8.4 
7.93 d 2.1 
7.90 d 15.0 
7.89 d 2.4 
7.82 s -
7.69 d 15.6 
7.65 d 7.6 
7.58-7.56 dd 2.4, 9.2 
7.50 t 8.0 
7.42 d 8.0 
6.94 d 5.6 
6.78 d 8.4 
3.85 s -
2.62-2.56 q 7.2 
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3.2.6 Cyclodeurin Inclusion Complucs 
Preparation of cyclodextrin inclusion complexes was attempted using CDM38 based 
on its hiological aeli, ity and availahility of malerial. Kneading and co-pr~cipitation 
methods were employed using ~-CD in both \:\ and 2: 1 (CD: guest) molar ratios and 
all aUempts were un~ucce~,ful, wilh the experim~n(al rXRD patterns matching those 
of native ~-CD, However, a y-CD complex was prepared hy the kneading method 
using a I: I molar ratio, with th~ rXRD pallem of lhe knea<kd material matching that 





0 b • ..-I' > ~ 
• • .. • 
Figur< 3.23: . ) C"mpu",d 1'\ Ril Iroo" rOf known -f ,CD ,,~mp l.x and .'p"Timent.i rXRD trace ~f (b) 
y_CD_CDM3M ,-ompk< 
A number ofpomly w lublc compound, haw be~n di"olved in aqueous solutions of 
the methylated CD, D1MER and TRIMER" It was proposed that inclusion of the 
targd compound,> \\hich ha\'C a stTong hydrophohic natur~. might ht: more successful 
in the more hydrophohic c:ciodextrin TRIMER. These experim~nts howe\er al~o 
failcd. Although ancmpts in cyciodcxtrin inclll'iion werc somcwhat fruitlcs,. 
successful inciusiOil of a guest often re<luires uni<lUC: design of a procedure 'ta!lor-
mad.: ' 10 th~ particular gllC~\. Fxhau,ti\'e analy,is of c:cirxkxlnns and their 
d~ri\'atiw~ and optimization of rcaction conditions (pH. ~oh' ent and tempo:ratun:) may 
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CHAPTER 4 
Biological Results and Discussion 
4.1 Introduction 
The following chapter discusses the results obtained from the biological evaluation of 
the synthesised compounds in vitro in appropriate cancer and malaria disease models. 
The synthesized target compounds were primarily generated in order to determine 
their abilities to inhibit both growth of malaria parasites and of tumour cells by 
determining the ICso and EDso values. The ICso and EDso are terms used to describe 
the inhibitory concentration and effective dose, respectively, of a drug necessary to 
produce a therapeutic effect in 50% of the test sample and are used interchangeably. 
The lower the ICso or EDso value of a compound, the greater is its efficacy. However, 
a property of equal importance for a good drug candidate is that it should be 
selectively cytotoxic towards the parasite or tumour cells and not towards normal 
human cells. Within the context of malaria, compounds were evaluated against both 
chloroquine-sensitive and chloroquine-resistant strains of the causative agent 
Plasmodium Jalciparum. In order to have a deeper understanding of the mechanistic 
basis of the observed activity, the target compounds were tested for inhibition of the 
cysteine protease falcipain 2 and haemozoin formation. The description of the assays 
and experimental details used in biological evaluation of the target compounds are 
given in the experimental section. 
4.2 In Vitro Antimalarial Activity of 4-Aminoquinoline Chalcones 
4.2.1 Results and Discussion 
The antimalarial activity of the 4-aminoquinoline-derived chalcones CDM04-CDM08 
and CDM13-CDMIS were evaluated in three different in vitro assays in the 
laboratories of Professor P. Rasoanaivo at Institut Malgache de recherches appliquees 
in Madagascar. In the first of these, the compounds were assayed against the 
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rCM29 P. jalciparum ,lrain and chiornquin,,·rc,i,;tanl FCM29 P. falciparom strains, 
using ~hloroquin~ as lh" (Control drug . Th~ re,ult, for the inde!'t'nd~nl I"" ar~ 
pr"s"nt~d in Table 10. 
CD:\-\o4-CDM08 CDMo{; 
COML3-CD~1 1 5 
>< CI 0.7.1 I 7~ 0.69 1.65 1.11 
C> n 1.2, Z,73 2,03 ,j,1] z,n 
>< n 0.18 0.13 016 >W 0,63 
OM,' 0,11 "~ O.5Z 1.17 0.48 
O\lc 0.22 0." 0". 0,87 0,68 
OM< 03~ 0.72 0.30 1 12 0." 
OM, OM, 0.39 0,82 055 1.16 0.79 



















Chapter 4: Biological Results and Discussion 
As can be seen from the data presented in the table, relative to chloroquine none of the 
compounds exhibited any significant antimalarial activity in both the chloroquine-sensitive and 
chloroquine-resistant strains. The most active compound emerging from this study was CDM06 
against the chloroquine-sensitive strain 307 (ICso = 0.43 11M), in which the 4-aminoquinoline 
moiety and the ketone linker have a meta relationship. On comparing the data obtained from 
CDM04 (lC so = 1.74 11M) and CDM06 (lCso = 0.43 11M), the meta position seems to be the most 
favourable position for substitution for target hybrid 1. This observation may indicate a steric 
element is possibly involved in the interaction necessary for activity. All the other compounds 
were over several hundred-fold less efficacious than chloroquine. CDMI3 (lCso of 0.87 11M) and 
CDM08 (lCso of 1.08 JlM) showed the best activity against the chloroquine-resistant strains 
FCM29 and W2 respectively, indicating that the presence of a methoxy group is an important 
structural feature associated with antimalarial activity. Previous structure-activity studies on the 
antimalarial activity of chalcones have reported that electron-withdrawing groups on ring A are 
important for activity. 1 The results from this rather limited series suggest that this is not 
necessarily so and what has proven of more importance is the presence of a methoxy group. 
Nevertheless, more compounds need to be evaluated in this series to confirm this hypothesis. A 
general trend observed against all three strains is that target hybrid 2, in which the 4-
aminoquinoline moiety is attached to ring B, is more active than target hybrid I, in which the 4-
aminoquinoline moiety is attached to ring A. A notable observation is that compounds CDM13-
CDMI5 all have meta relationships with regard to the 4-aminoquinoline ring and the enone 
linker, once again implicating a steric element in the interaction necessary for activity. The 
observation that some of the compounds had similar activities against chloroquine-resistant and 
chloroquine-sensitive P. Jalciparum strains suggests that this series of 4-aminoquinoline 
chalcones may have a mechanism of action different to that of chloroquine and/or that the 
chloroquine resistance mechanism is circumvented in in this case. Despite the lower 
antiplasmodial activities associated with these compounds compared to chloroquine, the target 
compounds on average possess favourable resistance indices (Table 11). The resistance index 
(ratio of the ICso in the resistant strain to that in the sensitive strain) is a measure of the cross 
resistance of a compound between two species of the parasite, with a low value being more 
favorable. 











Chapter 4: Biological Result, and Di.,cu%ion 
Target compollnds have resistanee inde\ \ 'alucs far belo\\ those of chloroquine and thus have 
lo,",cr cross-resislance betwcen thc chloroquinc-sensitivc and chlol'()~uinc-rcsi.,tant Itraim. 
Con,idering that the compounds bear the 4-aminoquinolinc moiety. it is possibk thatthcy may in 
part be acting b)' a mechani,m !.imibr l<J that for chloroquine, namely. the inhibition of 
haemozoin formation. Investigation of the Il-ha€matin inhibition of the,c compounds i, thu, of 
inten:st in order lC\ ~cces~ th~ contribution of tile 4-aminoquinoline ring to the antimalarial 
activity. Tile citrate ,alt derivatives or the 4-aminoquinoline chalcones \\ere screened for their 
ability to inhibit 1'-h""m~lin formation. with only C Il .\127 showing activit),. The lew value, an: 
measllred in eqllivalents, with a value of 0.449 equiv. de\<:rmined for CD:\127, \\hich is 4 times 
more activc than chloroqlline (1.91 c~ui\'). Th~ lower activity obsef\'ed in dim agaill~t th~ 
chloroquine-sensitivc and chloroquine-re,islam strain, compared to that of chloroquine might Ix 
dll<' to the absence of a basic terminal nitrogen atom and /or a lipophilic sid~ chain. v,hidl an: 
important for accumulation in tile acidic food vacllole of the parasi\<: and cro,sing the parasit~ 
membran~ respectively. Modilications ,uch as introdllcing a basic nitrogen in the sU'uctun: of the 
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4.3 In Vitro Anticancer Activity of 4-Aminoquinoline Chalconcs 
4.3.1 Resul', lind Di,cussiuD 
"j he anticancer activities of the 4-aminoquinoline chalcon~s were determined in the 
laboratories of Professor C. Medlen. of the [)epartment of Pharmacolog)' at the 
Uniwrsity of Pretoria. for evaluation of the anticancer activity. the cilrate salt 
derivatives CD:'I122-CD.\129 of the synthesised 4-aminoquinolinc chalcone, were 
tested against lIela (lluman adenocarcinoma of the cervix) cell" Each experiment 
was done in triplicat<! and the biological results are summarised in Table 12. 
~ ~R' 
H"~ 
~., 0 ,,"' 
~,,+,/ '''yw:><'' 
CI "I..:ce') I 
\. >UlC ./ 
CD.'IU2-CD.'tI26 CI) .'tI~4 
CDMZ7_CDMIQ 
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The <lata ,hown in this table reveals thaI citrate ,;alt deri"atives of target hybrid 2, 
CD:'I127·CDM29, were more a.:ti"C' tlhm those generated from target hybrid L 
C DM22-CDM26. with IC S(> values of the citrate salts ranging from 0.547 to 27.224 
i!M. The,>e ComP<)U1WS are ~ignifkanUy more polen! than chloroquine. with the most 
aClh'e compound CD:\129 (IC.o = osn J.l\1) being almo,! 140 time~ mor~ potent. A 
previol1~ study has revealed a large number of mctboxylutcd chukones with 
antimitotic activity against HcLa cclls/ with a preference for the mcthoxy group, on 
ring A. Indeed, the biological rcsult~ of the mcthoxy-substitutcd chalcone, CD1\.127 
(Ie", = 0.872 )1'\1). CDM211 (JC,,~ = 0.817 .lIM). CDM29 (lC.o = 0.547 )lM) and 
CDM24 (IC,,! = 2.972 jJM) c·onfinned thi~ ~tuJy ""ith the more potent seric, CDM27-
C DM29 having the methoxy groups located on ring A. The methoxylated series 
CDM27-CD:\U9 displayed good in vilro activity against HeLa cells with un increase 
in methoxy groups accompunied hy un increase in activity (Figure 4.1). 
" " _ 0.7 






No. of methoxy groups 
rigur~ 4.1; Plot dopicting "Ike! Oil acti,ily wi," increa,ing <lumbtr of ",. tooxy ~roups 
Compar;,,)ns ob~ervcd ",ilhin target hybrid L rev~als that th~ m~l(1 relationship \,ith 
regarJ to the position of the 4-aminoquinoline moiety and the cnone linker. displays 
superior activity to the para counterpart. Thi, may he a result of more stcrically 
favourable interactions betwe~n the drug and it~ site of action. 
It wa~ postulated that electron-withdrawing groups on nng H \\ould render the ~­
CarlxlO electron deficient by electron delocaliwtion along the a,~-unsaturated system, 
and accordingly, more inclined to nucleophilic attack by cellular thiots. Althongh the 











Chapter 4: Biological Results and Discussion 
more electronegative fluoro-substituted chalcone CDM25 (ICso = 6.05 ~M) showed 
superior activity to the chloro-substituted chalcone CDM22 (ICso = 27.224 ~M) and 
CDM23 (ICso = 26.76 ~M), the presence of an electron-donating methoxy group on 
ring B, CDM26 (ICso = 2.972 ~M), seemed more important for in vitro activity. As a 
consequence of the good in vitro activity displayed for CDM27-CDM29, attempts 
were made to form cyclodextrin inclusion complexes of these three compounds in 
order to potentially improve aqueous solubility and thus their efficacy. 
4.4 In Vitro Antimalarial Activity of Phenolic Mannich Base 
Derivatives of 4-Aminoquinoline Chalcones 
4.4.1 Results and Discussion 
The phenolic Mannich base derivatives CDM37-CDM44 were evaluated in four 
different in vitro assays. Firstly, the compounds were assayed against the chloroquine-
sensitive D lOP. Jalciparum strain, using chloroquine diphosphate as the control drug, 
at the Department of Pharmacology (UCT). The antiplasmodial activity of the 
Mannich base derivatives was determined against the W2 chloroquine-resistant P. 
Jalciparum strain and were also evaluated for their abilities to inhibit the activity of 
the plasmodial cysteine protease falcipain 2. These antiplasmodial and enzyme 
inhibition tests were conducted at the Department of Medicine, San Francisco General 
Hospital, University of California at San Francisco (UCSF), in collaboration with 
Professor P. J. Rosenthal. Lastly, the ability of the compounds to inhibit ~-haematin 
(haemozoin) formation was determined in the laboratories of Prof. TJ. Egan at the 
University of Cape Town. 
The antiplasmodial activities as well as the data for inhibition of falcipain 2 and ~­
haematin formation of chalcones CDM20-CDM21 and their Mannich base 
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CD_\120·C V_\12 L, CV_\1J7_CV:\-144 
Tahl. 13, f~ "Urn .nnm.l", i. 1 activity and inillbn ion of falcipain 2 .nd ~-h""mal in !'lrmal;O<l of 
Mannich bose der ;, ,,,i,", 
0.584 0_7584 >6JlOO 0.190 
OM" 0.462 0.4843 8.465 0_279 
n 0.111 0.0039 11.515 0.219 'V 
E 0 0.378 0.0428 24.130 0.235 
0 0.091 0.0503 59.415 
H 
~ 
"~ 0.195 0_152 2L650 0_223 
nd" 0.0-181 27 .835 od' 
E I 0.458 0.0178 24.820 nd" ,~ 
H G 0.344 0.0830 21.675 0.232 












Chapter 4: Biological Results and Discussion 
The data shown in this table reveals that as antiplasmodial agents, the Mannich base 
derivatives are significantly more active than their corresponding chalcones against 
the D 1 0 and W2 strains in vitro. One of the reasons for the increased potency of the 
Mannich base derivatives may be ascribed to the presence of an additional 
protonatable nitrogen atom, which is important for increased accumulation within the 
acidic food vacuole of the parasite. This property may also be explained by an 
increased interaction between these compounds and the cysteine protease at His 67 in 
the active site. Compared to chloroquine, all compounds showed weak to modest 
activity against the chloroquine-sensitive strain 010, with the most active compound 
being CDM39 (lCso = 0.09 ~M). This observation may be due to problems 
experienced in solubilizing the compounds in the appropriate medium necessary for 
biological evaluation. On the other hand, most Mannich base derivatives showed 
greater antiplasmodial activities in the resistant W2 strain (ICso ranging from 0.004 to 
0.08 ~M) than the reference drug chloroquine (lCso = 0.099 ~M), with exception of 
the chalcones CDM20-CDM21 and the Mannich base CDM40. There is a fairly good 
correlation between antimalarial activity against D 1 0 and inhibition of ~-haematin 
formation. This observed correlation may be a result of similar pKa values and thus 
comparable vacuolar accumulation of the Mannich base derivatives. Slight deviations 
in the correlation between the activity and ~-haematin inhibition may be a result of the 
small differences in pKa values. This correlation/lack of correlation between 
biological activity and ~-haematin inhibition is only considered in chloroquine 
sensitive strains due to other factors in play in chloroquine resistant strains that 
disallow an accurate comparison. Both the chalcones and their Mannich base 
derivatives (0.190-0.429 equiv.) were approximately 10 times more active than 
chloroquine (1.91 equiv.) on the inhibition of~-haematin formation. 
The phenolic Mannich base derivatives were stronger inhibitors of recombinant 
falcipain 2 than the corresponding chalcone CDM20 that may be attributed to the 
larger number of electrophilic centers available for nucleophilic attack by cellular 
thiols. Interestingly, the methoxy-substituted chalcone CDM21 (ICso = 8.465 ~M) 
showed the strongest inhibition of recombinant falcipain 2. There seems to be no 
correlation between the ability of a compound to inhibit falcipain 2 and 
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not the primary target of these compounds and/or that the observed activity is due to 
multiple mechanisms including p-haematin formation. In addition it may be that the 
target compounds may not be reaching the target (fa1cipain 2) in high enough 
concentrations due to unfavourable physio-chemical properties. In order for the target 
compounds to reach its site of action, they must cross the parasite membrane and 
accumulate in the food vacuole. The pyrrolidine-derived Mannich base CDM37 is a 
promising drug candidate as it shows superior activity in both the chloroquine-
sensitive (lC50 = 0.111 IlM) and chloroquine-resistant (IC5o = 0.0039 IlM) P. 
Jalciparum strains as well as strong inhibition of fa1cipain 2 (lC5o = 11.51 IlM) and P-
haematin formation (0.219 equiv). 
4.5 In Vitro Derivatives Anticancer Activity of Phenolic Mannich 
Base Derivatives of 4-Aminoquinoline Chalcones 
4.5.1 Results and Discussion 
The anticancer activities of hydroxylated cha1cones CDM20 and CDM21 and their 
Mannich base derivatives CDM37-CDM44 were assayed against HeLa cells in the 
laboratories of Professor C. Medlen, at the Department of Pharmacology at the 
University of Pretoria. This study was performed in order to determine the biological 
effect of conversion of these cha1cones into the corresponding Mannich bases. The 
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CD_\120·cn~12,C[)~137·C[)\I44 
To bit 14: /" ;'il,-() antKance, a<tivilY of Mannich b .. ", Jeri,'alive, of 4,ami"''GLJi n"lin< ch.lcoo", 
OM, 
H 0 0.770 
H 0 I 036 
.,-,0 0 US7 
H O_~76 
H O.R50 
H G L218 
OM, I 0.921 ,-
0,803 
It is dear from the data presented in Tahle 14 that the cOn\'crSHln of chalcnnes 
CD:\120 and CDM2I imo the corresponding Mmmich bases led 10 an increase in 
potency. The Mannich ba,e CDM44 (Ie,,, - 0.911 ,lM) was 1.7 time, mort' cytotoxic 
than the corresponding chalcone CD~21 (1.540 Il.\f). Of interest is that the 
introduction of a mcthoxy group \0 the hydroxylated chalcone CD.'t120. as in 
CD,\121. was accompanied hy an appre<:iabk increase in a<:tivity. This obsenatioll is 
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with good antimitotic activity in HeLa cdls.2 The \1annich base derivatives CDM37-
CO.\143 displa}ed significantly greater activity than the related chalcone (,D;\120. 
with most :v1annich bases having more than six times the potency than that of 
CO.\120. The most active compound emerging from this study was the pyrrolidine-
derived :v1annich base CDl\B7 wilh an Ie;,) = 0.770 f1M. which was comparable to 
the control dmg Cisplatin (ICjG = 0.803 f1M). As ShO,""l1 in Figure 4.2. there seems to 
be no trend between octi"it} and the type of amine (cydi~ or acydic) used in the 
aminomethylatio!1 or (he phenol ic ~h;!kones_ 
ll":~::::'~I_:'OOl,,:",--_CO·~='C;-.l1 I CDMH ~T>M-IO CDM)! CDMJ' I 
f jgu," 4.2: PI", depicting Ie ", vall~' of Mannich bas< derivat iwo 
The enhanced anticancer activity of the Mannich base derivatives in <:omparison to 
their chakone cOllllterpans may be attributed to a number of rad'..-s. The ohserved 
acti vity may be a result ofa greater nllmber of nuc leophilic sites in the molecule for 
eJectrophilic attack \\ith cellular thiols but also may he due to the concept of 
sequential cylowxicit/, in which the consecutive release of two or more C}101OXic 
compoll!lds is more damaging to malignant cdls rather than normal cells. In ordcr to 
access the viahility of these compound, a, prototypic anticat1(:er molecules, an 
eval uation or their seiect;, e toxicity towards neoplastic rather than normal cells needs 
to be carried om. 
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4.6 Conclusion 
In conclusion, we have successfully employed the 4-amino-7 -chloroquinoline moiety 
to discover new potential antiplasmodial and anticancer agents. The simplicity of the 
chemistry employed during synthesis, coupled with the commercial availability and 
economic cost of reagents makes the 4-aminoquinoline chalcones attractive potential 
lead compounds in the search for antiplasmodial and anticancer agents. The 4-
aminoquinoline chalcones showed weak to modest antiplasmodial activity against 
both chloroquine-resistant and chloroquine-sensitive P. Jalciparum strains. A meta 
relationship between the 4-aminoquinoline unit and the ketone linker was found to be 
preferential for both antimalarial and anticancer activity. Target hybrid 2 in which the 
4-aminoquinoline unit is attached to the aldehyde, was more potent than target hybrid 
1, in which the 4-aminoquinoline unit is attached to the ketone. This was observed in 
both malaria parasites and cancer cells. Electron withdrawing groups which 
potentially render the ~-carbon electron deficient and thus more susceptible to 
nucleophilic attack, were found to be of less structural importance than the presence 
of a methoxy substituents. The methoxy-substituted series CDM13-CDMI5 had good 
activity against HeLa cells and would be of interest to evaluate their selective toxicity 
towards neoplastic rather than normal cells. Despite the lower antiplasmodial activity 
of the 4-aminoquinoline chalcones than chloroquine, they possessed favourable 
resistance indices. This low activity may in part due to the hydrophobic nature of the 
molecule and introducing a terminal nitrogen atom or making different salt derivatives 
with a view to enhancing absorption under physiological conditions may increase 
activity. 
The low reaction yields obtained for the phenolic Mannich bases may be attributed to 
factors such as the competing reaction of deprotonation of the phenolic proton as well 
as difficulty in purification by column chromatography as a result of fractions 'co-
running'. Optimization of reaction conditions is required for use of these Mannich 
base derivatives as potential lead compounds. All Mannich base derivatives were 
found to be more potent than their corresponding chalcones against both the malaria 
parasite and tumour cells. These compounds showed significant activity in the W2 
chloroquine-resistant strain, with most compounds being more active than 
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times more active than chloroquine on the inhibition of ~-haematin formation. The 
pyrrolidine-derived Mannich base CDM37 is a promising potential drug candidate as 
it shows superior activity in both the chloroquine-sensitive (lC 50 = 0.111 J..lM) and 
chloroquine-resistant (IC50 = 0.0039 J..lM) P. Jalciparum strains as well as inhibition of 
falcipain 2 (lC50 = 11.51 J..lM) and ~-haematin formation (0.219 equiv). It would be of 
interest to test this compound in animal models, as the in vitro activity does not 















All commercial chemicals were purchased from Merck (South Africa) or Sigma-Aldrich. The 
host compounds P-cyciodextrin, y-cyclodextrin and TRIMEB were obtained from Cyclolab 
(Budapest, Hungary). All solvents were freshly distilled and dried by appropriate techniques 
with the exception of analytical reagent grade absolute ethanol (EtOH) and methanol (MeOH), 
anhydrous dimethylsulfoxide (DMSO), dichloromethane (DCM) and acetone. Triethylamine was 
dried over and distilled from calcium hydride and stored over potassium hydroxide pellets. 
Reactions were monitored by thin layer chromatography using Merck F254 silica gel plates and 
were visualized by ultraviolet light or staining with iodine vapour, ninhydrin or anisaldehyde. 
Silica gel chromatography was performed using Merck kieselgel 60. 
Melting points were determined on a Linkam THMS600 hot stage apparatus and are uncorrected. 
Infrared (IR) spectra were recorded on a Perkin-Elmer FT-IR spectrometer in the range from 
3800 to 800 cm-1 as chloroform solutions on sodium chloride discs. Microanalyses were 
determined using a Fison's EA 1108 CHNS-O instrument. Low resolution masses were 
determined by the Department of Pharmacology (UCT) on an API 2000 from Applied 
Biosystems Mass spectra were recorded on a VG micromass 16F spectrometer operating at 70eV 
with an accelerating voltage of 4kV and a variable temperature source. Accurate masses were 
recorded using VG70-SEQ (EI, operating at 8kV) instrument at the University of the 
Witswatersrand. 
Proton nuclear magnetic resonance eH NMR) spectra were recorded on a Varian Mercury 300 
MHz or a Varian Unity 400 MHz at ambient temperature. All spectra were recorded in 
deuterodimethylsulfoxide (d6-DMSO) and deuterochloroform (CDCh), using tetramethylsilane 
(TMS) as an internal standard. The chemical shifts (0) are given in ppm and the coupling constant 
J is given in Hz. Carbon-I 3 nuclear magnetic resonance e 3C NMR) spectra were recorded on the 
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General procedure for synthesis of 4-aminoquinoline-derived methyl ketones CDMOl-
CDM03 and benzyl alcohols CDM09-CDMI0 
A solution of aldehyde or ketone (1.0 eq) and 4,7-dichloroquinoline (1.0eq) in ethanol was stirred 
under reflux at 85-90°C for 4 h. The resulting suspension was cooled to room temperature and 
basified to pH 8 by the addition of a 25% ammonium hydroxide solution. The resulting 
precipitate was collected by filtration, washed with distilled water and dried in vacuo. To remove 
any remaining product, the aqueous filtrate was extracted with dichloromethane, dried over 
anhydrous Na2S04, and concentrated under reduced pressure to give a yellow solid. The 
combined organic products were recrystallized from ethanol to give the desired product isolated 
as yellow crystals. 






5 H5N 14 13 12 
6~'~3 
~"-:2 
CI 7 Sa N 
15 
16 
S 1 ellow crystals (5.7445g, 79%); Rf (EtOAc:hexane, 3:2) 0.55; OH 
(300MHz, d6-DMSO) 9.415 (1 H, s, NH), 8.62 (1 H, d, J 5.1, H-2), 8.41 (1 H, d, J 9.3, H-5), 7.99 
(3H, m, H-8, H-I0 and H-ll), 7.64 (1H, dd,J2.1, 8.7, H-6), 7.45 (2H, d,J9, H-9 and H-13), 
7.25 (IH, d, J 5.1, H-3), 2.55 (3H, s, CH3-16); Oc (75MHz, d6-DMSO) 196.2, 150.5 (2C), 147.0 
(2C), 144.9, 134.9, 131.7, 129.9 (2C), 128.2, 125.8, 124.9, 120.0, 118.7, 104.2, 26.4. 
1-[3-[ (7 -Chloro-4-q uinolinyl)amino] phenyl] -ethan-I-one, CDM02 
10 
9 -::?' 11 
~ 1 15 ..... 16 
5 H~N414 13 12 
6~·'-'::3 0 
~..-:2 
CI 7 Sa N 
S 1 ellow crystals (0.609g, 94%), Rf (EtOAc:hexane, 3:2) 0.306; OH 
(400MHz, d6-DMSO) 11.32 (1 H, s, NH), 8.95 (l H, d, J 9.2, H-5), 8.55 (1 H, d, J 6.8, H-2), 8.21 
(1 H, d, J 2.4, H-8), 8.04 (1 H, s, H-13), 7.99 (1 H, d, J 7.6, H-ll), 7.88 (1 H, dd, J 2.4, 9.2, H-6), 
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6c (lOOMHz, d6-DMSO) 199.7, 151.3, 149.0 (2C) 143.0, 137.5, 134.9, 129.5 (2C), 127.2, 122.5, 
120.0 (2C), 118.8, 113.1 (2C),29.4. 
1-[2-[(7-Chloro-4-quinolinyl)amino]phenyl]-ethan-l-one, CDM03 
~~ 16u:~D11 
5 H~N414 13 12 
6~'~3 
~/:2 
CI 7 8a N 
8 1 Yellow crystals (0.4298g, 60%); Rr (EtOAc:hexane, 3:2) 0.36; 6H 
(400MHz, d6-DMSO) 11.40 (l H, s, NH), 8.75 (1 H, d, J 8.8, H-5), 8.51 (l H, d, J 6.4, H-2), 8.19 
(lH, d, J2.0, H-8), 8.03 (lH, d, J7.6, H-lO), 7.84 (lH, dd, J2.0, 9.2, H-6), 7.74 (lH, t, J8.0, H-
12),7.60 (lH, d, J 7.6, H-13), 7.53 (lH, t, J, 7.6, H-l1), 6.64 (lH, d, J 6.8, H-3) 2.53 (3H, s, 
CH3-16); 6c (100MHz, d6-DMSO) 198.2, 151.5 (2C), 147.5 (2C), 145.3, 134.9, 134.0, 129.6 
(2C), 127.2, 122.8, 119.5, 118.7 (2C), 116.2,27.4. 





'-_________ .. Pale yellow crystals (2.0498g, 98%); Rr (5% MeOH in DCM) 
0.36; 6H (300MHz, d6-DMSO) 9.06 (l H, s, NH), 8.46 (1.H, d, J 5.7, H-2), 8.43 (l H, d, J 8.7, H-
5),7.88 (lH, d, J2.7, H-8), 7.58 (lH, dd, J2.4, 9.0, H-6), 7.38 (lH, t, J7.8, H-10), 7.34 (lH, s, 
H-13), 7.24 (lH, d, J8.1, H-ll), 7.12 (lH, d, J8.1, H-9), 6.93 (lH, d, J5.4, H-3), 5.24 (lH, t, J 
5.7, OH), 4.54 (2H, d, J 5.7, H-15); 6c(75MHz, d6-DMSO) 151.8, 149.5, 148.0, 143.9, 139.9, 















'-_______ .. Yellow crystals (0.2274g, 33%); Rf (EtOAc-Hexane, 3:2) 0.58; 8H 
(300MHz, d6-DMSO) 8.8 (l H, s, NH), 8.38 (l.H, d, J 6.0, H-2), 8.35 (l H, d, J 9, H-5), 7.88 (l H, 
d, J2.7, H-8), 7.61 (2H, m, H-6 and H-12), 7.35 (2H, m, H-9 and H-ll), 6.28 (lH, d, J5.7, H-3), 
5.24 (lH, s, OH), 4.52 (2H, s, H-15); 8c(75MHz, d6-DMSO) 151.5, 149.3, 148.1, 140.5 (2C), 
134.8, 129.5,128.5,127.3,123.9,122.0,120.9,119.7,117.6, 112.0,63.62. 
General procedure for oxidation of 4-aminoquinoline-derived benzyl alcohols 
The alcohol CDM09-CDMIO (1.0 eq) was stirred with Et3N (6.0 eq) in DMSO, followed by the 
addition of sulfur trioxide pyridine complex (3.0 eq), and stirred at room temperature for 72 h. 
The reaction mixture was extracted with ethyl acetate and the organic layers washed with 
distilled water and brine. The combined organic extracts were dried over anhydrous Na2S04 and 
the solvent removed under reduced pressure to yield the corresponding aldehyde as a yellow 
powder. 





'-___ ...... _____ .. Yellow crystals (2.60g, 97%); Rf (5% MeOH:DCM) 0.56; 8H 
(300MHz, d6-DMSO) 10.01 (lH, s, (C=O)H-16), 9.4 (lH, s, NH), 8.46 (IH, d,J5.4, H-2), 8.41 
(IH, d, J9.3, H-5), 7.89 (lH, d, J2.7, H-8), 7.68 (3H, m, H-9, H-I0 and H-ll), 7.58 (lH, dd, J 
2.1,9.0, H-6), 7.02 (1 H, d, J 5.4, H-3); 8c(75MHz, d6-DMSO) 192.9, 185.8, 151.8, 149.4, 147.3, 
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[2-(7 -Chloro-q uinolin-4-ylamino )-phenyl]-benzaldehyde, CDM 12 
:6
0 10 
H 15 9:::;:::--- 11 
16 I 
~ 12 
HN 14 13 
5 4 
-...:::::::.4a -...:::::::. 3 
--_______ ...... Yellow crystals (0.1475g, 81%); Rf (5% MeOH:DCM) 0.76; 6H 
(300MHz, d6-DMSO) 10.25 (1 H, s, (C=O)H-16), 10.07 (1 H, s, NH), 8.65 (1 H, d, J 5.1, H-2), 
8.31 (1H, d, J9.0, H-5), 8.01 (1H, d, J2.7, H-8), 7.73 (lH, d, J7.6, H-IO), 7.68 (4H, m, H-6, H-
II and H-13), 7.30 (lH, t, J 7.2, H-3), 7.21 (1H, d, J 5.4, H-3); 6c(75MHz, d6-DMSO) 191.8, 
151.3, 149.5, 147.8, 146.4, 136.6, 134.8, 130.5 (2C), 129.1, 127.3, 123.0, 119.5 (2C), 116.4, 
112.6. 
General procedure for protection of hydroxyacetophenones CDMI6-CDMI7 
A solution of 4-hydroxyacetophenone or 4-acetovanillone (1.0 eq), pyridinium p-toluenesulfonate 
(0.1 eq) and 3,4-dihydro-2H-pyran (1.6 eq) in dry DCM was stirred at room temperature for 72 h. 
The reaction mixture was washed with 1 M sodium carbonate, water and brine. The organic 
extracts were dried over Na2S04 and then concentrated in vacuo to give the tetrahydropyranyl 
ether as a yellow solid. 




'-_____ 3 __ ..... lYellow crystals (7.9747g, 98%); Rf (EtOAc:hexane, 2:3) 0.55; 6H 
(300MHz;d6-DMSO) 7.90 (2H, dd, J2.1, 6.9, H-2 and H-6), 7.10 (2H, dd, J2.1, 6.9, H-3 and H-
5),5.59 (lH, t,J3.3, H-2'), 3.85 (1H, m, H-6'a), 3.58 (1H, m, H-6'b), 3.26 (lH, s, COCH 3), 1.81 
(lH, m, H-3'a), 1.75 (2H, m, H-3'b and H-5'a), 1.55 (3H, m, H-4 and H-5'b); 6c (lOOMHz, d6-
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1-[3-Methoxy-4-(tetrahydro-pyran-2-yloxy)-phenyl]-ethanone, CDM17 
4' 5'u' 5 2' 
6' o 0 
OMe '-_______ ... Yellow crystals (1.47g, 95%); Rf (EtOAc:hexane, 3:2) 0.56; OH 
(300MHz;CDCI3) 7.53 (IH, d, J8.4, H-6), 7.50 (IH, s, H-2), 7.16 (IH, d, J8.4, H-5), 5.54 (lH, t, 
J3.2 H-2'), 3.90 (3H, s, OCH3), 3.87 (IH, m, H-6'a), 3.63 (lH, m, H-6'b), 2.54 (IH, s, COCH3), 
1.81 (lH, m, H-3'a), 1.75 (2H, m, H-3'b and H-5'a), 1.55 (3H, m, H-4' and H-5'b); oc(lOOMHz, 
d6-DMSO) 197.8, 151.0, 149.8, 129.5, 121.4, 115.2 (2C), 96.6, 62.8, 56.2, 30.1, 28.5, 25.4, 20.2. 
General procedure for synthesis of 4-aminoquinoline-derived chalcones CDM04-CDM08, 
CDM13-CDMIS and CDMI8-CDMI9 
A methanolic solution of NaOH (3% w/v) and methyl ketone (1.0 eq) were stirred together at 
room temperature. A methanolic solution of the substituted aldehyde (1.0 eq) was added 
dropwise, and the mixture was retluxed with stirring for 24-48 h. The precipitate was removed by 
filtration and washed with cold methanol. The collected yellow solid was dried further in vacuo, 
affording the desired product. 






HN 14::::""" 12 
4a 4 13 21 
~ 3 
I ..-: 2 
Sa N 
'-__ ...... :..-_______ .... Yellow crystals (0.2765g, 66%), m.p. 230-233 °C; Rf 
(Hexane-EtOAc, 3:2) 0.73; Vmax (CHCI3) / cm'l 3300 (N-H), 1676 (C=O), 1609 (Ar-C=C), 1565 
(C=C) and 865 (Ar-Cl); oH(400MHz, d6-DMSO) 9.43 (lH, s, NH), 8.62 (IH, d,J5.1, H-2), 8.41 
(lH, d, J8.8, H-5), 8.21 (2H, d, J8.8, H-I0 and H-12), 8.0 (lH, d, J 15.6, H-16), 7.97 (lH, d, J 
2.4, H-8), 7.92 (2H, d, J8.8, H-18 and H-22), 7.70 (lH, d, J 15.6, H-15), 7.64-7.61 (lH, dd, J2.4 
and 9.2, H-6), 7.53 (2H, d, J8.4, H-9and H-13), 7.50 (2H, d, J8.8, H-19 and H-21), 7.32 (lH, d, 
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133.8,131.3,130.8,130.4,130.4,128.8,128.2,127.6, 125.4, 124.7, 122.8,119.4,119.1,118.9, 
105.2; Elemental analysis: (Found C, 66.23; H, 3.94; N, 6.01. C24H16ChN20.0.9H20 requires C, 
66.19; H, 4.16; N 6.43%). 
1-[ 4-(7 -Chloro-q uinolin-4-ylamino )-phenyl]-3-(2,4-dichloro-phenyl)-propenone, CDM05 
CI 
'---....,;,,--_____ ..... Yellow crystals (0.3380g, 74%), m.p. 229-233 °C; Rf 
(Hexane-EtOAc, 3:2) 0.77; 8H (300MHz, d6-DMSO) 9.43 (lH, s, NH), 8.62 (lH, d, J 5.1, H-2), 
8.41 (l H, d, J 9.6, H-5), 8.26 (l H, d, J 9.0, H-22), 8.20 (2H, d, J 8.7, H-l 0 and H-12), 8.06 (l H, 
d, J 15.9, H-16), 7.97 (lH, d, J 15.6, H-15), 7.94 (lH, d, J8.7, H-21), 7.74 (lH, d, J2.1, H-8), 
7.59 (lH, d, J 2.4,9.0, H-6), 7.57 (2H, d, J 9.0, H-9 and H-13) and 7.27 (lH, d, J 5.1, H-3); 
8c(100MHz, d6-DMSO) 186.4, 151.8, 149.7, 146.2, 146.1, 141.5, 136.1, 135.2, 134.9, 133.9, 
131.6, 130.4, 129.7, 129.4, 128.2, 127.8, 127.5, 125.5, 125.1, 124.8, 119.4, 118.9, 118.9, 
105.142; EI-MS: (found m/z = 452.0236 C24H lSCI3N20 requires M 452.02; Elemental analysis: 
(Found C, 61.72; H, 3.42; N, 5.60 C24HlSCbN20. 0.7H20 requires C, 61.81; H, 3.67; N 6.01%). 
1-[3-(7 -Chloro-q uinolin-4-ylamino )-phenyl]-3-( 4-chloro-phenyl)-propenone, CDM06 
o 
'-__ ..... _______ ...... Yellow crystals (0.3135g, 75%), m.p. 218-223 °C; Rf 
(Hexane-EtOAc, 3:2) 0.29; 8H (400MHz, d6-DMSO) 9.33 (1 H, s, NH), 8.53 (1 H, d, J 5.6, H-2), 
8.46 (l H, d, J 8.8, H-5), 8.30 (l H, s, H-13), 8.07 (1 H, d, J 2.0, H-8), 7.94 (1 H, d, J 16.0, H-16), 
7.93 (2H, d, J8.4, H-17 and H-21), 7.91 (lH, d, J7.6, H-9), 7.78 (IH, d, J 15.6, H-15), 7.69 (lH, 
d, J8.0, H-ll), 7.64 (lH, t, J7.6, H-I0), 7.59 (lH, dd, J2.0, 8.8, H-6), 7.53 (2H, d, J 8.4, H-18 











Chapter 5: Experimental 
140.9,138.7, 135.1, 133.9, 133.5, 130.5, 129.8, 128.9, 127.7, 126.6, 125.1, 124.4, 123.9, 123.7, 
122.8, 121.8, 118.5, 102.2,48.5; EI-MS: (found mlz = 418.06397 C24H16ChN20 requires M 
418.06; Elemental analysis: (Found C, 68.57; H, 3.81; N, 6.27 C24H16ChN20 requires C, 68.25; 
H, 3.85; N 6.68%). 






HN 14~ 12 
5 4a 4 13 
6o;:? ~3 
~ I/.2 
CI 7 8 8a N 
21 
______ 1 _______ ..... Yellow crystals (0.0393g, 30%), m.p 189-192°C; Rf 
(Hexane-EtOAc, 3:2) 0.74; bH (400MHz, d6-DMSO) 9.43 (lH, s, NH), 8.63 (lH, d, J 5.2, H-2), 
8.42 (l H, d, J 9.2, H-5), 8.21 (l H, d, J 8.8, H-l 0 and H-12), 7.98 (2H, d, J 9.2, H-18 and H-22), 
7.96 (lH, d, J2.4, H-8), 7.94 (lH, d, J 16.0, H-16), 7.75 (lH, d, J 15.6, H-15), 7.63 (lH, dd, J 
2.4,9.2, H-6), 7.49 (2H, d, J8.8, H-9and H-13), 7.32 (2H, d, J9.2, H-19 and H-21), 7.28 (lH, d, 
J 5.2, H-3); bc(100MHz, d6-DMSO) 187.0, 152.1, 151.7, 146.1, 141.8, 134.1, 131.5, 131.4, 
131.1,130.9,130.4,127.7,125.4,124.7,121.9,119.4,119.1, 117.4, 115.9, 115.7,112.6, 105.1, 
103.2, 63.1; EI-MS: (found m/z = 402.942 C24H16ClFN20 requires M 402.92; Elemental 
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1-[ 4-(7 -Chloro-q uinolin-4-ylamino )-phenyl] -3-(2,4-dimethoxy-phenyl)-propenone, CDM08 
OMe 
'-__ .....;, ________ ...... Yellow crystals (0.2415g, 54%), m.p. 239-242 °C; Rf 
(Hexane-EtOAc, 3:2) 0.56; 6H (400MHz, d6-DMSO) 9.43 (1H, s, NH), 8.62 (1H, d, J 5.2, H-2), 
8.42 (1 H, d, J 8.8, H-5), 8.16 (2H, d, J 8.4, H-l 0 and H-12), 8.0 (1 H, d, J 15.6, H-16), 7.96 (1 H, 
d, J 2.1, H-8), 7.92 (1 H, d, J 8.4, H-22), 7.80 (1 H, d, J 8.4, H-15), 7.64 (1 H, dd, J 2.1, 8.8, H-6), 
7.49 (2H, d, J 8.4, H-9 and H-13), 7.65 (1 H, d, J 8.8, Hf ), 7.29 (1 H, d, J 5.6, H-3), 6.63(1 H, dd, J 
2.0,8.8, H-21), 6.62 (1H, d, J2.0, H-19), 3.91 (3H, s, OCH3), 3.85 (3H, s, OCH3); 6c(100MHz, 
d6-DMSO) 187.2, 162.9, 159.8, 151.9, 149.6, 146.1, 145.4, 137.9, 134.0, 132.1, 130.1, 130.0, 
129.9,127.7,125.4,124.6,119.1,116.1,106.3,104.9, 98.3, 55.8, 55.4, 30.5; EI-MS: (found m/z 
= 445.1 C26H21CIN203 requires M 444.91; Elemental analysis: (Found C, 69.91; H, 5.18; N, 6.27 
C26H21CIN203 requires C, 70.19; H, 4.76; N 6.30%). 
3-[3-(7 -Chloro-q uinolin-4-ylamino )-phenyl)-I-( 4-methoxy-phenyl)-propenone, CDM13 
5 15 o 
'-__ .....;, ________ ..... Yellow crystals (0.7830g, 75%), m.p. 254-257°C; Rf 
(EtOAc-Hexane, 3:2) 0.55; 6H (300MHz, d6-DMSO) 9.2 (1H, s, NH), 8.48 (1H, d, J 5.1, H-2), 
8.45 (1H, d, J9.0, H-5), 8.16 (2H, d, J8.7, H-17 and H-21), 7.95 (1H, d, J 15.6, H-15), 7.89 (1H, 
d, J 2.1, H-8), 7.84 (1H, s, H-13), 7.727 (1H, d, J 15.6, H-16), 7.65 (1H, d, J 7.6, H-l1), 7.59 
(1 H, dd, J 2.1, 9.0, H-6), 7.53 (1 H, t, J 7.6, H-l 0), 7.43 (I H, d, J 8.1, H-9), 7.08 (2H, d, J 8.7, H-
18 and H-20), 6.94 (lH, d, J5.1, H-3), 3.82 (3H, s, OCH3); 6c(100MHz, d6-DMSO) 187.3, 163.1, 
151.9,149,5,147.9,142.6,140.9,136.0,133.8,130.8, 130.9, 130.3, 129.9, 129.3, 127.5, 124.8, 
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C25 H]9CIN202 requires M 414.9; Elemental analysis: (Found C, 71.97; H, 4.66; N, 6.31 
C25H]9CIN202 requires C, 72.37; H, 4.62; N 6.75%). 
3-[3-(7 -Chloro-q uinolin-4-ylamino )-phenyl)-1-(2,4-methoxyphenyl)-propenone, CD M14 
______________ ..... Yellow crystals (0.5428g, 70%), m.p. 175-179 °C; Rr 
(EtOAc-Hexane, 3:2) 0.45; Ymax (CHCh) I cm-] 3300 (N-H), 1676 (C=O), 1609 (Ar-C=C), 1565 
(C=C) and 865 (Ar-CI); 8H (400MHz, d6-DMSO) 9.2 (1 H, s, NH), 8.51 (1.H, d, J 5.2, H-2), 8.44 
(I H, d, J 8.8, H-5), 7.92 (1 H, d, J 2.4, H-8), 7.69 (1 H, s, H-13), 7.64 (1 H, d, J 8.8, H-21), 7.59 
(I H, dd, J2.0, 8.8, H-6), 7.56 (1H, d, J 15.6, H-15), 7.50 (1H, d, J 15.6, H-16), 7.47-7.43 (3H, m, 
H-9, H-I0 and H-ll), 7.01 (lH, d, J5.2, H-3), 6.66 (IH, d, J2.0, H-18), 6.64 (1H, dd, J 2.4,8.8, 
H-20), 3.88 (3H, s, OCH3), 3.83 (3H, s, OCH3); 8c(100MHz, d6-DMSO) 189.1, 163.9, 151.7, 
140.9, 140.7, 136.1, 133.9, 131.9, 129.9, 127.6, 127.5, 124.9, 124.4, 123.9 (2C), 123.8 (2C), 
123.7, 121.7, 121.6, 118.4, 106.1, 102.2, 98.7, 55.9, 55.54. EI-MS: (found m/z = 445.1 
C26H21 CIN203 requires M 444.91; Elemental analysis: (Found C, 69.91; H, 5.18; N, 6.27 
C26H21 CIN203 requires C, 70.19; H, 4.76; N 6.30%). 
3-[3-(7 -Chloro-q uinolin-4-ylamino )-phenyl)-1-(2,3,4-methoxyphenyl)- propenone, CDM15 
______________ ..... Yellow crystals (0.1782g, 70%), m.p. 179-182 °C; Rr 
(EtOAc-Hexane, 3:2) 0.44; 8H (300M Hz, d6-DMSO) 9.2 (1H, s, NH), 8.51 (1.H, d, J 5.4, H-2), 
8.44 (1H, d, J9.0, H-5), 7.92 (1H, d, J2.1, H-8), 7.71 (1H, s, H-13), 7.60 (lH, dd, J2.1, 9.0, H-
6),7.55-7.42 (5H, m, H-9, H-I0, H-ll, H-15, H-16), 7.41 (1H, d, J8.7, H-21), 7.01 (IH, d, J5.1, 
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8c(100MHz, d6-DMSO) 189.5, 156.5, 152.6, 151.7, 149.3, 147.3, 141.6, 141.3, 140.7, 135.6, 
132.6, 129.6, 127.4, 126.6, 125.7, 124.9, 124.7 (2C), 123.8, 121.4, 118.1, 107.6, 102.9, 101.9, 
61.4,60.2,55.8. EI-MS: (found m/z = 474.1346 C27H23CIN20 4 requires M 474.95; Elemental 
analysis: (Found C, 68.18; H, 4.78; N, 5.27 C27H23CIN20 4 requires C, 68.28; H, 4.88; N 5.90%). 
3-[3-(7 -Chloro-q uinolin-4ylamino )-phenyl]-l- [4-( tetrahydro-2H-pyran-2-yloxy-phenyl]-
propenone, CDM18 
18 
17 ~ 0D2' Q 6' I 19 
~ 20 3' 5' 
22 21 4' 
o 
Yellow crystals (0.789g, 20%); Rf (EtOAc-
Hexane, 3:2) 0.23; 8H (400MHz, d6-DMSO) 9.2 (1 H, s, NH), 8.49 (1H, d, J 5.6, H-2), 8.46 (1 H, 
d, J 9.2, H-5), 8.14 (2H, d, J 8.8, H-17 and H-21), 7.94 (1 H, d, J 15.6, H-15), 7.90 (1 H, d, J 2.4, 
H-8), 7.85 (1 H, s, H-13), 7.74 (1 H, d, J 15.6, H-16), 7.68 (1 H, d, J 7.6, H-ll), 7.59 (1 H, dd, J 
2.4, 9.2, H-6), 7.51 (I H, t, J 7.6, H-I 0), 7.44 (1 H, d, J 8.1, H-9), 7.16 (2H, d, J 8.8, H-18 and H-
20),6.95 (1H, d, J5.2, H-3), 5.59 (1H, t, J3.3, H-2'), 3.85 (lH, m, H-6'a), 3.58 (lH, m, H-6'b), 
1.81 (1H, m, H-3'a), 1.75 (2H, m, H-3'b and H-5'a), 1.55 (3H, m, H-4 and H-5'b); 8c(100MHz, 
d6-DMSO) 187.3, 163.1, 151.9, 142.6, 143.6, 136.8, 131.8, 131.6, 131.4, 130.7, 128.9, 128.4, 
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3-[3-(7 -Chloro-q uinolin-4ylamino )-phenyl] -1- [3-methoxy-4-(tetrahyd ro-2H -pyran-2-yloxy-
phenyl]-propenone, CDM19 
Yellow crystals (1.553g, 58%); Rf (EtOAc-
Hexane, 3:2) 0.24; OH (400MHz, d6-DMSO) 9.15 (l H, s, NH), 8.48 (l H, d, J 5.6, H-2), 8.44 (l H, 
d, J9.2, H-5), 7.92 (lH, d, J 15.6, H-15), 7.89 (lH, d, J2.0, H-8), 7.83 (lH, s, H-13), 7.82 (lH, 
dd, J2.0, 8.8, H-21), 7.73 (lH, d, J 15.6, H-16), 7.68(IH, d, J7.6, H-ll), 7.63 (lH, d, J2.0, H-
17),7.58 (lH, dd, J2.0, 9.2, H-6), 7.50 (lH, t,J7.6, H-I0), 7.43 (lH, d,J7.6, H-9), 7.20 (lH, d, 
J 8.8, H-20), 6.95 (l H, d, J 5.2, H-3), 5.59 (I H, t, J 3.3, H-2'), 3.86 (3H, s, OCH3), 3.85 (I H, m, 
H-6'a), 3.58 (lH, m, H-6'b), 1.81 (lH, m, H-3'a), 1.75 (2H, m, H-3'b and H-5'a), 1.55 (3H, m, 
H-4 and H-5'b); oc(100MHz, d6-DMSO) 187.5, 152.0, 151.7, 147.8, 142.8, 143.6, 136.8, 131.8, 
130.7, 129.9, 127.6, 125.0, 124.9, 124.5, 123.3, 122.9, 122.7, 122.5, 116.9, 116.8,115.5, 111.7, 
102.7,102.4,96.2,61.5,55.6,29.6,24.5,18.3. 
General procedure for synthesis of CDM20-CDM21 
Hydrochloric acid was added to a stirred solution of CDMI8-CDMI9 in methanol, and the 
mixture was stirred for 4 h at room temperature, and then diluted with water. The mixture was 
neutralized to pH 8 and the resulting precipitate was filtered, dried over anhydrous phosphorous 
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3-[3-(7 -Chloro-q uinolin-4ylamino )-phenyl] -1- [4-hydroxyphenyl] -propenone, CD M20 
15 o 
'-____________ ... Yellow crystals (0.6281g, 98%); m.p.328-333 °C; Rf 
(EtOAc-Hexane, 3:2) 0.20; 6H (400MHz, d6-DMSO) 11.2 (1 H, s, NH), 8.79 (1.H, d, J 9.2, H-5), 
8.56 (1 H, d, J 7.2, H-2), 8.09 (1 H, d, J2.1, H-8), 8.07 (2H, d, J 8.8, H-17 and H-21), 8.02 (1 H, s, 
H-13), 7.99 (1H, d, J 15.6, H-15), 7.94 (IH, d, J7.6, H-ll), 7.92 (1H, dd, J2.0, 9.2, H-6), 7.75 
(1 H, d, J 15.6, H-16), 7.66 (1 H, t, J 7.6, H-l 0), 7.54 (1 H, d, J 8.0, H-9), 6.90 (2H, d, J 8.8, H-18 
and H-20), 6.87 (1H, d, J 7.2, H-3); 6c(100MHz, d6-DMSO) 187.7, 163.1, 159.6, 159.2, 158.8, 
155.8,144.4, 142.1,139.6,139.4,138.2,137.5,131.8,129.6,128.9, 128.3, 125.6,125.1, 123.4, 
120.5, 122.5, 116.9, 111.0, 101.34; Elemental analysis: (Found C, 65.11; H, 4.19; N, 6.31 
C24HI7CIN202.2H20 requires C, 65.98; H, 3.92; N 6.41 %). 
3-[3-(7 -Chloro-q uinolin-4ylamino )-phenyl] -1-[ 4-Hydroxy-3-methoxy-phenyl] propenone, 
CDM21 
15 
'-____________ ..... Yellow crystals (1.099g, 85%); m.p.225-227 °C; Rf 
(10%MeOH:DCM) 0.54; 6H (400MHz, d6-DMSO) 11.0 (1 H, s, OH), 10.15 (1 H, s, NH), 8.82 
(1 H, d, J 8.8, H-5), 8.51 (1 H, d, J 5.6, H-2), 8.13 (1 H, d, J 2.0, H-8), 7.99 (1 H, s, H-13), 7.98 
(1 H, d, J 15.6, H-15), 7.88 (1 H, d, J 8.0, H-II), 7.84 (1 H, dd, J 1.6, 8.8, H-6), 7.78 (1 H, dd, J2.0, 
8.4, H-17), 7.73 (lH, d, J 15.6, H-16), 7.62 (lH, t, J7.6, H-I0), 7.59 (lH, d, J2.0, H-21), 7.52 
(1 H, d, J 8.0, H-9), 6.92 (1 H, d, J 8.4, H-18), 6.85 (1 H, d, J 6.8, H-3), 3.85 (3H, s, OCH3); 
6c(l00MHz, d6-DMSO) 186.9, 153.7, 152.1, 147.8, 144.8, 141.5, 140.7, 137.1, 137.7, 136.7, 
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55.7; EI-MS: (found m/z = 430.1 C2s H'9ClN20 3 requires M 430.11; Elemental analysis: (Found 
C, 69.69; H, 4.44; N, 6.50 C2sH'9ClN203.0.1 H20 requires C, 69.39; H, 4.43; N 6.48%). 
General procedure for synthesis of citrate salt derivatives CDM22-29 
A 1.5 equivalent of citric acid dissolved in a minimum amount of acetone was added dropwise to 
a stirring solution of free base CDM04-CDM08, CDM13-CDMI5. The solution was then stirred 
for I h at 48-50°C. The product precipitated out of solution when cooled at 4°C for 24 h. The 
citrate salt derivatives were filtered, dried under vacuum and then over phosphorous pentoxide. 
Citrate salt of 1-[4-(7 -Chloro-quinolin-4-ylamino )-phenyl]-3-( 4-chloro-phenyl)-propenone, 
CDM22 
o 
10 16 18 
:a
~ 11 ,,-:::. 17 ~ 19 
I 15 I 20 
HN ~ 12 22"-:::' CI 
14 13 21 
4a 4 24 
I ~ 3 H°Y-COOH 
N""::: 2 HOOe' 123 
8a Hooe 
______________ ...... Yellow crystals (0.2703g, 93%), m.p. 197-198 °C; V
max 
(CHCh) I cm-' 3300 (N-H), 1722 (C=O), 1660 (C=C), 1591 (Ar-C=C), 1450 (CH2 bend) and 865 
(Ar-CI); 6H (400MHz, d6-DMSO) 9.43 (1 H, s, NH), 8.66 (1 H, d, J 5.1, H-2), 8.50 (I H, d, J 8.8, 
H-5), 8.21 (2H, d, J 8.8, H-I 0 and H-12), 8.0 (1 H, d, J 15.6, H-16), 8.03 (1 H, d, J 2.4, H-8), 7.92 
(2H, d, J8.8, H-18 and H-22), 7.70 (lH, d, J 15.6, H-15), 7.67 (1H, dd, J2.4 and 9.2, H-6), 7.53 
(2H, d, J8.4, H-9and H-13), 7.50 (2H, d, J8.8, H-19 and H-21), 7.32 (1H, d, J5.2, H-3), 2.70 
(2H, d, J 15.2, H-23), 2.65 (2H, d, J 15.2, H-24); 6c(100MHz, d6-DMSO) 187.0, 171.2, 158.6, 
153.2,152.0, 151.9, 149.6, 146.2, 146.1, 141.5, 134.8, 134.1, 133.8, 131.3, 130.8, 130.4, 130.4, 
128.8,128.2,127.6,125.4,124.7,122.8,119.4,119.1, 118.9, 105.2,72.1,70.1,42.9; Elemental 
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Citrate salt of 1-[4-(7 -Chloro-quinolin-4-ylamino )-phenyl]-3-(2,4-dichloro-phenyl)-
propenone, CDM23 
o CI 
10 16 17 18 
:Q-::?' 11 .0 ~ 19 1 15 1 20 HN 14~ 12 22.0 CI 
5 4a 4 13 24 21 
6 '7' 1 ~ 3 H0X-COOH 
~ ....:: 2 HOOC' / 23 
CI 7 8 8a N HOOC 
'-__ ....,;",1 _______ ..... Yellow crystals (0.2788g, 62%), m.p. 208-211 °C; OH 
(300MHz, d6-DMSO) 9.43 (IH, s, NH), 8.62 (lH, d, JS.I, H-2), 8.41 (IH, d, J9.6, H-S), 8.26 
(I H, d, J 9.0, H-22), 8.20 (2H, d, J 8.7, H-1 0 and H-12), 8.06 (l H, d, J IS.9, H-16), 7.97 (l H, d, J 
IS.6, H-1S), 7.94 (lH, d, J8.7, H-21), 7.74 (lH, d, J2.1, H-8), 7.S9 (lH, d, J2.4, 9.0, H-6), 7.S7 
(2H, d, J9.0, H-9 and H-13), 7.27 (lH, d, JS.1, H-3), 2.77 (2H, d, J IS.2, H-23), 2.67 (2H, d, J 
IS.2, H-24); oc(lOO, d6-DMSO) 19S.9, 186.4, 174.7, ISI.8, 149.7, 146.2, 146.1, 141.S, 136.1, 
13S.2, 134.9, 133.9, 131.6, 130.6, 130.4, 129.8, 129.6, 128.2, 127.8, 127.S, 126.7, 12S.S, 12S.1, 
124.8, 119.4, 118.9, 10S.I, 72.2, 46.S, 42.8; Elemental analysis: (Found C, SO.S2; H, 3.91; N, 
3.91 C24HlSCbN20. C6Hg07.4H20 requires C, SO.19; H, 3.22; N 3.90%). 
Citrate salt of 1-[3-(7 -Chloro-q uinolin-4-ylamino )-phenyl]-3-( 4-chloro-phenyl)-propenone, 
CDM24 
10 
9 -::?' 11 
~ 112 
HN 14 13 
5 4a 4 
~ 3 
~ I ....:: 2 24 
CI 7 8 8a N HOXCOOH 
o 
HOOC' /23 
HOOC '-__________ .... Yellow crystals (0.2182g, 60%), m.p. 219-221 °C; OH 
(400MHz, d6-DMSO) 9.43 (I H, s, NH), 8.62 (l H, d, J S.2, H-2), 8.42 (l H, d, J 8.8, H-S), 8.30 
(lH, s, H-13), 8.07 (IH, d, J2.0, H-8), 7.94 (lH, d, J 16.0, H-16), 7.93 (2H, d,J8.4, H-17 and H-
21),7.91 (lH, d, J7.6, H-9), 7.78 (lH, d, J IS.6, H-1S), 7.69 (lH, d, J8.0, H-l1), 7.64 (lH, t, J 
7.6, H-10), 7.S9 (l H, dd, J 2.0, 8.8, H-6), 7.S3 (2H, d, J 8.4, H-18 and H-20), 7.03 (l H, d, J S.6, 
H-3) 2.74 (2H, d, J IS.6, H-23), 2.64 (2H, d, J IS.2, H-24); oc(7SMHz, d6-DMSO)188.8, 174.9, 
171.1, ISI.9, 149.S, 148.4, 147.S, 142.7, 140.9, 138.7, 134.4, 13S.1, 133.9, 133.S, 130.S, 129.8, 
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Elemental analysis: (Found C, 58.93; H, 3.96; N, 4.58 C24H16CbN20.C6Hg07. 0.1 H20 requires C, 
58.79; H, 3.94; N 4.57 %). 
Citrate salt of 1-[4-(7 -Chloro-q uinolin-4-ylamino )-phenyl] -3-( 4-fluoro-phenyl)-propenone, 
CDM25 
Yellow crystals (0.4986g, 92%), m.p 226-228 °C;OH 
(300MHz, d6-DMSO) 9.43 (I H, s, NH), 8.69 (1 H, d, J 5.2, H-2), 8.50 (1 H, d, J 9.2, H-5), 8.21 
(I H, d, J 8.8, H-IO and H-12), 7.98 (2H, d, J 9.2, H-18 and H-22), 8.04 (1 H, d, J 2.4, H-8), 7.94 
(1 H, d, J 16.0, H-16), 7.75 (1 H, d, J 15.6, H-15), 7.63 (I H, dd, J 2.4,9.2, H-6), 7.49 (2H, d, J 8.8, 
H-9 and H-13), 7.32 (2H, d, J9.2, H-19 and H-21), 7.33 (IH, d, J5.2, H-3), 2.68 (2H, d, J 15.0, 
H-23), 2.59 (2H, d, J 15.3, H-24); oc(IOOMHz, d6-DMSO) 187.0, 152.1, 151.7, 146.1, 141.8, 
134.1,131.5,131.4,131.1,130.9,130.4,127.7,125.4,124.7, 121.9, 119.4, 119.1, 117.4, 115.9, 
115.7,112.6, 105.1, 103.2, 63.1; Elemental analysis: (Found C, 60.57; H, 4.14; N, 4.04 
C24H16CIFN20. C6Hg0 7 requires C, 60.56; H, 4.09; N 4.71 %). 
Citrate salt of 1-[4-(7 -Chloro-q uinolin-4-ylamino )-phenyl]-3-(2,4-dimethoxy-phenyl)-
propenone, CDM26 
o OMe 
10 16 17 18 
:a
~ 11 ...-:; ~ 19 
I 15 I 20 
HN 14~ 12 22"'-:; OMe 
13 21 
4a 4 HO~eooH 
~ 3 I Hooe 23 
N
/: 2 Hooe 
8a 
'-______________ .. Yellow crystals (0.2182g, 60%), m.p. 219-221 DC; OH 
(400MHz, d6-DMSO) 9.43 (I H, s, NH), 8.62 (1 H, d, J 5.2, H-2), 8.42 (1 H, d, J 8.8, H-5), 8.16 
(2H, d, J 8.4, H-I 0 and H-12), 8.0 (I H, d, J 15.6, H-16), 7.96 (1 H, d, J 2.1, H-8), 7.92 (I H, d, J 
8.4, H-22), 7.80 (I H, d, J 8.4, H-15), 7.64 (1 H, dd, J2.1, 8.8, H-6), 7.49 (2H, d, J 8.4, H-9 and H-
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2.0, H-19), 3.91 (3H, s, OCH3), 3.85 (3H, s, OCH3), 2.75 (2H, d, J 15.6, H-23), 2.66 (2H, d, J 
15.0, H-24); 8c(100MHz, d6-DMSO) 187.2, 174.7, 171.1, 162.9, 159.8, 151.9, 151.4, 149.6, 
146.1,145.4,137.9,134.0,132.4,132.1,130.1,130.0, 129.9, 127.7, 125.4, 124.6, 119.62, 119.5, 
119.1, 116.1, 106.3, 104.9, 104.6, 98.3, 72.2, 55.8, 55.4, 42.8; Elemental analysis: (Found C, 
61.66; H, 4.54; N, 4.78 C26H21CIN203. C6H80 7• 0.1 H20 requires C, 59.45; H, 4.26; N 4.38%). 





HOOC '-___________ ..... Yellow crystals (0.0727g, 47%), m.p. 250-254°C; 8H 
(400MHz, d6-DMSO) 9.2 (lH, s, NH), 8.48 (lH, d, J 5.1, H-2), 8.45 (IH, d, J 9.0, H-5), 8.16 
(2H, d, J8.7, H-17 and H-21), 7.95 (IH, d, J 15.6, H-15), 7.89 (lH, d, J2.1, H-8), 7.84 (lH, s, H-
13), 7.727 (1 H, d, J 15.6, H-16), 7.65 (1 H, d, J 7.6, H-ll), 7.59 (1 H, dd, J 2.1, 9.0, H-6), 7.53 
(1 H, t, J 7.6, H-I0), 7.43 (1 H, d, J 8.1, H-9), 7.08 (2H, d, J 8.7, H-18 and H-20), 6.94 (l H, d, J 
5.1, H-3), 3.82 (3H, s, OCH3), 2.74 (2H, d, J 15.2, H-23), 2.64 (2H, d, J 15.2, H-24); 
8c(100MHz, d6-DMSO) 187.3, 171.1, 163.1, 151.9, 150.8, 149,5,147.9,142.6,140.36,136.0, 
134.4,133.8, 130.8,130.9,130.3,129.9,129.3,127.5, 126.5, 124.8, 124.6, 124.4, 124.3, 122.6, 
122.5, 118.3, 113.9, 101.9,72.1,55.4,42.93. Elemental analysis: (Found C, 62.84; H, 4.44; N, 
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Citrate salt of 3-[3-(7 -Chloro-quinolin-4-ylamino )-phenyl)-1-(2,4-methoxy-phenyl)-
propenone, CDM28 
____ ..... ________ ...... Yellow crystals (0.0745g, 42%), m.p. 89-94 °C; OH 
(400MHz, d6-DMSO) 9.2 (l H, s, NH), 8.51 (1.H, d, J 5.2, H-2), 8.44 (l H, d, J 8.8, H-5), 7.92 
(lH, d, J2.4, H-8), 7.69 (IH, s, H-13), 7.64 (lH, d, J8.8, H-21), 7.59 (IH, dd, J2.0, 8.8, H-6), 
7.56 (lH, d, J 15.6, H-15), 7.50 (IH, d, J 15.6, H-16), 7.47-7.43 (3H, m, H-9, H-I0 and H-ll), 
7.01 (lH, d, J 5.2, H-3), 6.66 (IH, d, J2.0, H-18), 6.64 (IH, dd, J 2.4, 8.8, H-20), 3.88 (3H, s, 
OCH3), 3.83 (3H, s, OCH3), 2.51 (2H, d, J 14.8, H-23), 2.43 (2H, d, J 15.2, H-24); oc(100MHz, 
d6-DMSO) 189.1, 177.2, 171.2, 163.9, 160.3, 151.7, 149.5, 147.6, 140.9, 136.1, l33.9, 132.1, 
131.9,129.9,127.6,127.5, 127.4,124.9,124.4,123.9,123.7,121.7, 121.6,118.4,106.1,102.2, 
98.7, 96.6, 70.9, 55.9, 55.54, 44.5; Elemental analysis: (Found C, 60.03; H, 4.79; N, 3.99 
C26H21ClN203 C6Hg0 7 requires C, 60.33; H, 4.59; N 4.40%). 





'-___________ ...... Yellow crystals (0.2053g, 97%), m.p. 158-160 °C; Vrnax 
(CHCI3) / cm-
1 3200 (N-H), 1723 (C=O), 1649 (Ar-C=C), 1592 (C=C), 1478 (CH2 bend), and 
865 (Ar-Cl); OH (300MHz, d6-DMSO) 9.2 (1 H, s, NH), 8.63 (1.H, d, J 5.4, H-2), 8.48(1 H, d, J 
9.0, H-5), 7.85 (lH, d, J2.1, H-8), 7.71 (lH, s, H-13), 7.60 (lH, dd, J2.1, 9.0, H-6), 7.55-7.42 
(5H, m, H-9, H-I0, H-ll, H-15, H-16), 7.41 (1H, d, J8.7, H-21), 7.01 (lH, d, J5.1, H-3), 6.95 
(l H, d, J 8.7, H-20), 3.88 (3H, s, OCH3), 3.85 (3H, s, OCH3), 3.79 (3H, s, OCH3), 2.73 (2H, d, J 
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152.6,151.7,149.3,147.3,141.7,141.6,141.3, 140.7, 135.6, 134.4, 129.6, 127.4, 126.6, 125.7, 
124.9, 124.7 (2C), 122.0, 123.8, 121.4, 118.1, 107.6, 102.9, 101.9,72.0,61.4,60.2,55.8,42.9; 
Elemental analysis: (Found C, 58.15; H, 4.65; N, 3.52 C27H23ClN20 4 C6H80 7 . 0.8 H20 requires 
C, 58.16; H, 4.58; N 4.11 %). 
General procedure for synthesis of Mannich bases of 4-hydroxyacetophenone (CDM30-36) 
Amine (2.0 eq) was treated with paraformaldehyde (2.0 eq) in methanol at 65°C for 2 h. To the 
reaction, a solution of 4-hydroxyacetophenone (1.0 eq) in methanol was then added. After 
stirring for 24 h, the reaction mixture was cooled, concentrated in vacuo and then subjected to 
column chromatography on silica gel. 
1-( 4-Hydroxy-3-(pyrrolidin-l-ylmethyl)phenyl)ethanone, CDM30 
~~08 
6~ 11N 9 
OH 10 
5 Yellow crystals (0.70718g, 15%); Rf (2% MeOH:DCM) 0.36; 6H 
(300MHz, d6-DMSO), 7.74 (lH, d, J2.4, H-2), 7.72 (IH, dd, J2.4, 8.4, H-6), 6.78 (IH, d, J8.4, 
H-5), 4.18 (2H, s, H-7), 2.62 (4H, m, H-8 and H-ll), 2.44 (3H, s, COCH3), 1.76 (4H, m, H-9 and 
H-I0); 6c(l00MHz, d6-DMSO) 196.2, 162.4, 150.5 (2C), 128.5, 123.1, 115.3,51.4 (2C), 53.6, 
23.5 (2C), 23.9. 
1-( 4-Hyd roxy-3-(piperidin-l-ylmethyl)phenyl)ethanone, CD M31 
o 
, 3 ',():. 
5 OH 11 __________ .. Yellow crystals (0.1147g, 22%); Rf (Hexane: EtOAc, 3:2) 0.13; 6H 
(300MHz, d6-DMSO), 7.80 (lH, dd, J2.4, 8.4, H-6), 7.67 (lH, d, J2.0, H-2), 6.86 (lH, d, J8.4, 
H-5), 3.76 (2H, s, H-7), 2.52 (3H, s, COCH3), 2.74 (4H, m, H-8 and H-12), 1.75 (6H, m, H-9, H-
10 and H-ll); 6c(l00MHz, d6-DMSO) 196.5, 162.2, 130.5, 129.6, 128.7, 123.4, 115.3,61.7 (2C), 
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1-(4-Hydroxy-3,5-bis(morpholinomethyl)phenyl)ethanone,CDM32 
o 
2 7 8 
1 ,,-,:3 N1 9 
I .& 4 121 0 





_____ ........ ___ .. Yellow oil (0.3669g, 15%); Rf (Hexane: EtOAc, 3:2) 0.21; 6H 
(400MHz, d6-DMSO), 7.78 (2H, s, H-2 and H-6), 3.76 (4H, s, H-7 and H-T), 3.67 (8H, t, J 4.4, 
H-9/9' and H-l1111 '), 2.61 (8H, t, J 4.0, H-8/8' and H-12112'), 2.53 (3H, s, COCH3); 
6c(l00MHz, d6-DMSO) 196.5, 161.3, 128.7 (2C), 128.5, 122.4 (2C), 66.7,58.8,53.2,30.4. 
1-(3-( (4-Ethylpiperazin-l-yl)methyl)-4-hydroxyphenyl)ethanone, CDM33 
o 
___ ...... 5 _______ 12_ .. Pale yellow crystals (0.4271 g, 44%); Rf(5% MeOH:DCM) 0.24; 
6H (400MHz, d6-DMSO), 7.78 (lH, d, J2.0, H-2), 7.75 (lH, dd, J2.4, 8.0, H-6), 6.87 (lH, d, J 
8.0, H-5), 4.15 (lH, s, OH), 3.77 (2H, s, H-7), 2.45 (3H, s, COCH3), 2.43 (8H, m, H-8, H-9, H-I0 
and H-ll), 2.23 (2H, q, J 7.6, H-12), 1.01 (3H, t, J 7.6, H-13); 6cC75MHz, d6-DMSO) 195.9, 
161.7,129.7,129.3,128.4,122.1,115.2,58.3,52.1,52.0, 51.3,26.1,11.9. 
1-(3- «tert-Butylamino)methyl)-4-hydroxyphenyl)ethanone, CDM34 
5 
Yellow crystals (0.33g, 41%); Rf (2% MeOH:DCM) 0.13; 6H 
(400MHz, CDCI3), 7.77 (lH, d, J2.0, H-2), 7.75 (lH, dd, J2.4, 8.4, H-6), 6.83 (lH, d, J8.4, H-
5),4.04 (2H, s, H-7), 2.50 (3H, s, COCH3), 1.26 (9H, s, H-I0a,b,c); 6c(lOOMHz, CDCh) 195.9, 
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1-(3- «Dimethylamino )methyl)-4-hydroxyphenyl)ethanone, CDM35 
'-_.....; _____ .. Brown oil (0.554g, 78%); Rr (2% MeOH:DCM) 0.16; OH (400MHz, 
CDCh), 7.82 (l H, dd, J 2.0, 8.4, H-6), 7.74 (l H, s, OH), 7.64( I H, d, J 2.4, H-2), 6.82 (l H, d, J 
8.8, H-5), 3.65 (2H, s, H-7), 2.50 (3H, s, COCH3), 2.48 (6H, s, H-8a,b); oc(lOOMHz, CDCh) 
199.8, 163.7, 130.0(2C), 129.6, 122.4, 115.2, 59.8,26.8, 17.4. 
1-(3-( (Diethylamino )methyl)-4-hydroxy-phenyl)-ethanone, CDM36 
o 
'-_.....; _____ .... Yellow oil (0.3215g, 40%); Rr(hexane:EtOAc, 3:2) 0.18; OH (400MHz, 
d6-DMSO), 7.79 (lH, dd, J2.4, 8.4, H-6), 7.75( IH, d, J2.0, H-2), 6.79 (lH, d, J8.4, H-5), 3.80 
(2H, s, H-7), 2.61 (4H, q, J 7.2, H-9/9'), 2.44 (3H, s, COCH3), 1.02 (6H, t, J 7.2, H-IOIlO'); 
oc(lOOMHz, d6-DMSO) 199.8, 160.2, 130.4, 129.0, 128.8, 122.6,58.6,49.1,29.4,13.8. 
General procedure of synthesis of 4-aminoquinoline-based Mannich bases CDM37-CDM44 
A methanolic solution of NaOH (3% w/v) and the phenolic Mannich base (l.0 eq) were stirred 
together at room temperature. A methanolic solution of the 4-aminoquinoline-based aldehyde 
(1.0 eq) was added dropwise, and the mixture was refluxed with stirring for 72 h. The precipitate 
was removed by filtration and washed with cold methanol. The collected yellow solid was dried 
further in vacuo, affording the desired product. When little or no precipitate was obtained, the 
solution was diluted with water, neutralized with I M hydrochloric acid, and extracted with ethyl 
acetate. The organic layer was dried with anhydrous Na2S04 and removed by evaporation under 
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(£)-3-(3-(7 -Chloroq uinolin-4-ylamino )phenyl)-l-( 4-hydroxy-3-(pyrrolidin-l-
ylmethyl)phenyl)prop-2-en-l-one, CDM37 
CI 
'-________________ ... Yellow crystals (0.0621g, 17%); m.p.328-
333°C; m.p. 209-211 DC; Rf (5% MeOH:DCM) 0.33; 8H (300MHz, d6-DMSO) 9.20 (lH, s, NH), 
8.50 (l H, d, J 5.1, H-2), 8.47 (1.H, d, J 9.0, H-5), 8.04 (2H, m, H-18 and H-22), 7.92 (l H, d, J 
2.4, H-8), 7.91 (lH, d, J 15.6, H-15), 7.83 (lH, s, H-13), 7.72 (lH, d, J 15.6, H-16), 7.68 (lH, d, 
J 7.5, H-ll), 7.60 (l H, dd, J 2.1, 9.0, H-6), 7.54 (l H, t, J 7.8, H-I0), 7.48 (l H, d, J 8.1, H-9), 
6.95 (l H, d, J 5.1, H-3), 6.90 (l H, d, J 9.3, H-19), 3.99 (2H, s, H-24), 2.76 (4H, m, H-25 and H-
28), 1.82 (4H, m, H-26 and H-27); 8c(75MHz, d6-DMSO)186.9, 162.2, 151.9, 147.8, 142.2, 
140.8,136.1, 133.9, 130.7, 130.3, 129.8, 128.6, 127.5, 124.9, 124.6, 124.4, 124.3, 122.6, 115.4, 
101.9, 59.6, 55.1, 52.9, 22.9, 13.9; EI-MS: (found m/z = 483.4 C29H26CIN302 requires M 483.17; 
Elemental analysis: (Found C, 70.00; H, 5.11; N, 8.56 C29H26CIN302.1H20 requires C, 69.95; H, 
5.23; N 8.39%). 
(£)-3-(3-(7 -Chloroq uinolin-4-ylamino )phenyl)-l-( 4-hydroxy-3-(piperidin-l-
ylmethyl)phenyl)prop-2-en-l-one, CDM38 




Yellow crystals (0.2949g, 38%); m.p. 
223-225 DC; Rf (5% MeOH:DCM) 0.29; Vmax (CHCb) I cm-
1 3354 (C-N stretch), 2939-2855 (C-H 
stretch), 1719 (C=O), 1648 (C=C),1604 (Ar-C=C), 1578-1534 (C-N bend), 1441 (CH2 bend), and 
865 (Ar-CI); 8H (300MHz, CDCb) 8.53 (l H, d, J 5.4, H-2), 8.05 (1.H, d, J 9.3, H-5), 8.04 (l H, d, 











Chapter 5: Experimental 
7.55 (1H, d, J 15.6, H-16), 7.54 (1H, d, J2.4, H-22), 7.46 (3H, m, H-9, H-ll, H-18), 7.36 (1H, 
m, H-I0), 6.96 (1H, d, J5.4, H-3), 6.86 (1H, d, J8.4, H-19), 3.76 (2H, s, H-24), 2.55 (4H, m, H-
25 and H-29), 1.67 (4H, m, H-26 and H-28), 1.52 (2H, m, H-27); 8c(75MHz, CDC h) 188.2, 
163.7, 151.1 (2C), 148.9, 148.9, 148.1, 142.4, 140.1, 137.0, 135.9, 130.1, 129.7, 129.2, 128.3, 
136.4, 124.9, 124.3, 122.8, 122.3, 121.8, 121.6, 118.1, 116.0, 102.7,61.7 (2C), 53.8,25.6,23.7 
(2C). EI-MS: (found mlz = 497.2 C30H2sCIN302 requires M 497.19; Elemental analysis: (Found 
C, 70.26; H, 5.37; N, 8.12 C30H2sCIN302.1H20requires C, 69.83; H, 5.46; N 8.14%). 
(E)-3-(3-(7 -Chloroq uinolin-4-yIamino )phenyl)-l-( 4-hydroxy-3,5-bis 
(morpholinomethyI)phenyI)prop-2-en-l-one,CD M39 




Yellow crystals (0.0969g, 15%); m. p. 
233-235 °C; Rf (5% MeOH:DCM) 0.23; 8H (300M Hz, CDCh) 8.53 (1 H, d, J 5.4, H-2), 8.05 (1.H, 
d, J9.3, H-5), 8.04 (IH, d, J 1.8, H-8), 7.89 (IH, dd, J2.4, 8.7, H-6), 7.75 (1H, d, J 15.6, H-15), 
7.75 (1H, d, J 1.8, H-13), 7.55 (1H, d, J 15.6, H-16), 7.54 (1H, d, J2.4, H-22), 7.46 (3H, m, H-9, 
H-l1, H-18), 7.36 (1H, m, H-I0), 6.96 (1H, d, J5.4, H-3), 6.86 (1H, d, J8.4, H-19), 3.76 (2H, s, 
H-24), 2.55 (4H, m, H-25 and H-29), 1.67 (4H, m, H-26 and H-28), 1.52 (2H, m, H-27); 
8c(75MHz, CDCI3) 188.2, 163.7, 151.1 (2C), 148.9, 148.9, 148.1, 142.4, 140.1, 137.0, 135.9, 
130.1,129.7, 129.2, 128.3, 136.4, 124.9, 124.3, 122.8, 122.3, 121.8, 121.6, 118.1, 116.0, 102.7, 
61.7 (2C), 53.8, 25.6, 23.7 (2C). EI-MS: (found mlz = 598.3 C30H2sCIN302 requires M 598.23; 
Elemental analysis: (Found C, 64.84; H, 5.78; N, 9.26 C30H2sCIN302.2H20 requires C, 64.30; H, 
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Yellow crystals (0.0931 g, 17%); 
m.p. 214-216 °C; Rf (5% MeOH:DCM) 0.22; bH (300MHz, d6-DMSO)9.24 (l H, s, NH), 8.49 
(I H, d, J 5.4, H-2), 8.05 (1.H, d, J 8.8, H-5), 8.02 (2H, m, H-18 and H-22), 7.91 (l H, d , J2.4, H-
8),7.89 (lH, d, J 15.6, H-15), 7.82 (lH, s, H-13), 7.71 (lH, d, J 15.6, H-15), 7.65 (lH, d, J7.6, 
H-ll), 7.57 (1 H, dd, J 2.4,9.0, H-6), 7.51 (l H, t, J 8.0, H-l 0), 7.44 (l H, d, J 8.1, H-9), 6.96 (l H, 
d, J 5.4, H-3), 6.86 (1 H, d, J 8.4, H-19), 3.74 (2H, s, H-24), 2.43 (8H, m, H-25, H-26, H-27 and 
H-28), 2.23 (2H, m, H-29, H-12), 1.07 (3H, t, J7.2, H-30); bc(75MHz, d6-DMSO) 186.9, 161.5, 
151.6,149.2, 147.9, 142.2, 140.7, 136.1, 133.9, 130.9, 129.9,129.7,128.8, 127.4, 124.9, 124.5, 
124.4, 124.3, 122.5, 122.1, 118.2, 115.3, 101.9,79.24, 78.8(2C), 78.4, 57.0, 51.2, 50.9, 50.7; El-
MS: (found m/z = 526.4 C31H31ClN402 requires M 526.21 Elemental analysis: (Found C, 68.52; 
H, 5.73; N, 10.33 C31H31ClN402.1H20 requires C, 68.31; H, 5.73; N 10.28%). 
(£)-1-(3-( (tert-Butylamino )methyl)-4-hydroxyphenyl)-3-(3-(7 -chloroquinolin-4-
ylamino )phenyl)prop-2-en-l-one, CDM41 
CI 
'-___ ...,;"". ___________ ...... Yellow crystals (O.025g, II %); m.p. 232-
234°C; Rf (5% MeOH:DCM) 0.10; bH (400MHz, d6-DMSO) 9.22 (lH, s, NH), 8.48 (lH, d, J 
5.2, H-2), 8.46 (1.H, d, J 9.2, H-5), 8.08 (l H, s, H-13), 8.01 (l H, d , J 8.4, H-18), 7.92 (1 H, d, J 
15.6, H-15), 7.90 (lH, d, J2.0, H-8), 7.81 (lH, s, H-13), 7.69 (lH, d, J 15.6, H-15), 7.67 (lH, d, 
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6.94 (1 H, d, J 5.6, H-3), 6.82 (1 H, d, J 8.8, H -19), 4.02 (2H, s, H -24), 1.45 (1 H, s, CH2-NH), 1.24 
(9H, s, H-26a,b,c); 8c(75MHz, d6-DMSO) 186.9, 162.9, 152.8, 142.8, 136.9, 134.7, 132.9, 131.8, 
130.8,130.7, 128.4, 125.7, 125.1, 123.9, 123.7, 123.4, 120.8, 116.7, 111.0, 106.6, 106.5, 102.6, 
95.9, 93.2, 66.6, 27.1 (3C); EI-MS: (found mlz = 485.2 C29H28CIN302 requires M 485.19 
Elemental analysis: (Found C, 67.52; H, 5.69; N, 7.51 C29H28CIN302.2H20 requires C, 67.24; H, 
5.44; N 7.25%). 









'-___ ..;.... ___________ ... Yellow crystals (0.121g, 34%); m.p. 216-
218°C; Rr(5% MeOH:DCM) 0.14; 8H (300MHz, d6-DMSO) 9.19 (1H, s, NH), 8.50 (lH, d, J 
5.4, H-2), 8.48 (1.H, d, J9.0, H-5), 8.09 (lH, s, H-22), 8.06 (IH, d, J8.4, H-18), 7.92 (lH, d, J 
2.4, H-8), 7.91 (lH, d, J 15.6, H-15), 7.84 (lH, s, H-13), 7.74 (lH, d, J 15.6, H-15), 7.69 (lH, d, 
J 7.5, H-ll), 7.61 (lH, dd, J 2.4,9.0, H-6), 7.52 (IH, t, J 8.1, H-I0), 7.45 (lH, d, J 8.1, H-9), 
6.97 (1H, d, J8.4, H-19), 6.94 (tH, d, J5.1, H-3), 3.98 (2H, s, H-24), 2.29(overlap with DMSO, 
H-25a,b); 8c(75MHz, d6-DMSO) 187.2, 161.7, 151.3, 149.0, 148.6, 145.2, 142.9, 136.0, 134.9, 
131.6,130.2,129.8,129.5 (2C), 127.4, 123.8, 122.5, 121.0,119.8,116.4,116.1,115.5,113.6, 
110.7, 58.9, 45.5 (2C); EI-MS: (found m/z = 487.2 C27H24CIN302 requires M 457.16 Elemental 
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(E)-3-(3-(7 -Chloroq uinolin-4-ylamino )phenyl)-1-(3-( (diethylamino )methyl)-4-
hydroxyphenyl)prop-2-en-l-one, CDM43 
CI 
Yellow crystals (0.1198g, 20%); m.p. 
207-210 °C; Rf (5% MeOH:DCM) 0.16; vmax(CHCh) / cm-
1 3365 (C-N stretch), 2924-2851, (C-
H stretch), 1647 (C=O), 1604 (C=C),1604 (Ar-C=C), 1582-1542 (C-N bend), 1439 (CH2 bend), 
and 815 (Ar-Cl); 8H (400MHz, d6-DMSO) 9.15 (lH, s, NH), 8.48 (lH, d, J5.2, H-2), 8.45 (1.H, 
d, J9.2, H-5), 7.99 (lH, dd, J2.4, 8.4, H-18), 7.93 (lH, d, J2.0, H-8), 7.90 (lH, d, J2.4, H-22), 
7.89 (lH, d, J 15.6, H-15), 7.82 (lH, s, H-13), 7.69 (lH, d, J 15.6, H-15), 7.66 (lH, d, J7.6, H-
11),7.58 (I H, dd, J2.4, 9.2, H-6), 7.51 (IH, t, J8.0, H-I0), 7.42 (lH, d, J8.0, H-9), 6.94 (lH, d, 
J 5.6, H-3), 6.78 (1 H, d, J 8.4, H-9), 3.85 (2H, s, H-24), 2.61 (4H, q, J7.2, H-25a,b), 1.03 (6H, t, 
J 7.2, H-26a,b); 8c(75MHz, d6-DMSO) 186.9, 163.4, 151.9, 149.5, 148.3, 147.8, 142.0 (2C), 
140.7, 136.2, 134.2, 129.9, 129.8, 129.7, 128.4, 127.6, 124.9, 124.5, 124.4, 124.3, 122.6 (2C), 
115.5, 102.0,55.0,45.7 (2C), 10.8 (2C); EI-MS: (found mlz = 485.3 C29H28CIN302 requires M 
485.19 Elemental analysis: (Found C, 70.73; H, 5.68; N, 8.74 C29H28CIN302.0.5H20 requires C, 
70.38; H, 5.70; N 8.49%). 






8 '-_______________ ...... Yellow crystals (0.0226g, 20%); m.p. 280-
282°C; Rf (I 0% MeOH:DCM) 0.36; 8H (400MHz, d6-DMSO) 11.25 (I H, s, OH), 10.65 (I H, s, 
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8.12 (IH, d, J 15.2, H-15), 8.05 (IH, s, H-13), 8.00 (IH, d, J8.1, H-Il), 7.89 (IH, d, J9.2, H-6), 
7.78 (IH, d, J 15.2, H-16), 7.66 (IH, s, H-18), 7.65 (IH, t, J8.0, H-I0), 7.55 (IH, d, J7.6, H-9), 
6.86 (IH, d, J 7.2, H-3), 4.39 (2H, s, H-24), 3.98 (3H, s, C l90CH3), 2.71 (6H, s, H-25a,b); 
8c(75MHz, d6-DMSO) 187.7, 155.4, 151.6, 148.7, 144.6, 142.6, 140.1, 139.5, 138.5, 137.4, 
131.4,129.6, 128.7, 128.6, 127.9, 127.5, 126.2, 124.0, 117.5, 116.7, 112.3, 108.6, 101.4,56.9, 
54.6, 44.9; EI-MS: (found mlz = 487.2 C28H26CIN303 requires M 487.17 Elemental analysis: 
(Found C, 65.91; H, 5.24; N, 8.64 C28H26CIN303.IH20 requires C, 66.47; H, 5.18; N 8.31%). 
5.2 Single Crystal X-ray Diffraction 
Single crystals of CDM06 and CDM14 were prepared by dissolving the compounds in a 
minimum amount of heated ethyl acetate and methanol, respectively. Each solution was filtered 
while hot through a 0.45 f!M nylon microfilter and allowed to slowly evaporate at room 
temperature. A single crystal which extinguished plane polarized light was selected and cut to an 
appropriate size to minimize X-ray absorption. The crystal was coated with Paratone oil and 
mounted on a glass fibre on a goniometer head. Reflection intensity data were measured on a 
Nonius Kappa CCD single crystal diffractometer using graphite-monochromated MoKa radiation 
(A = 0.71069 A) generated by a Nonius FR590 generator operating at 53 kW and 23mA. Data 
collections were performed at low temperatures (I13K and 173K), which were maintained by a 
constant N2 gas flow of 20 cm3/min. Cell refinement and data reduction were performed by 
Denzo Scalepack and SADABS was used for absorption corrections. l XPREp2 was used to 
determine the crystal space group by examining systematic absences and intensity statistics. The 
structures were solved by direct methods using SHELXS-973 and refined by the method of least-
squares against F2 using SHELXL-97,4 incorporated in the X-Seed5 interface. 
5.3 Cyclodextrin Inclusion Complexes 
5.3.1 Materials 
The cyclodextrin host compounds ~-cyclodextrin, y-cyclodextrin and TRIMEB were obtained 
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5.3.2 Preparation Methods 
Kneading, co-precipitation and co-solvent methods were employed in attempts to include target 
compounds CDM13-15 and CDM38 in cyclodextrin hosts. Co-precipitation or co-solvent 
methods involve dissolving ~-CD or y-CD in a minimum amount of water at an elevated 
temperature. A stoichiometric amount of guest compound (1: 1 or 2: 1 host:guest) was slowly 
added to the stirring solution, either directly as for co-precipitation or as a methanol solution for 
the co-solvent method. The resulting suspension was stirred for 24 h and then filtered through a 
0.45 )lM nylon microfilter and allowed to evaporate slowly. A similar procedure was employed 
for attempted formation of TRIMEB inclusion complexes, the difference being due to TRIMEBs 
inverse solubility relationship with temperature and it was thus necessary to prepare saturated 
solutions of host compound at low temperatures (O°C- room temperature). After addition of the 
guest, the cold solution was stirred for 5 h, filtered through a 0.45 )lM nylon microfilter and 
heated at 60°C in order to encourage crystallization. The method of kneading involved making a 
paste of the cyclodextrin with water using a mortar and pestle. An equimolar amount of drug was 
slowly added with continual grinding for an hour. The consistency of the paste was maintained 
by dropwise addition of water during this period. 
5.3.3 Powder X-ray Diffraction (PXRD) 
PXRD was used to ascertain whether a CD complex had been formed by comparing the PXRD 
pattern of the kneaded material to that of the native CD and that of the guest. PXRD patterns that 
are different from those of the host and guest indicate that a potential complex has formed and are 
then used to determine if the complex is isostructural to any known isostructural series of 
complexes.5 PXRD patterns of kneaded samples were recorded on a HUBER Imaging Plate 
Guinier Camera 670 with Ni-filtered CuKa-radiation ()., = 1.5406A) generated by a Philips X-ray 
:g; 
generator operated at 40kY and 25mA. The kneaded paste was spread on Mylar film and 
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5.4 Thermogravimetric Analysis 
The three thermal analytical methods used in this study were Hot Stage Microscopy (HSM), 
Thermogravimetric Analysis (TGA) and Differential Scanning Calorimetry (DSC). 
5.4.1 Hot stage Microscopy (HSM) 
HSM was used to observe crystal morphologies and visual physical changes (melting, 
desolvation) as crystals were heated. Crystals were submerged in silicone oil and placed between 
cover-slides and viewed with a Nikon SMZ-I 0 stereoscopic microscope with the images captured 
by a real-time Sony Digital Hyper HAD colour video camera. These images were viewed with 
the Soft Imaging System program, analySIS.6 Heat was provided by a Linkam THMS600 hot 
stage apparatus and controlled with a Linkam TP92 temperature control unit. 
5.4.2 Thermogravimetric Analysis (TGA) 
TGA gives quantitative data for loss of mass with increasing temperature and was used to 
determine the solvent content of CDMI4. TGA experiments were performed on a Mettler Toledo 
Star TGA/SDT A 8S1 instrument. Samples of mass 2-4 mg were placed in an open crucible and 
heated at a constant rate of 10K min- I under nitrogen with a flow rate of 30 cm-3 min-I. 
5.4.3 Differential Scanning Calorimetry (DSC) 
DSC measures the heat flow required to increase the temperature of a sample at a constant rate 
relative to an empty reference pan. This analytical method was used to measure endothermic and 
exothermic changes in the inclusion complexes and guest compounds, and was used to accurately 
determine melting points and onset temperatures of thermal events. DSC experiments were 
performed on a Perkin- Elmer PC7-series Differential Scanning Calorimeter. Samples of mass 2-
Smg were sealed in a crimped, vented aluminum pan with a sealed, empty pan used as reference. 
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5.5 Procedures for Biological Assays 
In Vitro Activities of compounds against 3D7 
All samples were tested in triplicate against the P. jalciparum 307 strain, a clone ofNF54, which 
is known to be sensitive to all anti-malarials. The cultures are naturally asynchronous (65 - 75% 
ring stage) and are maintained in continuous log phase growth in RPMI1640 medium 
supplemented with 5% washed human A+erythrocytes, 25 mM Hepes, 32 nM NaHC03, and 
AlbuMAXII (lipid-rich bovine serum lbumin) (GIBCO, Grand Island, NY). All cultures and 
assays are conducted at 37°C under an atmosphere of 5% CO2 and 5% O2, with a balance of N2. 
Primary screen 
The preliminary screen uses the 307 strain. The compounds are tested at four concentrations (30, 
10, 3, 1, 0.3, and 0.1 flg/ml) and their potency classified according to the observed activity at 
these concentrations. The test compound is classified as inactive if it does not affect parasite 
growth at 10 flg/ml, is designated as partially active between 10 and 1 flg/ml, and if it affects 
parasite growth <1 flg/ml, the compound is classified as active and is further evaluated by three-
fold serial dilutions in a repeat test. 
Secondary screen 
The compound is diluted three-fold over at twelve different concentrations with an appropriate 
starting concentration based on the preliminary screen. For each assay, the IC 50 and IC90 values 
for each parasite line are determined against chloroquine. 
In Vitro Activities of compounds against W2 P. !alciparum, 
W2-strain P. jalciparum parasites (1 % parasitaemia, 2% hematocrit) were cultured in 0.5 ml of 
medium in 48-well culture dishes. 7 The test inhibitors from 10 mM stocks in OMSO were added 
to cultured parasites to a final concentration of 20 flM. From 48-well plates, 125 flM of culture 
was transferred to two 96 well plates (duplicates). Serial dilutions (1 %) of inhibitors were made 
to final concentrations of 10 flM, 2 flM, 0.4 flM, 80 nM, 16 nM and 3.2 nM. Cultures were 
maintained at 37°C for 2 days after which the parasites were washed and fixed with 1 % 
formaldehyde in PBS. After two days, parasitaemia was measured by flow cytometry using the 
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In Vitro Activities of compounds against DIO P. falciparum 
All experiments were performed in duplicate on a single occasion against the chloroquine-
sensitive strain of P. Jalciparum 010. Continuous in vitro cultures of asexual erythrocyte stages 
of P. Jalciparum were maintained using a modified method of Trager and Jensen.7 Quantitative 
assessment of anti plasmodial activity in vitro was determined via the parasite lactate 
dehydrogenase (pLOH) assay using a modified method described by Makler. 9 The average 
percentage parasite viability was determined at three different concentrations and compounds 
showing significant activity (reduction of parasite viability below 50%) were tested further to 
determine their 50% inhibitory concentration (lC so) values. These values were obtained from 
dose-response curves, using nonlinear dose-response curve fitting analyses with GraphPad 
Prism® v3.0 software. All compounds were dissolved in 100% OMSO and were then diluted 
with water to a concentration of 20 j..lg/ml. Samples were stored at -20DC until use. All samples 
were further diluted to 2 j..lg/ml in complete medium on the day of the experiment. The highest 
concentration of OMSO to which the parasites were exposed had no measurable effect on the 
parasite viability. Chloroquine diphosphate was used as the positive control in all experiments. 
\ 
In Vitro Activities of compounds against Falcipain-2 
ICso values against the recombinant enzyme (falcipain-2) were determined as described by 
Rosenthal and coworkers. 8 Briefly, an equal amount of recombinant protein (~1 nM) was 
incubated with different concentrations of test compounds (added from 100x stock solutions in 
OM SO) in 100 mM sodium acetate (pH 5.5)-10 mM dithiothreitol for 30 min at room 
temperature before addition of the substrate benzoxycarbonyl-Leu-Arg-7-amino-4-methyl-
coumarin. Fluorescence was continuously monitored for 30 min at room temperature in a 
Labsystems Fluoroskan® II spectrofluorometer. ICso values were determined from plots of 
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Assay of f3-Haematin inhibition 
All samples were screened for their ability to inhibit synthetic haemozoin (~-haematin) as 
describe by Egan and co-workers. lo ~-Haematin was prepared in 4.5 M acetate at 60°C from 
hemin dissolved in 0.1 M NaOH as described previously. I I High-throughput screening was 
performed using 1 and 5 equivalents of test compounds relative to haematin. A 20 III stock 
solution of haematin was mixed with aIM HCl or methanol solution of test compound. 
Prewarmed acetate solution was then added (11.4 Ill, 12.9 M, pH 5.0) and after 1 h incubation, 
250 III of 12% (v/v) pyridine solution (pH 7.5,20 mM Hepes, ambient temperature) was added. 
Supernatants were transferred to a 96-well plate and detection of ~-haematin inhibition was 
carried out by visual inspection and by absorbance measurement at 405 nm. 
In Vitro Activities of compounds against HeLa (human adenocarcinoma of the cervix) cells 
An adapted MTT method as desribed by Van Rensburg et alii was performed to establish the 
sensitivity of the HeLa cancer cell line to the test compounds. [3-(4,5-dimethylthiazol-2-yl)-2-5-
diphenyl tetrazolium bromide] (MTT) is a pale yellow substance that is metabolized to dark blue 
formazan crystals by metabolically active cells. An 80 III medium was dispensed into each well 
of a 96 well tissue culture plate and 100 III of cell suspension was then added to each well. 
Cultures were incubated at 37°C in an atmosphere of 5% CO2 for an hour and then 20 III 
dilutions of the test compound was added at different concentrations. Cultures were incubated for 
7 days, after which 20 III MTT (5mg/ ml) was added to each well, incubated for a further 4 hand 
then centrifuged for 10 min at 800g. Supernatant was carefully removed, washed with 150 III 
PBS and allowed to dry. DMSO was then added to solubilize the formazan crystals and then 
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